Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15900474,flow rate,The perfusate is perfused at a flow rate of 5 microL min(-1).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[μl] / [min],5,93,DB00120,L-Phenylalanine
,15900474,detection limit (3sigma),The response of the system is linearly related to the concentration of levodopa in the range 1 x 10(-8) to 1 x 10(-6) g mL(-1) (r2 = 0.9995) with a detection limit (3sigma) of 3 x 10(-9) g mL(-1) and sample throughput of 12 h(-1); RSD is 2.8% (n = 11).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[g] / [ml],3 x 10(-9),94,DB00120,L-Phenylalanine
,15900474,sample throughput,The response of the system is linearly related to the concentration of levodopa in the range 1 x 10(-8) to 1 x 10(-6) g mL(-1) (r2 = 0.9995) with a detection limit (3sigma) of 3 x 10(-9) g mL(-1) and sample throughput of 12 h(-1); RSD is 2.8% (n = 11).,Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),1/[h],12,95,DB00120,L-Phenylalanine
,15900474,Cmax,"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[ng] / [ml],16.60,96,DB00120,L-Phenylalanine
,15900474,AUC(0-t),"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),[ng] / [ml],20.92,97,DB00120,L-Phenylalanine
,15900474,Tmax,"The method has been successfully used to study the pharmacokinetics of levodopa in vivo; the values of the pharmacokinetics parameters Cmax, AUC(0-t) and Tmax were 16.60, 20.92 ng mL(-1), and 90 min, respectively.",Microdialysis sampling and high-performance liquid chromatography with chemiluminescence detection for in-vivo on-line determination and study of the pharmacokinetics of levodopa in blood. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900474/),min,90,98,DB00120,L-Phenylalanine
,10789721,overall response rate,Median survival after IHP (n = 21) was 19 months and the overall response rate was 29% (17 assessable patients; one complete and four partial remissions).,Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789721/),%,29,1226,DB00120,L-Phenylalanine
,3516430,disposition half-lives,"A high scattering of drug concentrations was observed in our patients, the disposition half-lives ranging in the whole group from 17.8 to 71.2 min.",Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3516430/),min,17.8 to 71.2,1802,DB00120,L-Phenylalanine
,3516430,areas under the curves,"The areas under the curves also showed a wide variation, ranging from 175 to 682 mg 1(-1) min-1.",Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3516430/),[mg] / [1·min],175 to 682,1803,DB00120,L-Phenylalanine
,6469754,enhancement ratios (SER),The sensitizer enhancement ratios (SER) of these derivatives were 2.2 and 2.3 respectively at 1 mM concentration after 2 hr exposure under hypoxia.,"Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469754/),,2.2,1836,DB00120,L-Phenylalanine
,6469754,enhancement ratios (SER),The sensitizer enhancement ratios (SER) of these derivatives were 2.2 and 2.3 respectively at 1 mM concentration after 2 hr exposure under hypoxia.,"Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469754/),,2.3,1837,DB00120,L-Phenylalanine
,6469754,apparent t 1/2,These agents were cleared from the plasma rapidly with an apparent t 1/2 of 18.8 and 15.6 min respectively.,"Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469754/),min,18.8,1838,DB00120,L-Phenylalanine
,6469754,apparent t 1/2,These agents were cleared from the plasma rapidly with an apparent t 1/2 of 18.8 and 15.6 min respectively.,"Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469754/),min,15.6,1839,DB00120,L-Phenylalanine
,6469754,Peak tumor concentration,Peak tumor concentration of approximately 217 micrograms/g was achieved within 15 min with phenylalanine analogue.,"Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469754/),[μg] / [g],217,1840,DB00120,L-Phenylalanine
,6469754,tumor to brain ratio,The tumor to brain ratio was 10:1 suggesting that this agent is excluded from CNS and that the phenylalanine analogue should be considered a potentially less neurotoxic radiosensitizer than misonidazole.,"Pharmacokinetic studies of amino acid analogues of 2-nitroimidazole, new hypoxic cell radiosensitizers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6469754/),,10:1,1841,DB00120,L-Phenylalanine
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],150.8,3087,DB00120,L-Phenylalanine
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],205.7,3088,DB00120,L-Phenylalanine
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],199.5,3089,DB00120,L-Phenylalanine
,1768561,area under the plasma concentration-time curves (AUC),The area under the plasma concentration-time curves (AUC) for the final dose of levodopa (150.8 +/- 22.0 micrograms ml-1 min) was lower than for the two preceding doses (205.7 +/- 41.8 and 199.5 +/- 51.8 micrograms ml-1 min) but not different from that of the single dose given at the same time of day (141.7 +/- 29.1 micrograms ml-1 min).,Gastric emptying in healthy volunteers after multiple doses of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768561/),[min·μg] / [ml],141.7,3090,DB00120,L-Phenylalanine
,22549288,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) of sorafenib in combination with ILI-M was 400 mg.,A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22549288/),mg,400,3531,DB00120,L-Phenylalanine
,3369621,mortality,"The mortality and morbidity rates were 0 and 6.8 percent, respectively.","Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369621/),%,0,4369,DB00120,L-Phenylalanine
,3369621,Local,"Local and regional recurrence rates were 0 and 3.4 percent, respectively, at 1 year.","Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369621/),%,0,4370,DB00120,L-Phenylalanine
,3369621,regional recurrence rates,"Local and regional recurrence rates were 0 and 3.4 percent, respectively, at 1 year.","Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369621/),%,3.4,4371,DB00120,L-Phenylalanine
,12621462,MTD,Mucositis was the dose-limiting toxicity and the MTD was 60 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),mg,60,5056,DB00120,L-Phenylalanine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],7.7,5057,DB00120,L-Phenylalanine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],26.3,5058,DB00120,L-Phenylalanine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],14.8,5059,DB00120,L-Phenylalanine
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],47.4,5060,DB00120,L-Phenylalanine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],423.2,5061,DB00120,L-Phenylalanine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],2581,5062,DB00120,L-Phenylalanine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],732.8,5063,DB00120,L-Phenylalanine
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],4590,5064,DB00120,L-Phenylalanine
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,28.6,5065,DB00120,L-Phenylalanine
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,38.5,5066,DB00120,L-Phenylalanine
,26391155,t,"In NHL patients, cumulative higher trough concentrations over the eight administrations of the first cycle (TotC min, categorized by the median 58.71 mg/L) had significant prognostic value regarding the 5-year progression-free survival (PFS: 73.6 vs 46.5 %, P = 0.015) and 5-year overall survival (OS: 74.0 vs 52.2 %, P = 0.034).",Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391155/),[mg] / [l],58.71,5582,DB00120,L-Phenylalanine
< or =,15613930,AUC,"However, significant increases in AUC and Cmax, and a significant reduction in Tmax by adding AsA were observed in 25 patients with baseline AUC < or =2500 ng.hour/mL.",The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15613930/),[h·ng] / [ml],2500,8056,DB00120,L-Phenylalanine
,30051172,area-under-the-concentration-versus-time curve (AUC),"Thirty-seven patients received PK-adjusted dosing guided by the results of the initial PK results, targeting a specific Bu exposure expressed as the area-under-the-concentration-versus-time curve (AUC) of between 4000 and 5000 μmol min/day (median 4800).",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4000 and 5000,9962,DB00120,L-Phenylalanine
,30051172,area-under-the-concentration-versus-time curve (AUC),"Thirty-seven patients received PK-adjusted dosing guided by the results of the initial PK results, targeting a specific Bu exposure expressed as the area-under-the-concentration-versus-time curve (AUC) of between 4000 and 5000 μmol min/day (median 4800).",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4800,9963,DB00120,L-Phenylalanine
,30051172,AUC,"For the purposes of the analysis, we selected a target AUC of 4800 μmol min/day in this group, equivalent to the median targeted AUC in the PK-adjusted group.",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4800,9964,DB00120,L-Phenylalanine
,30051172,AUCs,The respective median AUCs of 5064 μmol min/day (range 3639-6157 μmol min/day) and 4854 μmol min/day (range 3251-6305 μmol min/day) were not significantly different (p = 0.16).,The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],5064,9965,DB00120,L-Phenylalanine
,30051172,AUCs,The respective median AUCs of 5064 μmol min/day (range 3639-6157 μmol min/day) and 4854 μmol min/day (range 3251-6305 μmol min/day) were not significantly different (p = 0.16).,The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],4854,9966,DB00120,L-Phenylalanine
>,30051172,AUCs,"No correlation between AUC and grade 3-4 transplant-related toxicities were observed, although only three patients had AUCs > 6000 μmol min/day.",The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30051172/),[min·μM] / [d],6000,9967,DB00120,L-Phenylalanine
,8378355,k(inactivation)/K(i),"The intrinsic potency of these compounds, as exemplified by L-680,833 (k(inactivation)/K(i) of 622,000 M-1.s-1), is reflected at the cellular level where it inhibits generation of the specific N-terminal cleavage product A alpha-(1-21) from the A alpha chain of fibrinogen by enzyme released from isolated polymorphonuclear leukocytes stimulated with fMet-Leu-Phe with an IC50 of 0.06 microM.","Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8378355/),1/[M·s],"622,000",10258,DB00120,L-Phenylalanine
,8378355,IC50,"The intrinsic potency of these compounds, as exemplified by L-680,833 (k(inactivation)/K(i) of 622,000 M-1.s-1), is reflected at the cellular level where it inhibits generation of the specific N-terminal cleavage product A alpha-(1-21) from the A alpha chain of fibrinogen by enzyme released from isolated polymorphonuclear leukocytes stimulated with fMet-Leu-Phe with an IC50 of 0.06 microM.","Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8378355/),μM,0.06,10259,DB00120,L-Phenylalanine
,8378355,IC50,"The inhibitory activity of L-680,833 is also apparent in whole blood stimulated with A23187, where it inhibits formation of A alpha-(1-21) and PMNE-alpha 1-proteinase inhibitor complex formation with IC50 values of 9 microM.","Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8378355/),μM,9,10260,DB00120,L-Phenylalanine
,2685650,time to peak levodopa concentration,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,2.3,10955,DB00120,L-Phenylalanine
,2685650,time to peak levodopa concentration,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,1.1,10956,DB00120,L-Phenylalanine
,2685650,onset of maximal clinical improvement,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,2.2,10957,DB00120,L-Phenylalanine
,2685650,onset of maximal clinical improvement,"Compared to standard Sinemet 25/100, time to peak levodopa concentration (2.3 versus 1.1 hrs), onset of maximal clinical improvement (2.2 versus 1.1 hrs), and other indices were significantly delayed with Sinemet CR.",Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685650/),h,1.1,10958,DB00120,L-Phenylalanine
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,69,11889,DB00120,L-Phenylalanine
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,54,11890,DB00120,L-Phenylalanine
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,55,11891,DB00120,L-Phenylalanine
,8836933,relative bioavailability,"The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100 mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa.",Sustained-release of levodopa: single dose study of a new formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8836933/),%,100,11892,DB00120,L-Phenylalanine
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,2.3,12397,DB00120,L-Phenylalanine
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.2,12398,DB00120,L-Phenylalanine
,8726541,duration of motor response,"The duration of motor response to levodopa increased significantly from 2.3 h to 3.2 h (i.e., by 39%) after a single dose and to 3.4 h (i.e., by 48%) after 4 weeks' medication with entacapone.","Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8726541/),h,3.4,12399,DB00120,L-Phenylalanine
,31836899,limit of detection,"In this study, an alternative, a simple, sensitive high-performance liquid chromatography method has been developed (limit of detection: 15 ng/mL and limit of quantification: 50 ng/mL) for simultaneous estimation of this drug combination in rat plasma.",Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31836899/),[ng] / [ml],15,13370,DB00120,L-Phenylalanine
,31836899,limit of quantification,"In this study, an alternative, a simple, sensitive high-performance liquid chromatography method has been developed (limit of detection: 15 ng/mL and limit of quantification: 50 ng/mL) for simultaneous estimation of this drug combination in rat plasma.",Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31836899/),[ng] / [ml],50,13371,DB00120,L-Phenylalanine
,31836899,flow rate,"Using a Waters Nova-Pak C 18 column (150 × 3.9 mm, 4 μm) and a mobile phase of acetonitrile: 10 mM KH2PO4 (60: 40, V/V (volume by volume)) pH 3.5, the analysis was performed at 210 nm with a flow rate of 1.5 mL/min.",Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31836899/),[ml] / [min],1.5,13372,DB00120,L-Phenylalanine
,25875940,bioavailability,Levodopa bioavailability was 99 % for LCIG relative to LC-oral.,Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25875940/),%,99,13683,DB00120,L-Phenylalanine
,7565822,bioavailability,"The mean bioavailability varied between 14.7% and 40.2%, which was the bioavailability until the end of clinical benefit.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),%,14.7,13684,DB00120,L-Phenylalanine
,7565822,bioavailability,"The mean bioavailability varied between 14.7% and 40.2%, which was the bioavailability until the end of clinical benefit.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),%,40.2,13685,DB00120,L-Phenylalanine
,7565822,Cmax,"Also, despite the differences in dose, the values of the Cmax were similar, with average values of 12.7-25.6 ng/ml.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),[ng] / [ml],12.7-25.6,13686,DB00120,L-Phenylalanine
,7565822,Tmax,"Wide differences in Tmax were observed, with values varying between 16 min for the enema and 127.5 min for the Witepsol-H15 100-mg suppository.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,16,13687,DB00120,L-Phenylalanine
,7565822,Tmax,"Wide differences in Tmax were observed, with values varying between 16 min for the enema and 127.5 min for the Witepsol-H15 100-mg suppository.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,127.5,13688,DB00120,L-Phenylalanine
,7565822,onset time,"Onset of effect was similar for each of the preparations, with an average onset time of 14-28 min.",Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,14-28,13689,DB00120,L-Phenylalanine
,7565822,duration of effect,The duration of effect after administration of the Witepsol-H15 100-mg suppository was 156 +/- 43 min versus 50 +/- 13 min after rectal administration of the apomorphine solution.,Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,156,13690,DB00120,L-Phenylalanine
,7565822,duration of effect,The duration of effect after administration of the Witepsol-H15 100-mg suppository was 156 +/- 43 min versus 50 +/- 13 min after rectal administration of the apomorphine solution.,Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7565822/),min,50,13691,DB00120,L-Phenylalanine
,22727067,relative bioavailability,The relative bioavailability of the test formulation was estimated to be 102.1% (13.5%).,"Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727067/),%,102.1,14459,DB00120,L-Phenylalanine
,15457357,perfusate/plasma area under the curve from 0 to 60 minutes ratios,"Melphalan levels in the perfusate were not significantly different in the two study groups (the mean perfusate/plasma area under the curve from 0 to 60 minutes ratios were 463 and 501, respectively).",True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15457357/),,463,14949,DB00120,L-Phenylalanine
,15457357,perfusate/plasma area under the curve from 0 to 60 minutes ratios,"Melphalan levels in the perfusate were not significantly different in the two study groups (the mean perfusate/plasma area under the curve from 0 to 60 minutes ratios were 463 and 501, respectively).",True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15457357/),,501,14950,DB00120,L-Phenylalanine
,8120868,IC50,"In particular, (S)-3-[N-[2- [(phosphonomethyl)amino]-3-(4-biphenylyl)propionyl]amino]propionic acid (10a) (CGS 24592) displayed high inhibitory potency in vitro (IC50 = 1.9 +/- 0.1 nM) and a long plasma half-life in rats but lacked oral bioavailability.","N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120868/),nM,1.9,17254,DB00120,L-Phenylalanine
,3168148,clearance,"Total melphalan clearance after the 5 mg/m2 dose ranged from 66.0 to 272 ml/min per m2; the percentage of the dose excreted unchanged in urine, from 2.5% to 92.8%; renal clearance, from 4.1 to 188 ml/min per m2; the fraction unbound in plasma, from 0.0598 to 0.460; and t1/2 beta, from 39.4 to 84.3 min.",Renal clearance and protein binding of melphalan in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),[ml] / [m2·min],66.0 to 272,17389,DB00120,L-Phenylalanine
,3168148,renal clearance,"Total melphalan clearance after the 5 mg/m2 dose ranged from 66.0 to 272 ml/min per m2; the percentage of the dose excreted unchanged in urine, from 2.5% to 92.8%; renal clearance, from 4.1 to 188 ml/min per m2; the fraction unbound in plasma, from 0.0598 to 0.460; and t1/2 beta, from 39.4 to 84.3 min.",Renal clearance and protein binding of melphalan in patients with cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),[ml] / [m2·min],4.1 to 188,17390,DB00120,L-Phenylalanine
,3168148,fraction unbound in plasma,"Total melphalan clearance after the 5 mg/m2 dose ranged from 66.0 to 272 ml/min per m2; the percentage of the dose excreted unchanged in urine, from 2.5% to 92.8%; renal clearance, from 4.1 to 188 ml/min per m2; the fraction unbound in plasma, from 0.0598 to 0.460; and t1/2 beta, from 39.4 to 84.3 min.",Renal clearance and protein binding of melphalan in patients with cancer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),,0.0598 to 0.460,17391,DB00120,L-Phenylalanine
,3168148,t1/2 beta,"Total melphalan clearance after the 5 mg/m2 dose ranged from 66.0 to 272 ml/min per m2; the percentage of the dose excreted unchanged in urine, from 2.5% to 92.8%; renal clearance, from 4.1 to 188 ml/min per m2; the fraction unbound in plasma, from 0.0598 to 0.460; and t1/2 beta, from 39.4 to 84.3 min.",Renal clearance and protein binding of melphalan in patients with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),min,39.4 to 84.3,17392,DB00120,L-Phenylalanine
,3168148,Unbound melpha,"Unbound melphalan clearance and renal clearance calculated from the unbound fraction in plasma for each patient ranged from 441 to 3356 ml/min per m2 and 15 to 961 ml/min per m2 respectively and were not related to serum albumin, serum creatinine or creatinine clearance.",Renal clearance and protein binding of melphalan in patients with cancer. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),[ml] / [m2·min],441 to 3356,17393,DB00120,L-Phenylalanine
,3168148,clearance,"Unbound melphalan clearance and renal clearance calculated from the unbound fraction in plasma for each patient ranged from 441 to 3356 ml/min per m2 and 15 to 961 ml/min per m2 respectively and were not related to serum albumin, serum creatinine or creatinine clearance.",Renal clearance and protein binding of melphalan in patients with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),[ml] / [m2·min],441 to 3356,17394,DB00120,L-Phenylalanine
,3168148,renal clearance,"Unbound melphalan clearance and renal clearance calculated from the unbound fraction in plasma for each patient ranged from 441 to 3356 ml/min per m2 and 15 to 961 ml/min per m2 respectively and were not related to serum albumin, serum creatinine or creatinine clearance.",Renal clearance and protein binding of melphalan in patients with cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),[ml] / [m2·min],441 to 3356,17395,DB00120,L-Phenylalanine
,3168148,unbound fraction,"Unbound melphalan clearance and renal clearance calculated from the unbound fraction in plasma for each patient ranged from 441 to 3356 ml/min per m2 and 15 to 961 ml/min per m2 respectively and were not related to serum albumin, serum creatinine or creatinine clearance.",Renal clearance and protein binding of melphalan in patients with cancer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168148/),[ml] / [m2·min],15 to 961,17396,DB00120,L-Phenylalanine
,7972908,content,The 10B content of blood (12.0 +/- 0.5 micrograms/g) was slightly higher than that of skin (10.0 +/- 0.5 micrograms/g) after oral dosing with BPA.,Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7972908/),[μg] / [g],12.0,18399,DB00120,L-Phenylalanine
,7972908,content,The 10B content of blood (12.0 +/- 0.5 micrograms/g) was slightly higher than that of skin (10.0 +/- 0.5 micrograms/g) after oral dosing with BPA.,Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7972908/),[μg] / [g],10.0,18400,DB00120,L-Phenylalanine
,7972908,CBE factor,"BSH, which was possibly excluded from the cytoplasm of epidermal cells, had a low CBE factor value (0.56 +/- 0.06) while BPA, which may be selectively accumulated in epidermal cells had a very high CBE factor (3.74 +/- 0.7).",Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7972908/),,0.56,18401,DB00120,L-Phenylalanine
,7972908,CBE factor,"BSH, which was possibly excluded from the cytoplasm of epidermal cells, had a low CBE factor value (0.56 +/- 0.06) while BPA, which may be selectively accumulated in epidermal cells had a very high CBE factor (3.74 +/- 0.7).",Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7972908/),,3.74,18402,DB00120,L-Phenylalanine
,30977301,Tmax,"For both formulations, the median Tmax for levodopa was 1.0 and 3.0 hours for carbidopa.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.0,19348,DB00120,L-Phenylalanine
,30977301,Tmax,"For both formulations, the median Tmax for levodopa was 1.0 and 3.0 hours for carbidopa.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,3.0,19349,DB00120,L-Phenylalanine
,30977301,half-life,The levodopa half-life harmonic mean was 1.6 hour for both formulations.,Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.6,19350,DB00120,L-Phenylalanine
,30977301,half-life,"The carbidopa half-life harmonic mean was 1.9 and 2.0 hour, respectively, for the LCIG-HV and LCIG-LV formulations.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,1.9,19351,DB00120,L-Phenylalanine
,30977301,half-life,"The carbidopa half-life harmonic mean was 1.9 and 2.0 hour, respectively, for the LCIG-HV and LCIG-LV formulations.",Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30977301/),h,2.0,19352,DB00120,L-Phenylalanine
,24418777,binding affinities,"Compared to DOTA-Ahx-(D-Lys(6)-GnRH1) (36.1 nM), the introduction of D-Phe improved the GnRH receptor binding affinities of DOTA-D-Phe-Ahx-(D-Lys(6)-GnRH) (16.3 nM) and DOTA-Ahx-D-Phe-(D-Lys(6)-GnRH) (7.6 nM).",Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418777/),nM,16.3,20098,DB00120,L-Phenylalanine
,24418777,binding affinities,"Compared to DOTA-Ahx-(D-Lys(6)-GnRH1) (36.1 nM), the introduction of D-Phe improved the GnRH receptor binding affinities of DOTA-D-Phe-Ahx-(D-Lys(6)-GnRH) (16.3 nM) and DOTA-Ahx-D-Phe-(D-Lys(6)-GnRH) (7.6 nM).",Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418777/),nM,7.6,20099,DB00120,L-Phenylalanine
,3396150,elimination half-life (t 1/2 beta),"When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5 +/- 3.7 l/m2, and 306.8 +/- 34.4 ml/min per square meter.",Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396150/),min,46.4,20128,DB00120,L-Phenylalanine
,3396150,plasma clearance (Clp),"When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5 +/- 3.7 l/m2, and 306.8 +/- 34.4 ml/min per square meter.",Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396150/),[l] / [m2],20.5,20129,DB00120,L-Phenylalanine
,3396150,volume of distribution (Vd beta),"When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5 +/- 3.7 l/m2, and 306.8 +/- 34.4 ml/min per square meter.",Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396150/),[ml] / [meter·min·square],306.8,20130,DB00120,L-Phenylalanine
,3396150,t 1/2 beta,"When L-PAM was inoculated 24 h after DDP, t 1/2 beta, Clp, and Vd beta were 47.5 +/- 6.3 min, 20.4 +/- 2.8 l/m2, and 322.0 +/- 54.1 ml/min per square meter.",Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396150/),min,47.5,20131,DB00120,L-Phenylalanine
,3396150,Clp,"When L-PAM was inoculated 24 h after DDP, t 1/2 beta, Clp, and Vd beta were 47.5 +/- 6.3 min, 20.4 +/- 2.8 l/m2, and 322.0 +/- 54.1 ml/min per square meter.",Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396150/),[l] / [m2],20.4,20132,DB00120,L-Phenylalanine
,3396150,Vd beta,"When L-PAM was inoculated 24 h after DDP, t 1/2 beta, Clp, and Vd beta were 47.5 +/- 6.3 min, 20.4 +/- 2.8 l/m2, and 322.0 +/- 54.1 ml/min per square meter.",Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396150/),[ml] / [meter·min·square],322.0,20133,DB00120,L-Phenylalanine
,18342586,flow rate,"All analytes including the internal standard (Repaglinide) were chromatographed on reverse phase C(18) column (50 mm x 4.6mm i.d., 5 microm) using acetonitrile: 2mM ammonium acetate buffer, pH 3.4 (90:10, v/v) as mobile phase at a flow rate 0.4 ml/min in an isocratic mode.","Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18342586/),[ml] / [min],0.4,20739,DB00120,L-Phenylalanine
>,18342586,recoveries,The recoveries from spiked control samples were >79% for all analytes and internal standard.,"Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18342586/),%,79,20740,DB00120,L-Phenylalanine
,11844689,IC50,"The compounds showed excellent potency with a wide variety of neutral, polar, electron withdrawing or donating groups on the phenylalanine ring (IC50 approximately 1 nM).","Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11844689/),nM,1,20869,DB00120,L-Phenylalanine
,20661024,time at which the maximum peaks,"The time at which the maximum peaks occurred was delayed from 25 (15-240) to 105 (20-240) minutes, respectively.",Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20661024/),min,25,22114,DB00120,L-Phenylalanine
,20661024,time at which the maximum peaks,"The time at which the maximum peaks occurred was delayed from 25 (15-240) to 105 (20-240) minutes, respectively.",Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20661024/),min,105,22115,DB00120,L-Phenylalanine
,15735919,maximal concentration,In tumour tissue the extracellular concentration of BPA followed that of blood with a maximal concentration of 31.2 ppm and a maximal ratio vs. blood of 1.07.,Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735919/),ppm,31.2,22810,DB00120,L-Phenylalanine
,15735919,maximal ratio vs. blood,In tumour tissue the extracellular concentration of BPA followed that of blood with a maximal concentration of 31.2 ppm and a maximal ratio vs. blood of 1.07.,Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735919/),,1.07,22811,DB00120,L-Phenylalanine
,15735919,maximal concentration,"In BAT, the maximal concentration of BPA was 18.0 ppm with the peak level delayed for 4-6 h compared to the peak in blood with a maximal ratio of 1.2.",Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735919/),ppm,18.0,22812,DB00120,L-Phenylalanine
,15735919,maximal ratio,"In BAT, the maximal concentration of BPA was 18.0 ppm with the peak level delayed for 4-6 h compared to the peak in blood with a maximal ratio of 1.2.",Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735919/),,1.2,22813,DB00120,L-Phenylalanine
,15735919,Maximal blood concentration,Maximal blood concentration found was 41.0 ppm.,Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735919/),ppm,41.0,22814,DB00120,L-Phenylalanine
,7381698,absolute bioavailability,"The absolute bioavailability of orally administered levodopa was estimated to be about 35% in both dogs and patients; however, the total amount absorbed of intact drug and levodopa metabolites was estimated to be 80--90% of the administered dose.",Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7381698/),%,35,23555,DB00120,L-Phenylalanine
,7381698,total amount absorbed,"The absolute bioavailability of orally administered levodopa was estimated to be about 35% in both dogs and patients; however, the total amount absorbed of intact drug and levodopa metabolites was estimated to be 80--90% of the administered dose.",Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7381698/),%,80--90,23556,DB00120,L-Phenylalanine
,11501854,leakage,The leakage measured with 99mTc-albumin microcolloid ranged from 1.5 to 18%/h (mean 8%/h).,Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11501854/),[%] / [h],8,24117,DB00120,L-Phenylalanine
,30922814,Cmax,Single oral doses of 2.5-80 mg/kg CNSA-001 caused dose-related increases in plasma sepiapterin (mean Cmax 0.58-2.92 ng/mL) and BH4 (mean Cmax 57-312 ng/mL).,"Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30922814/),[ng] / [ml],0.58-2.92,24121,DB00120,L-Phenylalanine
,30922814,Cmax,Single oral doses of 2.5-80 mg/kg CNSA-001 caused dose-related increases in plasma sepiapterin (mean Cmax 0.58-2.92 ng/mL) and BH4 (mean Cmax 57-312 ng/mL).,"Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30922814/),[ng] / [ml],57-312,24122,DB00120,L-Phenylalanine
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],113.5,25323,DB00120,L-Phenylalanine
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],94.2,25324,DB00120,L-Phenylalanine
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],127.6,25325,DB00120,L-Phenylalanine
,8074076,whole-body clearance (Cltot),"In ARF, CRF, and RDT groups, whole-body clearance (Cltot) of the 10 amino acids was elevated (113.5 +/- 1.5; 94.2 +/- 1.5 and 127.6 +/- 12.4, respectively, vs 85.2 +/- 4.8 mL.kg-1.min-1 in control subjects, P < 0.001).",Elimination of amino acids in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074076/),[ml] / [kg·min],85.2,25326,DB00120,L-Phenylalanine
,26536022,half-life,"It was quickly eliminated with a half-life of 0.520 to 0.793 hour, suggesting no accumulation during multiple-dose phase.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),h,0.520 to 0.793,27119,DB00120,L-Phenylalanine
,26536022,Cmax,The Cmax of apomorphine at effective dose was presumed to be approximately 20 ng/mL.,A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27120,DB00120,L-Phenylalanine
,26536022,effective blood concentration,"Two-hour interval injections did not cause reduced responses, and effective blood concentration was presumed to be approximately 20 ng/mL similar, to the previous study conducted at North America.",A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26536022/),[ng] / [ml],20,27121,DB00120,L-Phenylalanine
,19447633,peak (10)B concentration,In particular we note that the peak (10)B concentration in blood was 28.1 mg/ml for a total BPA administration of 350 mg/kg which is very consistent with the previous experience with BPA-fructose reported by the Helsinki group.,A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19447633/),[mg] / [ml],28.1,27413,DB00120,L-Phenylalanine
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],281.6,28359,DB00120,L-Phenylalanine
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],268.6,28360,DB00120,L-Phenylalanine
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],921.8,28361,DB00120,L-Phenylalanine
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],821.8,28362,DB00120,L-Phenylalanine
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2652,28363,DB00120,L-Phenylalanine
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2077,28364,DB00120,L-Phenylalanine
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,1.7,28365,DB00120,L-Phenylalanine
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,2.9,28366,DB00120,L-Phenylalanine
,3486861,enhancement ratios (ER's),"The mean enhancement ratios (ER's) determined from the L-PAM dose response curves were 1.4 for 3'-dG, 1.3 for 3'-dA, and 1.4 for N6-BC.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),,1.4,28854,DB00120,L-Phenylalanine
,3486861,enhancement ratios (ER's),"The mean enhancement ratios (ER's) determined from the L-PAM dose response curves were 1.4 for 3'-dG, 1.3 for 3'-dA, and 1.4 for N6-BC.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),,1.3,28855,DB00120,L-Phenylalanine
,3486861,half-life,"In addition 3'-dG also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 28 minutes to 35 minutes.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),min,28,28856,DB00120,L-Phenylalanine
,3486861,half-life,"In addition 3'-dG also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 28 minutes to 35 minutes.",The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3486861/),min,35,28857,DB00120,L-Phenylalanine
,9390741,detection limits,"The within-run and between-run coefficients of variations, for the two compounds, were less than 10%, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/10(9) platelets, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [10],2,29375,DB00120,L-Phenylalanine
,9390741,detection limits,"The within-run and between-run coefficients of variations, for the two compounds, were less than 10%, in both platelets and plasma; the detection limits for platelet levels of L-dopa and 3-OMD were 2 and 6 ng/10(9) platelets, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [10],6,29376,DB00120,L-Phenylalanine
,9390741,detection limits,"In plasma, the detection limits for L-dopa and 3-OMD were 1 and 3 ng/ml, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [ml],1,29377,DB00120,L-Phenylalanine
,9390741,detection limits,"In plasma, the detection limits for L-dopa and 3-OMD were 1 and 3 ng/ml, respectively.",Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9390741/),[ng] / [ml],3,29378,DB00120,L-Phenylalanine
,17609685,renal clearance (CL(R)),"In clinical studies, we found that in subjects homozygous for the L503F variant, gabapentin renal clearance (CL(R)) approximates the glomerular filtration rate (mean+/-SE: 110+/-12 ml/min, n=9), whereas in subjects homozygous for the reference allele, gabapentin undergoes net secretion in the kidney (141+/-7.8 ml/min, n=11, P<0.05).","Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17609685/),[ml] / [min],110,29796,DB00120,L-Phenylalanine
,17609685,net secretion,"In clinical studies, we found that in subjects homozygous for the L503F variant, gabapentin renal clearance (CL(R)) approximates the glomerular filtration rate (mean+/-SE: 110+/-12 ml/min, n=9), whereas in subjects homozygous for the reference allele, gabapentin undergoes net secretion in the kidney (141+/-7.8 ml/min, n=11, P<0.05).","Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17609685/),[ml] / [min],141,29797,DB00120,L-Phenylalanine
,11981235,plasma levodopa concentration,Mean plasma levodopa concentration ranged between 0.45 to 7.07 microg/mL and peak concentrations between 0.95 to 13.75 microg/mL.,Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981235/),[μg] / [ml],0.45 to 7.07,31667,DB00120,L-Phenylalanine
,11981235,peak concentrations,Mean plasma levodopa concentration ranged between 0.45 to 7.07 microg/mL and peak concentrations between 0.95 to 13.75 microg/mL.,Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981235/),[μg] / [ml],0.95 to 13.75,31668,DB00120,L-Phenylalanine
,29059133,maximum plasma concentration,MK-0657 7 mg achieved the target mean maximum plasma concentration of 400 nM.,A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29059133/),nM,400,31926,DB00120,L-Phenylalanine
,11307044,Peak plasma L-Dopa levels,Peak plasma L-Dopa levels and area under the curve did not differ significantly between the first-ever dose and after 1 month of continuous treatment (0.9 +/- 0.1 vs.,"The pharmacokinetic profile of the ""first ever"" oral dose of levodopa in de novo patients with Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307044/),,0.9,32478,DB00120,L-Phenylalanine
,28451811,overall filter efficiency,Pharmacokinetic analysis of blood samples showed an overall filter efficiency of 86% (range 71.1-95.5%).,Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28451811/),%,86,33000,DB00120,L-Phenylalanine
,7738660,biologic half-times,"The whole-body clearance of 125I-ChL6, 90Y- and 111In-DOTA-peptide-ChL6 was monoexponential with biologic half-times of 92, 104 and 160 hr, respectively.",Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738660/),h,92,34334,DB00120,L-Phenylalanine
,7738660,biologic half-times,"The whole-body clearance of 125I-ChL6, 90Y- and 111In-DOTA-peptide-ChL6 was monoexponential with biologic half-times of 92, 104 and 160 hr, respectively.",Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738660/),h,104,34335,DB00120,L-Phenylalanine
,7738660,biologic half-times,"The whole-body clearance of 125I-ChL6, 90Y- and 111In-DOTA-peptide-ChL6 was monoexponential with biologic half-times of 92, 104 and 160 hr, respectively.",Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738660/),h,160,34336,DB00120,L-Phenylalanine
,28055204,oral bioavailability,"Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat.","Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28055204/),%,63,34627,DB00120,L-Phenylalanine
,28055204,oral bioavailability,"Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat.","Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28055204/),%,61,34628,DB00120,L-Phenylalanine
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],"11,802",34890,DB00120,L-Phenylalanine
,15965309,AUC,"The mean (+/-SD) plasma levodopa AUC was 39% (P = 0.0001) higher with entacapone (11,802 +/- 1454 ng/hour/mL) compared with placebo (8465 +/- 927 ng/hour/mL).",Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15965309/),[ng] / [h·ml],8465,34891,DB00120,L-Phenylalanine
>,22632782,T(max),"The gastric emptying study showed that T(max) ((13)C)>60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p<0.05), total of 50.7 ± 16.4 min in all 31 patients.",Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632782/),min,60,35327,DB00120,L-Phenylalanine
,22632782,T(max),"The gastric emptying study showed that T(max) ((13)C)>60 min was more common in patients with a plasma levodopa peak at 2 hours (14/18, 69%) than in those with a plasma levodopa peak at 1 hour (4/13, 22%) (p<0.05), total of 50.7 ± 16.4 min in all 31 patients.",Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22632782/),min,50,35328,DB00120,L-Phenylalanine
,1922125,relative bioavailability,The relative bioavailability of SL apomorphine ranged from 10 to 22% of a parenteral apomorphine dose.,Absorption of apomorphine by various routes in parkinsonism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),%,10 to 22,35334,DB00120,L-Phenylalanine
less,1922125,bioavailable,"Oral apomorphine was less than 4% bioavailable, and the transdermal dose did not produce detectable plasma levels.",Absorption of apomorphine by various routes in parkinsonism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),%,4,35335,DB00120,L-Phenylalanine
,1922125,latency to effect,"Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min.",Absorption of apomorphine by various routes in parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),min,20-40,35336,DB00120,L-Phenylalanine
,1922125,duration of effect,"Three patients with motor fluctuations responded to SL apomorphine, with a latency to effect of 20-40 min and a duration of effect of 15-100 min.",Absorption of apomorphine by various routes in parkinsonism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1922125/),min,15-100,35337,DB00120,L-Phenylalanine
,17350841,IC(50),"The phenylalanine series afforded compounds such as 10 that were potent and selective (DPP-4, IC(50)=28nM), but exhibited limited oral bioavailability.","4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350841/),nM,28,37368,DB00120,L-Phenylalanine
,25814518,half-life,"Radiolabeled amino acids are superior PET tracers for the imaging of malignant tumors, and amino acids labeled with (76)Br, an attractive positron emitter because of its relatively long half-life (16.2 h), could potentially be a widely usable tumor imaging tracer.",Development of a Widely Usable Amino Acid Tracer: ⁷⁶Br-α-Methyl-Phenylalanine for Tumor PET Imaging. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25814518/),h,16.2,37527,DB00120,L-Phenylalanine
,11781625,AUC per 6 h,Doses were adjusted to reach a target mean AUC per 6 h between 4 and 6 microg.h.ml(+1).,Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11781625/),h·ml(+1)·μg,4 and 6,38713,DB00120,L-Phenylalanine
,7905404,dissociation half-life,"GST was found to react only with the aziridinium intermediate formed from melphalan and to dissociate slowly from the resultant GST-product complex (dissociation half-life, 1 hr at pH 7.4 and 3.5 hr at pH 6.5).","Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905404/),h,1,39519,DB00120,L-Phenylalanine
,7905404,dissociation half-life,"GST was found to react only with the aziridinium intermediate formed from melphalan and to dissociate slowly from the resultant GST-product complex (dissociation half-life, 1 hr at pH 7.4 and 3.5 hr at pH 6.5).","Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905404/),h,3.5,39520,DB00120,L-Phenylalanine
,19026037,apparent clearance,"Total bodyweight was the only significant covariate identified, the inclusion of which on both the apparent clearance (mean = 2100 L/h/70 kg) and central volume of distribution (mean = 8350 L/70 kg) substantially improved the model's ability to describe the data.",Pharmacokinetics of sapropterin in patients with phenylketonuria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026037/),[l] / [70·h·kg],2100,40021,DB00120,L-Phenylalanine
,19026037,central volume of distribution,"Total bodyweight was the only significant covariate identified, the inclusion of which on both the apparent clearance (mean = 2100 L/h/70 kg) and central volume of distribution (mean = 8350 L/70 kg) substantially improved the model's ability to describe the data.",Pharmacokinetics of sapropterin in patients with phenylketonuria. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026037/),[l] / [70·kg],8350,40022,DB00120,L-Phenylalanine
,19026037,terminal half-life,"The mean (SD) terminal half-life of sapropterin was 6.69 (2.29) hours and there was little evidence of accumulation, even at the highest dose.",Pharmacokinetics of sapropterin in patients with phenylketonuria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026037/),h,6.69,40023,DB00120,L-Phenylalanine
,16320098,V1,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],11.4,40352,DB00120,L-Phenylalanine
,16320098,CL,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],30.9,40353,DB00120,L-Phenylalanine
,16320098,V2,"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·kg],27.3,40354,DB00120,L-Phenylalanine
,16320098,CL(ic),"Population parameter estimates (geometric mean) and population parameter variability (PPV; SD of normal distribution) were V1 11.4 l/70 kg (0.44), CL 30.9 l/h/70 kg (0.25), V2 27.3 l/70 kg (0.27), and CL(ic) 34.6 l/h/70 kg (0.48).",Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16320098/),[l] / [70·h·kg],34.6,40355,DB00120,L-Phenylalanine
,32493164,Overall survival,"Overall survival was shorter in patients with a lower Hb (113 vs. 2536 days; p = 0.004), due to an increased rate of nonrelapse mortality (NRM) (p = 0.0005).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,113,41430,DB00120,L-Phenylalanine
,32493164,Overall survival,"Overall survival was shorter in patients with a lower Hb (113 vs. 2536 days; p = 0.004), due to an increased rate of nonrelapse mortality (NRM) (p = 0.0005).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,2536,41431,DB00120,L-Phenylalanine
,32493164,Overall survival,"Overall survival was also worse in patients with lower CrCl (75 vs. 317 days; p = 0.003), with a significantly worse nonrelapse mortality (p = 0.0023).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,75,41432,DB00120,L-Phenylalanine
,32493164,Overall survival,"Overall survival was also worse in patients with lower CrCl (75 vs. 317 days; p = 0.003), with a significantly worse nonrelapse mortality (p = 0.0023).","Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32493164/),d,317,41433,DB00120,L-Phenylalanine
more,8953191,Recovery,Recovery from plasma proved to be more than 90%.,High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8953191/),%,90,41678,DB00120,L-Phenylalanine
,32279799,IC50,"The IC50 of 4.3% melphalan-containing PDCM-3 NP was 70 mg/L, 72 h post administration.",Electrosprayed nanoparticles of poly(p-dioxanone-co-melphalan) macromolecular prodrugs for treatment of xenograft ovarian carcinoma. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279799/),[mg] / [l],70,42381,DB00120,L-Phenylalanine
,32279799,tumor growth rate,"After a 20-day treatment, the tumor growth rate of the PDCM-3 NP group was (266 ± 178%) which was lower than those in the free melphalan group (367 ± 150%) and control group (648 ± 149%).",Electrosprayed nanoparticles of poly(p-dioxanone-co-melphalan) macromolecular prodrugs for treatment of xenograft ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279799/),%,266,42382,DB00120,L-Phenylalanine
,32279799,tumor growth rate,"After a 20-day treatment, the tumor growth rate of the PDCM-3 NP group was (266 ± 178%) which was lower than those in the free melphalan group (367 ± 150%) and control group (648 ± 149%).",Electrosprayed nanoparticles of poly(p-dioxanone-co-melphalan) macromolecular prodrugs for treatment of xenograft ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279799/),%,367,42383,DB00120,L-Phenylalanine
,32279799,tumor growth rate,"After a 20-day treatment, the tumor growth rate of the PDCM-3 NP group was (266 ± 178%) which was lower than those in the free melphalan group (367 ± 150%) and control group (648 ± 149%).",Electrosprayed nanoparticles of poly(p-dioxanone-co-melphalan) macromolecular prodrugs for treatment of xenograft ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32279799/),%,648,42384,DB00120,L-Phenylalanine
,2404503,time to 90% emptying,3. In the presence of levodopa the time to 90% emptying was prolonged from 32 +/- 24 min to 81 +/- 20 min (P less than 0.01).,The influence of levodopa on gastric emptying in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2404503/),min,32,42414,DB00120,L-Phenylalanine
,2404503,time to 90% emptying,3. In the presence of levodopa the time to 90% emptying was prolonged from 32 +/- 24 min to 81 +/- 20 min (P less than 0.01).,The influence of levodopa on gastric emptying in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2404503/),min,81,42415,DB00120,L-Phenylalanine
,1811168,Tmax,"The mean Tmax value of levodopa in plasma and muscle was 0.16 h and 1.0 h, respectively.",In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811168/),h,0.16,44183,DB00120,L-Phenylalanine
,1811168,Tmax,"The mean Tmax value of levodopa in plasma and muscle was 0.16 h and 1.0 h, respectively.",In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1811168/),h,1.0,44184,DB00120,L-Phenylalanine
,30502553,flow rate,"Chromatographic separation was performed on Ace Phenyl column (150 × 4.6 mm, 5 μm), using a mixture of buffer (2 mM ammonium acetate in 0.01% formic acid), acetonitrile and methanol (20:70:10, v/v/v) as mobile phase at a flow rate of 0.8 mL/min.",High sensitive LC-MS/MS method for estimation of eluxadoline in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30502553/),[ml] / [min],0.8,44477,DB00120,L-Phenylalanine
,30502553,run time,The run time of analyte was 4.0 min.,High sensitive LC-MS/MS method for estimation of eluxadoline in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30502553/),min,4.0,44478,DB00120,L-Phenylalanine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,2.58,44913,DB00120,L-Phenylalanine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,0.94,44914,DB00120,L-Phenylalanine
,11563410,plasma t 1/2,Nateglinide was rapidly eliminated with plasma t 1/2 = 1.4 hours.,The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563410/),h,1.4,45558,DB00120,L-Phenylalanine
,11563410,plasma renal clearance,"Its plasma renal clearance, 20.7 ml/min, appears to be due mostly to active tubular secretion.",The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563410/),[ml] / [min],20.7,45559,DB00120,L-Phenylalanine
,2360790,distribution,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,8.9,45941,DB00120,L-Phenylalanine
,2360790,distribution,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,4.9,45942,DB00120,L-Phenylalanine
,2360790,elimination half-lives,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,49.2,45943,DB00120,L-Phenylalanine
,2360790,elimination half-lives,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,4.9,45944,DB00120,L-Phenylalanine
,2360790,elimination half-lives,"Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively).",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,33.2,45945,DB00120,L-Phenylalanine
,2360790,elimination half-life,"In contrast to cisternal CSF, the disappearance of L-dopa from lumbar CSF fits an open, one-compartment model with an elimination half-life of 100 minutes.",L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360790/),min,100,45946,DB00120,L-Phenylalanine
,10656432,MTD,The MTD was 30 mg/m2.,A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10656432/),[mg] / [m2],30,46670,DB00120,L-Phenylalanine
,10656432,MTD,"In conclusion, melphalan MTD was determined to be 30 mg/m2 when administered as a 24-h infusion.",A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10656432/),[mg] / [m2],30,46671,DB00120,L-Phenylalanine
,9520073,Cmax,"The pharmacokinetics of levodopa and 3-OMD after one intact or two halved tablets were very similar with average Cmax and tmax 1.9 mg x l(-1) and 1.2 h, respectively.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],1.9,47997,DB00120,L-Phenylalanine
,9520073,tmax,"The pharmacokinetics of levodopa and 3-OMD after one intact or two halved tablets were very similar with average Cmax and tmax 1.9 mg x l(-1) and 1.2 h, respectively.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],1.9,47998,DB00120,L-Phenylalanine
,9520073,tmax,"The pharmacokinetics of levodopa and 3-OMD after one intact or two halved tablets were very similar with average Cmax and tmax 1.9 mg x l(-1) and 1.2 h, respectively.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),h,1.2,47999,DB00120,L-Phenylalanine
,9520073,Cmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],2.1,48000,DB00120,L-Phenylalanine
,9520073,Cmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),[mg] / [l],1.5,48001,DB00120,L-Phenylalanine
,9520073,tmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),h,1.3,48002,DB00120,L-Phenylalanine
,9520073,tmax,"Cmax and tmax were on average 2.1 mg x l(-1) and 1.3 h, respectively, in the fed condition and 1.5 mg x l(-1) and 2.5 h in the fasted condition.","Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9520073/),h,2.5,48003,DB00120,L-Phenylalanine
,8175404,tumor:blood boron concentration ratio,The results for the metastatic melanoma patients are encouraging with an average tumor:blood boron concentration ratio and standard deviation of about 4.4 +/- 3.2 and a maximum value of 10 for the cerebral metastasis.,The pharmacokinetics of p-Boronophenylalanine. fructose in human patients with glioma and metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175404/),,4.4,49075,DB00120,L-Phenylalanine
,8175404,maximum,The results for the metastatic melanoma patients are encouraging with an average tumor:blood boron concentration ratio and standard deviation of about 4.4 +/- 3.2 and a maximum value of 10 for the cerebral metastasis.,The pharmacokinetics of p-Boronophenylalanine. fructose in human patients with glioma and metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175404/),,10,49076,DB00120,L-Phenylalanine
,8175404,tumor:blood ratio,The glioma patients involved high grade glioma for which the tumor:blood ratio was 2.2 +/- 1.2.,The pharmacokinetics of p-Boronophenylalanine. fructose in human patients with glioma and metastatic melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175404/),,2.2,49077,DB00120,L-Phenylalanine
,26504386,critical micelle concentration,"This copolymer was determined to have a fairly low critical micelle concentration (2.56×10(-3) mg/mL) and passive targeting potential to tumor tissue, and thus was applied to develop a polymeric micellar formulation of DMC for the first time.","Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504386/),[mg] / [ml],2.56×10(-3),49664,DB00120,L-Phenylalanine
,26504386,polydispersity index,"The DMC-loaded micelles prepared by thin-film hydration method had typical shell-core structure, with an average particle size of 17.9±0.4 nm and a polydispersity index of 0.045±0.011.","Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504386/),,0.045,49665,DB00120,L-Phenylalanine
,26504386,drug loading capacity,"The drug loading capacity and entrapment efficiency were 9.94%±0.15% and 97.22%±0.18%, respectively, indicating a high-affinity interaction between DMC and the copolymer.","Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504386/),%,9.94,49666,DB00120,L-Phenylalanine
,26504386,entrapment efficiency,"The drug loading capacity and entrapment efficiency were 9.94%±0.15% and 97.22%±0.18%, respectively, indicating a high-affinity interaction between DMC and the copolymer.","Preparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504386/),%,97.22,49667,DB00120,L-Phenylalanine
,28810925,perfusion blood flow rate,"Tumor exposure to drug using these two methods did not statistically differ and both methods, therefore, can be adopted interchangeably, utilizing a perfusion blood flow rate of approximately 120 ml/min.",Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810925/),[ml] / [min],120,50104,DB00120,L-Phenylalanine
,15548480,onset of effect,"Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations.",Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548480/),min,34.6,53141,DB00120,L-Phenylalanine
,15548480,onset of effect,"Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations.",Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15548480/),min,68.5,53142,DB00120,L-Phenylalanine
,641809,Recovery,Recovery of 1 microgram added to 1 ml of plasma at 23 degrees was 94% but was greatly reduced at higher temperature.,High-pressure liquid chromatographic analysis of melphalan in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/641809/),%,94,53724,DB00120,L-Phenylalanine
,28089878,maximum alemtuzumab concentration,"The median maximum alemtuzumab concentration was 2.39 µg/mL (interquartile range, 1.98 to 2.92).",Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089878/),[μg] / [ml],2.39,54118,DB00120,L-Phenylalanine
,28089878,terminal half-life,"The median terminal half-life was 5.2 days (interquartile range, 2.7 to 7.8).",Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28089878/),d,5.2,54119,DB00120,L-Phenylalanine
,12476274,clearance,"A significantly (P < 0.005) higher clearance was observed in children after the first and the last dose (3.61 and 3.79 ml/min/kg, respectively) compared to adults (2.40 and 2.33 ml/min/kg, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),[ml] / [kg·min],3.61,54701,DB00120,L-Phenylalanine
,12476274,clearance,"A significantly (P < 0.005) higher clearance was observed in children after the first and the last dose (3.61 and 3.79 ml/min/kg, respectively) compared to adults (2.40 and 2.33 ml/min/kg, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),[ml] / [kg·min],3.79,54702,DB00120,L-Phenylalanine
,12476274,clearance,"A significantly (P < 0.005) higher clearance was observed in children after the first and the last dose (3.61 and 3.79 ml/min/kg, respectively) compared to adults (2.40 and 2.33 ml/min/kg, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),[ml] / [kg·min],2.40,54703,DB00120,L-Phenylalanine
,12476274,clearance,"A significantly (P < 0.005) higher clearance was observed in children after the first and the last dose (3.61 and 3.79 ml/min/kg, respectively) compared to adults (2.40 and 2.33 ml/min/kg, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),[ml] / [kg·min],2.33,54704,DB00120,L-Phenylalanine
,12476274,elimination half-lives,"The elimination half-lives after the first and the last dose were significantly (P < 0.005) shorter in children (2.59 and 2.72 h, respectively) compared to adults (3.35 and 3.61 h, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),h,2.59,54705,DB00120,L-Phenylalanine
,12476274,elimination half-lives,"The elimination half-lives after the first and the last dose were significantly (P < 0.005) shorter in children (2.59 and 2.72 h, respectively) compared to adults (3.35 and 3.61 h, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),h,2.72,54706,DB00120,L-Phenylalanine
,12476274,elimination half-lives,"The elimination half-lives after the first and the last dose were significantly (P < 0.005) shorter in children (2.59 and 2.72 h, respectively) compared to adults (3.35 and 3.61 h, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),h,3.35,54707,DB00120,L-Phenylalanine
,12476274,elimination half-lives,"The elimination half-lives after the first and the last dose were significantly (P < 0.005) shorter in children (2.59 and 2.72 h, respectively) compared to adults (3.35 and 3.61 h, respectively).",A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12476274/),h,3.61,54708,DB00120,L-Phenylalanine
,9572915,bioavailability,"Thus, for PEG in rat, bioavailability decreased sharply from 79 to around 2% with increasing MM between 282 and 591 Da, and then tapered to around 1. 5% up to 1295 Da.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,79,55536,DB00120,L-Phenylalanine
,9572915,bioavailability,"Thus, for PEG in rat, bioavailability decreased sharply from 79 to around 2% with increasing MM between 282 and 591 Da, and then tapered to around 1. 5% up to 1295 Da.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,2,55537,DB00120,L-Phenylalanine
,9572915,bioavailability,"Thus, for PEG in rat, bioavailability decreased sharply from 79 to around 2% with increasing MM between 282 and 591 Da, and then tapered to around 1. 5% up to 1295 Da.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,1,55538,DB00120,L-Phenylalanine
,9572915,bioavailability,"Whereas in dog, bioavailability remained around 100% for oligomers up to 600 Da and then decreased quite sharply with increasing MM, tending to plateau around 13% beyond 900 Da.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,100,55539,DB00120,L-Phenylalanine
,9572915,bioavailability,"Whereas in dog, bioavailability remained around 100% for oligomers up to 600 Da and then decreased quite sharply with increasing MM, tending to plateau around 13% beyond 900 Da.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,13,55540,DB00120,L-Phenylalanine
,9572915,bioavailability,"Likewise, for the d-peptides in rat, bioavailability decreased from 30 to 1% with increasing MM between 236 and 406 Da, whereas in dog it was 100%, declining to 16% over the same molecular range.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,30,55541,DB00120,L-Phenylalanine
,9572915,bioavailability,"Likewise, for the d-peptides in rat, bioavailability decreased from 30 to 1% with increasing MM between 236 and 406 Da, whereas in dog it was 100%, declining to 16% over the same molecular range.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,1,55542,DB00120,L-Phenylalanine
,9572915,bioavailability,"Likewise, for the d-peptides in rat, bioavailability decreased from 30 to 1% with increasing MM between 236 and 406 Da, whereas in dog it was 100%, declining to 16% over the same molecular range.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,100,55543,DB00120,L-Phenylalanine
,9572915,bioavailability,"Likewise, for the d-peptides in rat, bioavailability decreased from 30 to 1% with increasing MM between 236 and 406 Da, whereas in dog it was 100%, declining to 16% over the same molecular range.",Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572915/),%,16,55544,DB00120,L-Phenylalanine
,3966973,peak concentrations,With or without heat peak concentrations were achieved by 20 min and were 3 to 4 micrograms ml-1 in plasma and 1-3 micrograms g-1 in tumour.,The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3966973/),[μg] / [ml],3 to 4,56753,DB00120,L-Phenylalanine
,3966973,peak concentrations,With or without heat peak concentrations were achieved by 20 min and were 3 to 4 micrograms ml-1 in plasma and 1-3 micrograms g-1 in tumour.,The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3966973/),[μg] / [g],1-3,56754,DB00120,L-Phenylalanine
,3966973,apparent plasma elimination half-life (t1/2),The apparent plasma elimination half-life (t1/2) was 17.5-25 min in unheated and 24-44 min in heated animals.,The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3966973/),min,17.5-25,56755,DB00120,L-Phenylalanine
,3966973,apparent plasma elimination half-life (t1/2),The apparent plasma elimination half-life (t1/2) was 17.5-25 min in unheated and 24-44 min in heated animals.,The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3966973/),min,24-44,56756,DB00120,L-Phenylalanine
,8138904,maximum concentration (Cmax),"The mean maximum concentration (Cmax) for L-dopa in plasma was 173.10 +/- 9.85 ng/mL, whereas in skeletal muscle extracellular fluid, it was 14.56 +/- 2.27 ng/mL.",Simultaneous in vivo microdialysis in plasma and skeletal muscle: a study of the pharmacokinetic properties of levodopa by noncompartmental analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138904/),[ng] / [ml],173.10,56813,DB00120,L-Phenylalanine
,8138904,maximum concentration (Cmax),"The mean maximum concentration (Cmax) for L-dopa in plasma was 173.10 +/- 9.85 ng/mL, whereas in skeletal muscle extracellular fluid, it was 14.56 +/- 2.27 ng/mL.",Simultaneous in vivo microdialysis in plasma and skeletal muscle: a study of the pharmacokinetic properties of levodopa by noncompartmental analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8138904/),[ng] / [ml],14.56,56814,DB00120,L-Phenylalanine
,12464717,maximum plasma concentration (C(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[mg] / [l],1.99,57497,DB00120,L-Phenylalanine
,12464717,maximum plasma concentration (C(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[mg] / [l],0.82,57498,DB00120,L-Phenylalanine
,12464717,time to reach maximum concentration (t(max),"The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,0.7,57499,DB00120,L-Phenylalanine
,12464717,area under the plasma concentration-time curve (AUC(0- infinity ),2.6 h) and area under the plasma concentration-time curve (AUC(0- infinity ) 4.52 vs. 3.18 mg x h x l-1).,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[h·mg] / [l],4.52,57500,DB00120,L-Phenylalanine
,12464717,area under the plasma concentration-time curve (AUC(0- infinity ),2.6 h) and area under the plasma concentration-time curve (AUC(0- infinity ) 4.52 vs. 3.18 mg x h x l-1).,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),[h·mg] / [l],3.18,57501,DB00120,L-Phenylalanine
,12464717,C(max),The respective values after multiple doses (day 8) were: C(max) 1.98 vs.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.98,57502,DB00120,L-Phenylalanine
,12464717,t(max),"0.93 mg x l-1, t(max) 0.7 vs.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,0.7,57503,DB00120,L-Phenylalanine
,12464717,AUC(0-infinity ),2.3 h and AUC(0-infinity ) 4.84 vs.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,4.84,57504,DB00120,L-Phenylalanine
,12464717,relative bioavailability,The relative bioavailability (Madopar DR vs. Madopar HBS) was 1.73 on day 1 and 1.32 on day 8.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.73,57505,DB00120,L-Phenylalanine
,12464717,relative bioavailability,The relative bioavailability (Madopar DR vs. Madopar HBS) was 1.73 on day 1 and 1.32 on day 8.,Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12464717/),,1.32,57506,DB00120,L-Phenylalanine
,32554330,Cmax,"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),[ng] / [ml],9.0,58534,DB00120,L-Phenylalanine
,32554330,Tmax,"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),min,41.4,58535,DB00120,L-Phenylalanine
,32554330,area under the blood concentration-time curve up to 4 h (AUC4hr),"The Cmax of levodopa was 9.0 ± 4.0 ng/mL, Tmax was 41.4 ± 40.2 min, and area under the blood concentration-time curve up to 4 h (AUC4hr) was 12.3 ± 3.7 ng/mL*4hr.","Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32554330/),[ng] / [4hr·ml],12.3,58536,DB00120,L-Phenylalanine
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],2.9,59538,DB00120,L-Phenylalanine
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],17.1,59539,DB00120,L-Phenylalanine
,23229334,C(avg),"Mean (SD) C(avg) (μg/mL) were 2.9 (0.84) for levodopa, 17.1 (4.99) for 3-OMD, and 0.22 (0.08) for carbidopa.","Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23229334/),[μg] / [ml],0.22,59540,DB00120,L-Phenylalanine
,2233283,peak plasma concentration (Cmax,"For plasma phenylalanine following capsule ingestion, there was a smaller peak plasma concentration (Cmax; 103.3 v 126.6 mumol/L), a longer time to peak concentration (tmax; 108.6 v 36.6 minutes), but no significant difference in the area under the plasma concentration-time curve (AUC) (7,656 v 7,200 mumol.min/L) when compared with solution ingestion.",Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),[μM] / [l],103.3,60272,DB00120,L-Phenylalanine
,2233283,peak plasma concentration (Cmax,"For plasma phenylalanine following capsule ingestion, there was a smaller peak plasma concentration (Cmax; 103.3 v 126.6 mumol/L), a longer time to peak concentration (tmax; 108.6 v 36.6 minutes), but no significant difference in the area under the plasma concentration-time curve (AUC) (7,656 v 7,200 mumol.min/L) when compared with solution ingestion.",Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),[μM] / [l],126.6,60273,DB00120,L-Phenylalanine
,2233283,time to peak concentration (tmax,"For plasma phenylalanine following capsule ingestion, there was a smaller peak plasma concentration (Cmax; 103.3 v 126.6 mumol/L), a longer time to peak concentration (tmax; 108.6 v 36.6 minutes), but no significant difference in the area under the plasma concentration-time curve (AUC) (7,656 v 7,200 mumol.min/L) when compared with solution ingestion.",Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),min,108.6,60274,DB00120,L-Phenylalanine
,2233283,time to peak concentration (tmax,"For plasma phenylalanine following capsule ingestion, there was a smaller peak plasma concentration (Cmax; 103.3 v 126.6 mumol/L), a longer time to peak concentration (tmax; 108.6 v 36.6 minutes), but no significant difference in the area under the plasma concentration-time curve (AUC) (7,656 v 7,200 mumol.min/L) when compared with solution ingestion.",Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),min,36.6,60275,DB00120,L-Phenylalanine
,2233283,area under the plasma concentration-time curve (AUC),"For plasma phenylalanine following capsule ingestion, there was a smaller peak plasma concentration (Cmax; 103.3 v 126.6 mumol/L), a longer time to peak concentration (tmax; 108.6 v 36.6 minutes), but no significant difference in the area under the plasma concentration-time curve (AUC) (7,656 v 7,200 mumol.min/L) when compared with solution ingestion.",Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),[min·μM] / [l],"7,656",60276,DB00120,L-Phenylalanine
,2233283,area under the plasma concentration-time curve (AUC),"For plasma phenylalanine following capsule ingestion, there was a smaller peak plasma concentration (Cmax; 103.3 v 126.6 mumol/L), a longer time to peak concentration (tmax; 108.6 v 36.6 minutes), but no significant difference in the area under the plasma concentration-time curve (AUC) (7,656 v 7,200 mumol.min/L) when compared with solution ingestion.",Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),[min·μM] / [l],"7,200",60277,DB00120,L-Phenylalanine
,2233283,maximum plasma Phe/LNAA ratio,The maximum plasma Phe/LNAA ratio was smaller (0.16 v 0.19) with capsules.,Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),,0.16,60278,DB00120,L-Phenylalanine
,2233283,maximum plasma Phe/LNAA ratio,The maximum plasma Phe/LNAA ratio was smaller (0.16 v 0.19) with capsules.,Bioavailability of phenylalanine and aspartate from aspartame (20 mg/kg) in capsules and solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2233283/),,0.19,60279,DB00120,L-Phenylalanine
,34366380,steady-state exposure,Foslevodopa/foscarbidopa infusion provides stable LD and CD exposures compared to oral LD/CD dosing with the average steady-state exposure ranging from 747-4660 ng/mL for the different groups.,Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34366380/),[ng] / [ml],747-4660,60341,DB00120,L-Phenylalanine
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,212,60621,DB00120,L-Phenylalanine
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,166,60622,DB00120,L-Phenylalanine
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,227,60623,DB00120,L-Phenylalanine
,21856105,m/z,"Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),,181,60624,DB00120,L-Phenylalanine
higher,21856105,recovery rates,"The method shown to be specific, precise, accurate and provided recovery rates higher than 85% for all analytes.",Simultaneous quantitation of levodopa and 3-O-methyldopa in human plasma by HPLC-ESI-MS/MS: application for a pharmacokinetic study with a levodopa/benserazide formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21856105/),%,85,60625,DB00120,L-Phenylalanine
,12368378,half-life,"166Ho with beta-emission (half-life, 26.8 h; beta-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%]; gamma-photons, 80.6 keV [6.6%] and 1.38 MeV [0.9%]) was complexed to DOTMP, a macrocyclic tetraphosphonate.","High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12368378/),h,26.8,60650,DB00120,L-Phenylalanine
,12368378,beta-particle energies,"166Ho with beta-emission (half-life, 26.8 h; beta-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%]; gamma-photons, 80.6 keV [6.6%] and 1.38 MeV [0.9%]) was complexed to DOTMP, a macrocyclic tetraphosphonate.","High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12368378/),Mev,1.85,60651,DB00120,L-Phenylalanine
,12368378,beta-particle energies,"166Ho with beta-emission (half-life, 26.8 h; beta-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%]; gamma-photons, 80.6 keV [6.6%] and 1.38 MeV [0.9%]) was complexed to DOTMP, a macrocyclic tetraphosphonate.","High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12368378/),Me,1.77,60652,DB00120,L-Phenylalanine
,12368378,beta-particle energies,"166Ho with beta-emission (half-life, 26.8 h; beta-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%]; gamma-photons, 80.6 keV [6.6%] and 1.38 MeV [0.9%]) was complexed to DOTMP, a macrocyclic tetraphosphonate.","High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12368378/),Mev,1.38,60653,DB00120,L-Phenylalanine
,26879446,AUC,"Melphalan AUC ranged from 4.9 to 24.6 mg l(-1) h, median 12.84 mg l(-1) h.",High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26879446/),[h·mg] / [l],12.84,60867,DB00120,L-Phenylalanine
,16019958,oral bioavailability,"Results indicate extensive clearance of TR-14035 and low oral bioavailability, 17% and 13% in the rat and dog, respectively, at an oral dose of 10 mg/kg.","Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019958/),%,17,61399,DB00120,L-Phenylalanine
,16019958,oral bioavailability,"Results indicate extensive clearance of TR-14035 and low oral bioavailability, 17% and 13% in the rat and dog, respectively, at an oral dose of 10 mg/kg.","Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019958/),%,13,61400,DB00120,L-Phenylalanine
,16485914,elimination half-life (t(1/2)),The elimination half-life (t(1/2)) of levodopa from plasma (in combination with a decarboxylase inhibitor) of about 1.5 hours becomes more influential as the disease progresses.,Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485914/),h,1.5,61864,DB00120,L-Phenylalanine
,8722343,clearance rate,The mean VP-16 clearance rate was 17.3 ml/min/m2 with continuous infusion.,Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[ml] / [m2·min],17.3,62274,DB00120,L-Phenylalanine
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],24.2,62275,DB00120,L-Phenylalanine
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],28.3,62276,DB00120,L-Phenylalanine
,2452031,half-life,Degradation of melphalan proceeded via monohydroxy-melphalan (MOH) to dihydroxymelphalan [M(OH)2] with a half-life of 66 min for melphalan and 58 min for MOH.,Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452031/),min,66,62577,DB00120,L-Phenylalanine
,2452031,half-life,Degradation of melphalan proceeded via monohydroxy-melphalan (MOH) to dihydroxymelphalan [M(OH)2] with a half-life of 66 min for melphalan and 58 min for MOH.,Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452031/),min,58,62578,DB00120,L-Phenylalanine
,10704270,elimination rate constant,"Peak concentrations in arterial blood of methyldopa were similar in both groups of rats but the elimination rate constant was 0.31+/-0.09 h(-1)for sham rats (n =6) and 1.28+/-0.31 h(-1)for SAD rats (n =6, P<0.05).",Study of the evolution of blood and striatal levels of methyldopa: a microdialysis study in sinaortic denervated rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704270/),1/[h],0.31,62666,DB00120,L-Phenylalanine
,10704270,elimination rate constant,"Peak concentrations in arterial blood of methyldopa were similar in both groups of rats but the elimination rate constant was 0.31+/-0.09 h(-1)for sham rats (n =6) and 1.28+/-0.31 h(-1)for SAD rats (n =6, P<0.05).",Study of the evolution of blood and striatal levels of methyldopa: a microdialysis study in sinaortic denervated rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10704270/),1/[h],1.28,62667,DB00120,L-Phenylalanine
,11260663,half-lives,"The (10)B concentration profile in blood exhibits a characteristic rise during the infusion to a peak of approximately 32 microg/g (for infusion of 350 mg/kg over 90 min) followed by a biphasic exponential clearance profile with half-lives of 0.34 +/- 0.12 and 9.0 +/- 2.7 h, due to redistribution and primarily renal elimination, respectively.",A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260663/),h,0.34,63106,DB00120,L-Phenylalanine
,11260663,half-lives,"The (10)B concentration profile in blood exhibits a characteristic rise during the infusion to a peak of approximately 32 microg/g (for infusion of 350 mg/kg over 90 min) followed by a biphasic exponential clearance profile with half-lives of 0.34 +/- 0.12 and 9.0 +/- 2.7 h, due to redistribution and primarily renal elimination, respectively.",A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260663/),h,9.0,63107,DB00120,L-Phenylalanine
,11260663,k(1),"The model rate constants k(1), k(2) and k(3) are 0.0227 +/- 0.0064, 0.0099 +/- 0.0027 and 0.0052 +/- 0.0016 min(-1), respectively, and the central compartment volume of distribution, V(1), is 0.235 +/- 0.042 kg/kg.",A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260663/),1/[min],0.0227,63108,DB00120,L-Phenylalanine
,11260663,k(2),"The model rate constants k(1), k(2) and k(3) are 0.0227 +/- 0.0064, 0.0099 +/- 0.0027 and 0.0052 +/- 0.0016 min(-1), respectively, and the central compartment volume of distribution, V(1), is 0.235 +/- 0.042 kg/kg.",A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260663/),1/[min],0.0099,63109,DB00120,L-Phenylalanine
,11260663,k(3),"The model rate constants k(1), k(2) and k(3) are 0.0227 +/- 0.0064, 0.0099 +/- 0.0027 and 0.0052 +/- 0.0016 min(-1), respectively, and the central compartment volume of distribution, V(1), is 0.235 +/- 0.042 kg/kg.",A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260663/),1/[min],0.0052,63110,DB00120,L-Phenylalanine
,11260663,"central compartment volume of distribution, V(1)","The model rate constants k(1), k(2) and k(3) are 0.0227 +/- 0.0064, 0.0099 +/- 0.0027 and 0.0052 +/- 0.0016 min(-1), respectively, and the central compartment volume of distribution, V(1), is 0.235 +/- 0.042 kg/kg.",A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11260663/),[kg] / [kg],0.235,63111,DB00120,L-Phenylalanine
,6889512,half-lives,Patients receiving 8-28.5 mg melphalan i.v. showed alpha and beta plasma decays with half-lives of 7.7 +/- 3.3 (mean +/- S.D.) and 83 +/- 14 min respectively.,Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),min,7.7,63116,DB00120,L-Phenylalanine
,6889512,half-lives,Patients receiving 8-28.5 mg melphalan i.v. showed alpha and beta plasma decays with half-lives of 7.7 +/- 3.3 (mean +/- S.D.) and 83 +/- 14 min respectively.,Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),min,83,63117,DB00120,L-Phenylalanine
,6889512,apparent volume of the central compartment,"The apparent volume of the central compartment was 12.8 +/- 4.3 1, and the total volume of distribution was 0.62 +/- 0.21 l/kg.",Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),1,12.8,63118,DB00120,L-Phenylalanine
,6889512,total volume of distribution,"The apparent volume of the central compartment was 12.8 +/- 4.3 1, and the total volume of distribution was 0.62 +/- 0.21 l/kg.",Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),[l] / [kg],0.62,63119,DB00120,L-Phenylalanine
,6889512,half-life of the absorption phase,The half-life of the absorption phase varied from 2.1 to 62.1 min (22.8 +/- 18.1 min) with delays (before absorption started) of 0-113 min.,Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),min,2.1 to 62.1,63120,DB00120,L-Phenylalanine
,6889512,half-life of the absorption phase,The half-life of the absorption phase varied from 2.1 to 62.1 min (22.8 +/- 18.1 min) with delays (before absorption started) of 0-113 min.,Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),min,22.8,63121,DB00120,L-Phenylalanine
,6889512,fraction of dose absorbed,"The fraction of dose absorbed varied from 0.32 to 1.03 (0.72 +/- 0.23), and the half-life of the beta phase was 92 +/- 27 min.",Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),,0.32 to 1.03,63122,DB00120,L-Phenylalanine
,6889512,fraction of dose absorbed,"The fraction of dose absorbed varied from 0.32 to 1.03 (0.72 +/- 0.23), and the half-life of the beta phase was 92 +/- 27 min.",Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),,0.72,63123,DB00120,L-Phenylalanine
,6889512,half-life of the beta phase,"The fraction of dose absorbed varied from 0.32 to 1.03 (0.72 +/- 0.23), and the half-life of the beta phase was 92 +/- 27 min.",Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889512/),min,92,63124,DB00120,L-Phenylalanine
,11751398,boron concentration,Mean tumor boron concentration was 36.9 +/- 17.5 ppm at 3.5 h and the mean boron ratios were 2.4:1 for tumor:normal pouch tissue and 3.2:1 for tumor:blood.,The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: selective delivery of boron by boronophenylalanine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751398/),ppm,36.9,63262,DB00120,L-Phenylalanine
,11751398,boron ratios,Mean tumor boron concentration was 36.9 +/- 17.5 ppm at 3.5 h and the mean boron ratios were 2.4:1 for tumor:normal pouch tissue and 3.2:1 for tumor:blood.,The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: selective delivery of boron by boronophenylalanine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751398/),,2.4,63263,DB00120,L-Phenylalanine
,11751398,boron ratios,Mean tumor boron concentration was 36.9 +/- 17.5 ppm at 3.5 h and the mean boron ratios were 2.4:1 for tumor:normal pouch tissue and 3.2:1 for tumor:blood.,The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: selective delivery of boron by boronophenylalanine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751398/),,3.2,63264,DB00120,L-Phenylalanine
,6678879,terminal half-life (t 1/2 beta),Plasma levels of melphalan declined in a biexponential fashion with a mean terminal half-life (t 1/2 beta) of 61 min (range 40.3-132.8 min).,Pharmacokinetics of high dose melphalan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678879/),min,61,64431,DB00120,L-Phenylalanine
,6678879,peak concentrations,Estimated peak concentrations ranged from 5.45 to 16.57 mcg/ml.,Pharmacokinetics of high dose melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678879/),[mcg] / [ml],5.45 to 16.57,64432,DB00120,L-Phenylalanine
,6678879,volume of distribution at steady state (Vdss),"The average volume of distribution at steady state (Vdss) and clearance were 0.479 +/- 0.164 l/kg and 6.73 +/- 1.60 ml/min/kg, respectively.",Pharmacokinetics of high dose melphalan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678879/),[l] / [kg],0.479,64433,DB00120,L-Phenylalanine
,6678879,clearance,"The average volume of distribution at steady state (Vdss) and clearance were 0.479 +/- 0.164 l/kg and 6.73 +/- 1.60 ml/min/kg, respectively.",Pharmacokinetics of high dose melphalan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678879/),[ml] / [kg·min],6.73,64434,DB00120,L-Phenylalanine
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],27.9,64634,DB00120,L-Phenylalanine
,33093598,apparent clearances (CL/F),"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·h·kg],17.5,64635,DB00120,L-Phenylalanine
,33093598,apparent volume of distribution,"The final model was a one compartment model with a high fixed absorption rate constant, and a first order elimination, with estimated apparent clearances (CL/F), of 27.9 L/h/70 kg for LCIG versus 17.5 L/h/70 kg for LECIG, and apparent volume of distribution of 74.4 L/70 kg.",Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33093598/),[l] / [70·kg],74.4,64636,DB00120,L-Phenylalanine
,8780091,time of onset in,"The time of onset in clinical benefit was significantly earlier with Std-L (47 minutes, range 15 to 75 minutes) as the first dose as compared with L-CR (58 minutes, range 30 to 105 minutes).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,47,64766,DB00120,L-Phenylalanine
,8780091,time of onset in,"The time of onset in clinical benefit was significantly earlier with Std-L (47 minutes, range 15 to 75 minutes) as the first dose as compared with L-CR (58 minutes, range 30 to 105 minutes).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,58,64767,DB00120,L-Phenylalanine
,8780091,Tmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,36,64768,DB00120,L-Phenylalanine
,8780091,Cmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),[μg] / [ml],"1,501",64769,DB00120,L-Phenylalanine
,8780091,Tmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),min,111,64770,DB00120,L-Phenylalanine
,8780091,Cmax,"Similarly, there was a significant difference in the peak plasma dopa levels (Cmax) and the time to reach peak plasma dopa levels (Tmax) with administration of Std-L (Tmax 36 minutes; Cmax 1,501 micrograms/ml) as compared with L-CR (Tmax 111 minutes, Cmax 1,260 micrograms/ml).",Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780091/),[μg] / [ml],"1,260",64771,DB00120,L-Phenylalanine
,30927450,run times,"Here we present the validation of the method for the quantitation of mithramycin SA-tryptophan (MTMSA-Trp) as well as the applicability of the methodology for assaying additional analogs, including MTM, mithramycin SK (MTMSK) and mithramycin SA-phenylalanine (MTMSA-Phe) with run times of 6 min.",Bioanalytical method for quantitative determination of mithramycin analogs in mouse plasma by HPLC-QTOF. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30927450/),min,6,65110,DB00120,L-Phenylalanine
,2668324,MCR,"The MCR for exogenous GIP was approximately 6 mL/kg.min; the decay after ceasing infusion was exponential with a t1/2 of about 18 min, and the resulting volume of distribution was about 140 mL/kg.","Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668324/),[ml] / [kg·min],6,65441,DB00120,L-Phenylalanine
,2668324,t1/2,"The MCR for exogenous GIP was approximately 6 mL/kg.min; the decay after ceasing infusion was exponential with a t1/2 of about 18 min, and the resulting volume of distribution was about 140 mL/kg.","Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668324/),min,18,65442,DB00120,L-Phenylalanine
,2668324,volume of distribution,"The MCR for exogenous GIP was approximately 6 mL/kg.min; the decay after ceasing infusion was exponential with a t1/2 of about 18 min, and the resulting volume of distribution was about 140 mL/kg.","Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668324/),[ml] / [kg],140,65443,DB00120,L-Phenylalanine
,2668324,Peak glucose concentrations,Peak glucose concentrations after oral glucose (7.6 +/- 0.6 mmol/L) were similar to mean plasma glucose values during clamp experiments (8.2 +/- 0.1 mmol/L; P = 0.124).,"Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668324/),[mM] / [l],7.6,65444,DB00120,L-Phenylalanine
,2668324,Peak glucose concentrations,Peak glucose concentrations after oral glucose (7.6 +/- 0.6 mmol/L) were similar to mean plasma glucose values during clamp experiments (8.2 +/- 0.1 mmol/L; P = 0.124).,"Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2668324/),[mM] / [l],8.2,65445,DB00120,L-Phenylalanine
,25869243,IC50,SAB inhibited the methylation of l-DOPA with an IC50 value of 2.08 μM in vitro.,Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869243/),μM,2.08,66282,DB00120,L-Phenylalanine
,24339234,total daily off time,The mean total daily off time was reduced from baseline by a mean (± standard error) of 2.7 hours (± 0.48 hours) for immediate-release carbidopa-levodopa and 3.0 hours (± 0.57 hours) for XP21279-carbidopa (P = 0.49).,Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24339234/),h,2.7,66635,DB00120,L-Phenylalanine
,24339234,total daily off time,The mean total daily off time was reduced from baseline by a mean (± standard error) of 2.7 hours (± 0.48 hours) for immediate-release carbidopa-levodopa and 3.0 hours (± 0.57 hours) for XP21279-carbidopa (P = 0.49).,Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24339234/),h,3.0,66636,DB00120,L-Phenylalanine
,26590007,IC50,"Further examination showed that MFLX was an uncompetitive inhibitor, with an IC50 value of 4.29 ± 1.29 mm.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),mm,4.29,66918,DB00120,L-Phenylalanine
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],171,66919,DB00120,L-Phenylalanine
,26590007,maximum plasma concentration (C(max)),"In an in vivo study in rats, the maximum plasma concentration (C(max)) of orally administered Phe-Ψ-Ala was significantly decreased in the presence of MFLX (171 ± 1 ng/ml) compared with that in its absence (244 ± 9 ng/ml).",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [ml],244,66920,DB00120,L-Phenylalanine
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],338,66921,DB00120,L-Phenylalanine
,26590007,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of orally administered Phe-Ψ-Ala in the presence of MFLX (338 ± 50 ng/ml · h) tended to decrease compared with that in its absence (399 ± 75 ng/ml · h).,Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),[ng] / [h·ml],399,66922,DB00120,L-Phenylalanine
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,41.7,66923,DB00120,L-Phenylalanine
,26590007,oral bioavailability,"The oral bioavailability of Phe-Ψ-Ala in the presence and absence of MFLX was 41.7 ± 6.2% and 49.2 ± 9.2%, respectively.",Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26590007/),%,49.2,66924,DB00120,L-Phenylalanine
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,1.76,67810,DB00120,L-Phenylalanine
,8133901,t 1/2 beta,The elimination half-life of L-dopa in the controls was higher in muscle (t 1/2 beta = 1.76 h) than in blood plasma (t 1/2 beta = 0.50 h).,The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8133901/),h,0.50,67811,DB00120,L-Phenylalanine
,498715,plasma terminal phase half-life (t1/2),Oral melphalan had a mean plasma terminal phase half-life (t1/2) of 90 +/- 17 min.,Oral melphalan kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/498715/),min,90,67885,DB00120,L-Phenylalanine
,498715,area under the plasma concentration:time curve (CXT),The mean area under the plasma concentration:time curve (CXT) was 53 +/- 33 micrograms . min/ml.,Oral melphalan kinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498715/),[min·μg] / [ml],53,67886,DB00120,L-Phenylalanine
,498715,Urinary excretion,Urinary excretion of oral melphalan averaged 10.9 +/- 4.9% during the first 24 hr.,Oral melphalan kinetics. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498715/),%,10.9,67887,DB00120,L-Phenylalanine
,498715,CXT ratio,The CXT ratio (oral:intravenous) for the 5 patients studied after both oral and intravenous melphalal (0.6 mg/kg) ranged between 0.25 and 0.89 and averaged 0.56.,Oral melphalan kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498715/),,0.25 and 0.89,67888,DB00120,L-Phenylalanine
,498715,CXT ratio,The CXT ratio (oral:intravenous) for the 5 patients studied after both oral and intravenous melphalal (0.6 mg/kg) ranged between 0.25 and 0.89 and averaged 0.56.,Oral melphalan kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498715/),,0.56,67889,DB00120,L-Phenylalanine
,498715,time at which,"After oral dosing in 14 fasting patients, the time at which melphalan first appeared in the plasma varied between 15 min and 6 hr.",Oral melphalan kinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498715/),min,15,67890,DB00120,L-Phenylalanine
,498715,time at which,"After oral dosing in 14 fasting patients, the time at which melphalan first appeared in the plasma varied between 15 min and 6 hr.",Oral melphalan kinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498715/),h,6,67891,DB00120,L-Phenylalanine
,9117089,Ki,"The Ki value was 4.34 +/- 0.04 x 10(7) M, and the displacement potency of A-4166 was between that of glibenclamide and tolbutamide, being similar to that of gliclazide.","Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117089/),M,4.34,68040,DB00120,L-Phenylalanine
,8474536,plasma half-life,"More than 150 min of COMT inhibition were required for endogenous MOPEG to disappear from plasma, since the plasma half-life of MOPEG was 54 min.","The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474536/),min,54,68127,DB00120,L-Phenylalanine
,8474536,plasma half-life,"The results concerning the effect of COMT inhibition on the plasma kinetics of infused DOPA and DOPEG were as follows: the plasma clearance of DOPA was not altered, whereas that of DOPEG fell by 41%; the plasma half-life of DOPA increased from 4.9 to 13.0 min and that of DOPEG from 4.8 to 31.0 min; there was an increase in the volume of distribution of DOPA (2 to 3-fold) and DOPEG (4 to 5-fold).","The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474536/),min,4.9 to 13.0,68128,DB00120,L-Phenylalanine
,8474536,plasma half-life,"The results concerning the effect of COMT inhibition on the plasma kinetics of infused DOPA and DOPEG were as follows: the plasma clearance of DOPA was not altered, whereas that of DOPEG fell by 41%; the plasma half-life of DOPA increased from 4.9 to 13.0 min and that of DOPEG from 4.8 to 31.0 min; there was an increase in the volume of distribution of DOPA (2 to 3-fold) and DOPEG (4 to 5-fold).","The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474536/),min,4.8 to 31.0,68129,DB00120,L-Phenylalanine
,2502388,Peak plasma L-phenylalanine concentrations,Peak plasma L-phenylalanine concentrations of approximately 2000 mumoles/l occurred 1-4 h after the highest dose of L-phenylalanine or aspartame.,"Lack of effect of aspartame or of L-phenylalanine on photically induced myoclonus in the baboon, Papio papio. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2502388/),[mumoles] / [l],2000,68548,DB00120,L-Phenylalanine
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],951,69384,DB00120,L-Phenylalanine
,9695725,C50,"The second was C50(carbidopa) = 951 ng/ml; C50(benserazide) = 1238 ng/ml, where C50 is the steady-state plasma concentration of levodopa eliciting half of maximum attainable effect, and carbidopa and benserazide are the dopa decarboxylase inhibitors given in the study.",Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695725/),[ng] / [ml],1238,69385,DB00120,L-Phenylalanine
,7735206,total clearance,The total clearance of exogenous L-dopa in plasma was 3.13(l/h)/kg.,Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735206/),[l] / [h)·kg],3.13,69856,DB00120,L-Phenylalanine
,7735206,production rate constant,The production rate constant of endogenous L-dopa in plasma was 6.59(mg/h)/kg.,Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. I. Pharmacokinetic analysis of L-dopa in rat plasma and striatum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735206/),[mg] / [h)·kg],6.59,69857,DB00120,L-Phenylalanine
,24490806,oral bioavailability,"Fexofenadine hydrochloride (FXD) is a slightly soluble, bitter-tasting, drug having an oral bioavailability of 35%.","Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),%,35,70023,DB00120,L-Phenylalanine
,24490806,T(max),The maximum plasma concentration is reached 2.6 h (T(max)) post-dose.,"Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),h,2.6,70024,DB00120,L-Phenylalanine
,24490806,f(2),Drug release profiles of F23 and the phenylalanine-containing Allegra(®) ODT were similar (f(2) = 96).,"Phenylalanine-free taste-masked orodispersible tablets of fexofenadine hydrochloride: development, in vitro evaluation and in vivo estimation of the drug pharmacokinetics in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24490806/),,96,70025,DB00120,L-Phenylalanine
,18778758,gastric residence time,"It was shown that the three formulations offered almost the same mean gastric residence time, which was about 240 min.",Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18778758/),min,240,70100,DB00120,L-Phenylalanine
,8739811,halflife,"Despite the long halflife of 3-O-methyltolcapone (39 h), only minor accumulation occurred due to suppression of its formation by tolcapone.",Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739811/),h,39,70334,DB00120,L-Phenylalanine
,18489992,Relapse rate,Relapse rate was 25% at 2 years.,Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18489992/),%,25,71153,DB00120,L-Phenylalanine
,22377973,first maximum time,"Compared with C-ER, both gastroretentive ER tablets significantly extended the first maximum time (6.0 vs 2.5 h; P < 0.025) and had smoother plasma concentration-time profiles while achieving a similar maximum plasma concentration and area under the curve.",Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),h,6.0,71779,DB00120,L-Phenylalanine
,22377973,first maximum time,"Compared with C-ER, both gastroretentive ER tablets significantly extended the first maximum time (6.0 vs 2.5 h; P < 0.025) and had smoother plasma concentration-time profiles while achieving a similar maximum plasma concentration and area under the curve.",Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),h,2.5,71780,DB00120,L-Phenylalanine
,22377973,peak/trough ratio,PK modeling predicts a steady-state levodopa peak/trough ratio of 4 for both IR/ER and ER formulations and a ratio of 21 for C-ER.,Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377973/),,4,71781,DB00120,L-Phenylalanine
,15039453,C(max),"Pulmonary administration of L-dopa (2 mg) to rats resulted in a rapid elevation of plasma levels (C(max) = 4.8 +/- 1.10 microg/ml at 2 min), whereas oral administration of L-dopa produced a much delayed and lower C(max) (1.8 +/- 0.40 microg/ml at 30 min).",A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039453/),[μg] / [ml],4.8,72290,DB00120,L-Phenylalanine
,15039453,C(max),"Pulmonary administration of L-dopa (2 mg) to rats resulted in a rapid elevation of plasma levels (C(max) = 4.8 +/- 1.10 microg/ml at 2 min), whereas oral administration of L-dopa produced a much delayed and lower C(max) (1.8 +/- 0.40 microg/ml at 30 min).",A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15039453/),[μg] / [ml],1.8,72291,DB00120,L-Phenylalanine
,3428307,bioavailability,"Although the bioavailability after oral dosing is reduced as compared with standard Madopar (60-70%), this difference seems to be due to incomplete absorption rather than altered disposition of the drug.",Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428307/),%,60-70,72523,DB00120,L-Phenylalanine
,3428307,bioavailability,"The presence or absence of food in the stomach has no effect on the absorption of L-dopa from Madopar HBS, but administration of antacids further reduces the bioavailability (45%).",Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428307/),%,45,72524,DB00120,L-Phenylalanine
,22036030,oral bioavailability,"The oral pharmacokinetic studies using (14)C-advantame showed that advantame undergoes rapid but incomplete absorption, with an oral bioavailability of total radioactivity in the range of 4-23%.","Pharmacokinetics and metabolism of N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-L-phenylalanine 1-methyl ester, monohydrate (advantame) in the rat, dog, and man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22036030/),%,4-23,73386,DB00120,L-Phenylalanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,85.8,73658,DB00120,L-Phenylalanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,80.0,73659,DB00120,L-Phenylalanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,66.4,73660,DB00120,L-Phenylalanine
,30865315,Renal excretion,"Renal excretion of unchanged solriamfetol over 48 hours was 85.8%, 80.0%, 66.4%, and 57.1% in normal, mild, moderate, and severe renal impairment groups, respectively; mean maximum concentration and time to maximum concentration did not vary substantially.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),%,57.1,73661,DB00120,L-Phenylalanine
>,30865315,half-life,"Geometric mean area under the plasma concentration-time curve from time zero to time of last quantifiable concentration increased 357% and 518% vs normal in ESRD with and without hemodialysis, respectively, with half-life >100 hours in both groups.",Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865315/),h,100,73662,DB00120,L-Phenylalanine
,16969695,K(m),"TR-14035 was taken up by rat and human hepatocytes by an apparently single saturable mechanism with K(m) of 6.7 and 2.1 microM, respectively, and taurocholate and digoxin reduced this uptake.","Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969695/),μM,6.7,74863,DB00120,L-Phenylalanine
,16969695,K(m),"TR-14035 was taken up by rat and human hepatocytes by an apparently single saturable mechanism with K(m) of 6.7 and 2.1 microM, respectively, and taurocholate and digoxin reduced this uptake.","Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969695/),μM,2.1,74864,DB00120,L-Phenylalanine
,16969695,K(m),"OATP1B1/OATP-C and OATP1B3/OATP8 expressed in oocytes mediated the TR-14035 uptake with K(m) of 7.5 and 5.3 microM, respectively.","Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969695/),μM,7.5,74865,DB00120,L-Phenylalanine
,16969695,K(m),"OATP1B1/OATP-C and OATP1B3/OATP8 expressed in oocytes mediated the TR-14035 uptake with K(m) of 7.5 and 5.3 microM, respectively.","Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969695/),μM,5.3,74866,DB00120,L-Phenylalanine
,10530956,IC90,"In this study, inhibitor 48 was the most potent [IC90 (CEM/HIV-1 IIIB) 27 nM] and showed good pharmacokinetics in rats.",Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530956/),nM,27,75128,DB00120,L-Phenylalanine
,9316818,constant rate,The rat hindlimbs were perfused with Krebs-Heinseleit buffer containing 4.7% bovine serum albumin (BSA) or 2.8% dextran 40 at a constant rate of 3.8 ml/min.,Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316818/),[ml] / [min],3.8,75166,DB00120,L-Phenylalanine
,9316818,half life (t1/2),The estimated half life (t1/2) for melphalan removal from skin and fat was 59 +/- 2 min for both BSA and dextran perfusates.,Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316818/),min,59,75167,DB00120,L-Phenylalanine
,9316818,t1/2,"However, the estimated t1/2 for melphalan removal from muscle was 79 and 96 min for BSA and dextran washout perfusates, respectively.",Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316818/),min,79,75168,DB00120,L-Phenylalanine
,9316818,t1/2,"However, the estimated t1/2 for melphalan removal from muscle was 79 and 96 min for BSA and dextran washout perfusates, respectively.",Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316818/),min,96,75169,DB00120,L-Phenylalanine
,2049250,AUC,"4. By contrast, the AUC for levodopa following the low protein meal (193.9 +/- 15.7 micrograms ml-1 min) was significantly lower compared with administration in the fasted state (216.5 +/- 26.1 micrograms ml-1 min).",The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049250/),[min·μg] / [ml],193.9,76030,DB00120,L-Phenylalanine
,2049250,AUC,"4. By contrast, the AUC for levodopa following the low protein meal (193.9 +/- 15.7 micrograms ml-1 min) was significantly lower compared with administration in the fasted state (216.5 +/- 26.1 micrograms ml-1 min).",The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049250/),[min·μg] / [ml],216.5,76031,DB00120,L-Phenylalanine
,29121571,flow rate,"The extracted samples were separated on Acquity BEH™ C18 column (100×2.1mm, 1.7μm) using mobile phase elution of acetonitrile: 20mM ammonium acetate (80:20, v/v) at a flow rate of 0.3mLmin-1.",High throughput μ-SPE based elution coupled with UPLC-MS/MS for determination of eluxadoline in plasma sample: Application in pharmacokinetic characterization of PLGA nanoparticle formulations in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29121571/),1/[mlmin],0.3,76257,DB00120,L-Phenylalanine
,8894500,Tmax,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),min,34,76953,DB00120,L-Phenylalanine
,8894500,Tmax,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),min,18,76954,DB00120,L-Phenylalanine
,8894500,T1/2,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),h,0.64,76955,DB00120,L-Phenylalanine
,8894500,T1/2,"When 1 mg of NN623 or 60 mg of A4166 was administered just before the meal, Tmax of NN623 and A4166 was 34 +/- 18 min and 18 +/- 6 min, while T1/2 was 0.64 +/- 0.12 h and 0.98 +/- 0.06 h, respectively.","Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894500/),h,0.98,76956,DB00120,L-Phenylalanine
,9483165,plasma elimination half-life,"It has an appropriate receptor affinity profile, with potent and long-lasting dopaminergic stimulatory effects in 6-hydroxydopamine-lesioned rats and in MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine)-lesioned primates; it has a consistent pharmacokinetic profile, with a very long mean plasma elimination half-life of 65 to 110 hours, and its absorption and excretion are unaffected by food, age or renal or hepatic disease; moreover, when given concomitantly, cabergoline does not influence levodopa pharmacokinetics.",Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483165/),h,65 to 110,77725,DB00120,L-Phenylalanine
,28101657,time to maximum improvement,"The mean time to maximum improvement in sum of six UPDRS items score was 78 min (±59) (n = 16), and the mean time to TRS score maximum effect was 54 min (±51) (n = 15).",Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,78,78650,DB00120,L-Phenylalanine
,28101657,time to TRS score maximum effect,"The mean time to maximum improvement in sum of six UPDRS items score was 78 min (±59) (n = 16), and the mean time to TRS score maximum effect was 54 min (±51) (n = 15).",Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,54,78651,DB00120,L-Phenylalanine
,28101657,time to onset of dyskinesia,Mean time to onset of dyskinesia was 41 min (±38) (n = 13).,Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28101657/),min,41,78652,DB00120,L-Phenylalanine
,2545349,t1/2 alpha,"The plasma disappearance of mitoxantrone fitted into a three-compartment model with a mean t1/2 alpha of 10 min, a mean t1/2 beta of 96 min, and a slow elimination phase of 172 h.",High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2545349/),min,10,79036,DB00120,L-Phenylalanine
,2545349,t1/2 beta,"The plasma disappearance of mitoxantrone fitted into a three-compartment model with a mean t1/2 alpha of 10 min, a mean t1/2 beta of 96 min, and a slow elimination phase of 172 h.",High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2545349/),min,96,79037,DB00120,L-Phenylalanine
,2545349,distribution volume,The mean distribution volume was 4294 +/- 3836 liters.,High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2545349/),l,4294,79038,DB00120,L-Phenylalanine
,12942590,Tmax,Tmax (time at which the maximal L-DOPA concentration was reached) were 69 +/- 12 min and 64 +/- 11 min for Sinemet and Grifoparkin respectively (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,69,79425,DB00120,L-Phenylalanine
,12942590,Tmax,Tmax (time at which the maximal L-DOPA concentration was reached) were 69 +/- 12 min and 64 +/- 11 min for Sinemet and Grifoparkin respectively (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,64,79426,DB00120,L-Phenylalanine
,12942590,Cmax (maximal L-DOPA concentration reached,Cmax (maximal L-DOPA concentration reached) was 3161 +/- 345 ng/ml for Sinemet and 3274 +/- 520 ng/ml for Grifoparkin (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[ng] / [ml],3161,79427,DB00120,L-Phenylalanine
,12942590,Cmax (maximal L-DOPA concentration reached,Cmax (maximal L-DOPA concentration reached) was 3161 +/- 345 ng/ml for Sinemet and 3274 +/- 520 ng/ml for Grifoparkin (NS).,[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[ng] / [ml],3274,79428,DB00120,L-Phenylalanine
,12942590,t1/2 (half life time),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,159,79429,DB00120,L-Phenylalanine
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[1] / [h],51.7,79430,DB00120,L-Phenylalanine
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),min,161,79431,DB00120,L-Phenylalanine
,12942590,CL (clearance),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [h],58.7,79432,DB00120,L-Phenylalanine
,12942590,volume of distribution (Vd),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [kg],3.6,79433,DB00120,L-Phenylalanine
,12942590,volume of distribution (Vd),"The t1/2 (half life time), CL (clearance) and volume of distribution (Vd) values calculated were 159 +/- 32 min, 51.7 +/- 5.1 1/h and 3.6 +/- 1.2 l/kg for Sinemet and 161 +/- 48 min, 58.7 +/- 8 l/h and 3.0 +/- 0.7 l/kg for Grifoparkin (NS).",[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942590/),[l] / [kg],3.0,79434,DB00120,L-Phenylalanine
,3006735,enhancement ratio (ER),"When given at this time, the nicotinamide had a dose-modifying effect on all L-PAM doses tested, giving rise to a mean enhancement ratio (ER) of 2.2.",Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006735/),,2.2,79627,DB00120,L-Phenylalanine
,3006735,half-life,"In addition the inhibitor also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 41 min to 143 min.",Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006735/),min,41,79628,DB00120,L-Phenylalanine
,3006735,half-life,"In addition the inhibitor also delayed the clearance of L-PAM from the plasma of C3H mice, such that the half-life of the chemotherapeutic agent was extended from 41 min to 143 min.",Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3006735/),min,143,79629,DB00120,L-Phenylalanine
,10606836,overall clearance,"The overall clearance of tolcapone could be estimated with good precision (approximately 4. 5-5 l h-1 ), and none of the investigated covariates (e.g. sex, age, body weight) had any clinically significant influence on this parameter.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),[l] / [h],4. 5-5,80316,DB00120,L-Phenylalanine
,10606836,volume of distribution,"The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),l,30,80317,DB00120,L-Phenylalanine
,10606836,half-life,"The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h.",Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10606836/),h,5-8,80318,DB00120,L-Phenylalanine
,12189539,plasma half-life,Pharmacokinetic parameters of melphalan were not significantly altered with its plasma half-life 1.5 h.,Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189539/),h,1.5,80474,DB00120,L-Phenylalanine
,11796347,highest measured concentration,"Systemic exposure to the metabolite was also low, with a highest measured concentration of 3.25 ng/ml.","Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11796347/),[ng] / [ml],3.25,82094,DB00120,L-Phenylalanine
,29345156,half-life,"It significantly decreases COMT activity, with half-life of COMT inhibition in human erythrocytes of 61.6 h and increases systemic exposure to L-Dopa.",Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29345156/),h,61.6,84649,DB00120,L-Phenylalanine
,9195565,flow rate,Rat hindlimbs were perfused with Krebs-Hen-seleit buffer containing 4.7% bovine serum albumin at 37 or 41.5 degrees C at a flow rate of 4 ml/min.,Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9195565/),[ml] / [min],4,86174,DB00120,L-Phenylalanine
,6717507,cardiac index,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[l] / [meter·min·square],1.8,87296,DB00120,L-Phenylalanine
,6717507,cardiac index,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[l] / [meter·min·square],2.4,87297,DB00120,L-Phenylalanine
,6717507,systemic vascular resistance,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[dyn·s] / [(cm)^5],1905,87298,DB00120,L-Phenylalanine
,6717507,systemic vascular resistance,"Peak hemodynamic responses occurred one hour after the ingestion of levodopa, with the mean (+/- S.E.M.) cardiac index increasing from 1.8 +/- 0.1 to 2.4 +/- 0.2 liters per minute per square meter of body-surface area (P less than 0.01) and systemic vascular resistance declining from 1905 +/- 112 to 1513 +/- 121 dyn X sec X cm-5 (P less than 0.01).",Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[dyn·s] / [(cm)^5],1513,87299,DB00120,L-Phenylalanine
,6717507,peak level,Plasma concentrations of dopamine rose to a peak level of 34 +/- 5 ng per milliliter one hour after drug ingestion and decreased toward base line over the ensuing five hours.,Beneficial hemodynamic effects of oral levodopa in heart failure. Relation to the generation of dopamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6717507/),[ng] / [milliliter],34,87300,DB00120,L-Phenylalanine
,17103263,overall response rate,"Complete and partial responses were observed in three and nine out of 17 evaluable patients, respectively (overall response rate = 70%).",Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17103263/),%,70,87784,DB00120,L-Phenylalanine
,17103263,perfusate-to-plasma drug leakage,The pharmacokinetics study showed a 3% mean perfusate-to-plasma drug leakage (range 1-6%).,Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17103263/),%,3,87785,DB00120,L-Phenylalanine
,23523799,run time,"The stable isotope dilution LC-MS/MS method was first validated by determining the linearity (R(2)≥0.9990), sensitivity (lower limit of quantitation of 0.05 ng mL(-1)), accuracy (83.3-108.3), precision (RSD≤15.6%) and stability (≥75.0%), and was approved for the determination OTA in plasma, heart, liver, spleen, lung, kidney and brain with a run time of 7.0 min.",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),min,7.0,88205,DB00120,L-Phenylalanine
,23523799,total run time,"Simultaneously, an LC-TOF-MS method could unambiguously identify the metabolites of OTA in a total run time of 14 min.",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),min,14,88206,DB00120,L-Phenylalanine
,23523799,maximum value,"OTA in rat indicated that OTA could reach a maximum value of 1932.4±124.9 ng mL(-1) within 5h due to its fast absorption, and then was slowly eliminated in plasma with a half-life time (t1/2) of 75.6±29.0 h.",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),[ng] / [ml],1932.4,88207,DB00120,L-Phenylalanine
,23523799,half-life time (t1/2),"OTA in rat indicated that OTA could reach a maximum value of 1932.4±124.9 ng mL(-1) within 5h due to its fast absorption, and then was slowly eliminated in plasma with a half-life time (t1/2) of 75.6±29.0 h.",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),h,75.6,88208,DB00120,L-Phenylalanine
,23523799,concentration,"OTA during 20 days showed that the highest concentration of OTA was observed in lung (95.9±13.7 ng g(-1)), followed by liver (76.0±9.7 ng g(-1)), heart (62.0±4.2 ng g(-1)) and kidney (55.7±4.7 ng g(-1)).",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),[ng] / [g],95.9,88209,DB00120,L-Phenylalanine
,23523799,concentration,"OTA during 20 days showed that the highest concentration of OTA was observed in lung (95.9±13.7 ng g(-1)), followed by liver (76.0±9.7 ng g(-1)), heart (62.0±4.2 ng g(-1)) and kidney (55.7±4.7 ng g(-1)).",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),[ng] / [g],76.0,88210,DB00120,L-Phenylalanine
,23523799,concentration,"OTA during 20 days showed that the highest concentration of OTA was observed in lung (95.9±13.7 ng g(-1)), followed by liver (76.0±9.7 ng g(-1)), heart (62.0±4.2 ng g(-1)) and kidney (55.7±4.7 ng g(-1)).",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),[ng] / [g],62.0,88211,DB00120,L-Phenylalanine
,23523799,concentration,"OTA during 20 days showed that the highest concentration of OTA was observed in lung (95.9±13.7 ng g(-1)), followed by liver (76.0±9.7 ng g(-1)), heart (62.0±4.2 ng g(-1)) and kidney (55.7±4.7 ng g(-1)).",Combinatorial approach of LC-MS/MS and LC-TOF-MS for uncovering in vivo kinetics and biotransformation of ochratoxin A in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23523799/),[ng] / [g],55.7,88212,DB00120,L-Phenylalanine
,3143009,bioavailability,"While intratracheal administration to dogs gave approximately 50% bioavailability, rapid clearance was still a problem.",Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3143009/),%,50,89706,DB00120,L-Phenylalanine
,21343562,duration of in-field response,"Median duration of in-field response among the 17 CRs was 5 months, and median time to in-field progression among 41 evaluable patients was 4.6 months (95% CI, 4.0 to 7.1 months).",Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21343562/),month,5,92117,DB00120,L-Phenylalanine
,21343562,time to in-field progression,"Median duration of in-field response among the 17 CRs was 5 months, and median time to in-field progression among 41 evaluable patients was 4.6 months (95% CI, 4.0 to 7.1 months).",Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21343562/),month,4.6,92118,DB00120,L-Phenylalanine
,11432539,CURSsigma,"At baseline (day 1, before the first levodopa dose), CURSsigma averaged 40 +/- 10 points.",Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432539/),points,40,92445,DB00120,L-Phenylalanine
,11432539,CURSsigma,CURSsigma declined to 20 +/- 9 points.,Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432539/),points,20,92446,DB00120,L-Phenylalanine
,11432539,50% effective concentration (EC50),The population mean of the 50% effective concentration (EC50) of levodopa was 1350 microg/L with an standard error of the population parameter estimate of 18%: adding tolcapone treatment as a covariate did not significantly change the population fit.,Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432539/),[μg] / [l],1350,92447,DB00120,L-Phenylalanine
,30203852,flow rate,"The chromatographic analysis was achieved on a Shimadzu LC 20A HPLC system equipped with a Zorbax Eclipse XDB C18 column and an isocratic mobile phase consisting of 20 mm KH2 PO4 (pH 2.5) and methanol (95:5, v/v) run at a flow rate of 1 mL/min.",A new validated HPLC method for the determination of levodopa: Application to study the impact of ketogenic diet on the pharmacokinetics of levodopa in Parkinson's participants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30203852/),[ml] / [min],1,93057,DB00120,L-Phenylalanine
,14646613,tmax,Plasma levodopa tmax was significantly shorter with all three modes of administration of etilevodopa (mean of about 30 minutes) than with levodopa treatment (mean of 54 minutes).,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),min,30,93618,DB00120,L-Phenylalanine
,14646613,tmax,Plasma levodopa tmax was significantly shorter with all three modes of administration of etilevodopa (mean of about 30 minutes) than with levodopa treatment (mean of 54 minutes).,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),min,54,93619,DB00120,L-Phenylalanine
,14646613,Cmax,Mean levodopa Cmax was in the range 2.3 to 2.7 microg/mL for all treatments.,"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14646613/),[μg] / [ml],2.3 to 2.7,93620,DB00120,L-Phenylalanine
,597816,half-lives,"The disappearance of L-PAM (intact drug) from the serum was biphasic after iv administration, with half-lives of 14 and 66 minutes for the alpha and beta phases, respectively.","Pharmacokinetics of the absorption, distribution, and elimination of melphalan in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/597816/),min,14,93691,DB00120,L-Phenylalanine
,597816,half-lives,"The disappearance of L-PAM (intact drug) from the serum was biphasic after iv administration, with half-lives of 14 and 66 minutes for the alpha and beta phases, respectively.","Pharmacokinetics of the absorption, distribution, and elimination of melphalan in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/597816/),min,66,93692,DB00120,L-Phenylalanine
,12083775,half-life,"The effectiveness of PET as a diagnostic tool, the convenient half-life of (18)F (110 min) and the favorable pharmacokinetics of 6-[(18)F]FDOPA have combined to make this an extremely valuable reagent to study dopaminergic activity.","Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12083775/),min,110,95910,DB00120,L-Phenylalanine
,31406224,AUC,Overall there was an 11-fold variation in melphalan AUC with a median of 27.88 mg h/L (10.06-110.26).,"Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31406224/),[h·mg] / [l],27.88,96076,DB00120,L-Phenylalanine
,8422688,elimination half-life,"Its median elimination half-life was 1.73 (range, 0.72-2.41) h.",Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422688/),h,1.73,96150,DB00120,L-Phenylalanine
,8422688,degradation half-lives,"The stability of some of the peptides was drastically decreased in blood, the degradation half-lives being only about 1 min.",Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422688/),min,1,96151,DB00120,L-Phenylalanine
,3411624,maximum tolerated dose,The maximum tolerated dose was 120 mg of cisplatin/m2 and 20 mg of melphalan/m2.,Intraperitoneal chemotherapy with cisplatin and melphalan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411624/),mg,120,97741,DB00120,L-Phenylalanine
,6861266,half-life,"Analysis of the disposition of melphalan gave a mean half-life of 1.3 +/- 1.0 (SD) h, clearance 18.4 +/- 9.4 l X h-1 X m-2, and apparent volume of distribution 26.3 +/- 18.0 l X m-2.",Pharmacokinetics of melphalan in children following high-dose intravenous injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861266/),h,1.3,97840,DB00120,L-Phenylalanine
,6861266,clearance,"Analysis of the disposition of melphalan gave a mean half-life of 1.3 +/- 1.0 (SD) h, clearance 18.4 +/- 9.4 l X h-1 X m-2, and apparent volume of distribution 26.3 +/- 18.0 l X m-2.",Pharmacokinetics of melphalan in children following high-dose intravenous injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861266/),[l] / [(m)^2·h],18.4,97841,DB00120,L-Phenylalanine
,6861266,apparent volume of distribution,"Analysis of the disposition of melphalan gave a mean half-life of 1.3 +/- 1.0 (SD) h, clearance 18.4 +/- 9.4 l X h-1 X m-2, and apparent volume of distribution 26.3 +/- 18.0 l X m-2.",Pharmacokinetics of melphalan in children following high-dose intravenous injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861266/),[l] / [(m)^2],26.3,97842,DB00120,L-Phenylalanine
,7553617,IC50,"On the basis of an IC50 estimate of about 1.6 microM for inhibition of gamma-glutamylcysteine synthetase, the target enzyme of BSO, the population model predicted near identical GSH concentration time profiles over the dose range studied.",Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7553617/),μM,1.6,97884,DB00120,L-Phenylalanine
,8012555,recoveries,"The intra- and inter-assay precision varied in the 2.4-6.9% and 3.2-9.1% ranges respectively, whereas the recoveries were close to 85% for L-DOPA and 3-OMD and 70% for DA and LDME.","Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012555/),%,85,98555,DB00120,L-Phenylalanine
,8012555,recoveries,"The intra- and inter-assay precision varied in the 2.4-6.9% and 3.2-9.1% ranges respectively, whereas the recoveries were close to 85% for L-DOPA and 3-OMD and 70% for DA and LDME.","Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8012555/),%,70,98556,DB00120,L-Phenylalanine
,18248312,transit time,"Levodopa is only absorbed in the small intestine, where transit time is approximately 3 h and the plasma elimination half-life is short.",Irregular gastrointestinal drug absorption in Parkinson's disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18248312/),h,3,98632,DB00120,L-Phenylalanine
,3574137,Peak plasma phenylalanine levels,"Peak plasma phenylalanine levels were significantly higher (191 +/- 65.4 v 117 +/- 39.5 mumol/L, mean +/- SD) and were reached significantly earlier (32 +/- 15 v 123 +/- 74 minutes) when aspartame was administered in solution than when it was administered in capsules.",Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3574137/),[μM] / [l],191,98712,DB00120,L-Phenylalanine
,3574137,Peak plasma phenylalanine levels,"Peak plasma phenylalanine levels were significantly higher (191 +/- 65.4 v 117 +/- 39.5 mumol/L, mean +/- SD) and were reached significantly earlier (32 +/- 15 v 123 +/- 74 minutes) when aspartame was administered in solution than when it was administered in capsules.",Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3574137/),[μM] / [l],117,98713,DB00120,L-Phenylalanine
,3574137,area under the four-hour plasma phenylalanine concentration-time curve,"The area under the four-hour plasma phenylalanine concentration-time curve was significantly higher (15,340 +/- 4,820 v 8,465 +/- 3,356 mumol/L X min) when aspartame was ingested in solution.",Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3574137/),[μM] / [l·min],"15,340",98714,DB00120,L-Phenylalanine
,3574137,area under the four-hour plasma phenylalanine concentration-time curve,"The area under the four-hour plasma phenylalanine concentration-time curve was significantly higher (15,340 +/- 4,820 v 8,465 +/- 3,356 mumol/L X min) when aspartame was ingested in solution.",Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3574137/),[μM] / [l·min],"8,465",98715,DB00120,L-Phenylalanine
,3574137,peak plasma aspartate concentrations,"Similarly, peak plasma aspartate concentrations were significantly higher 26.2 +/- 16.3 v 10.4 +/- 5.0 mumol/L) and were reached significantly earlier (30 +/- 14 v 106 +/- 61.3 min) when aspartame was administered in solution.",Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3574137/),[μM] / [l],26.2,98716,DB00120,L-Phenylalanine
,3574137,peak plasma aspartate concentrations,"Similarly, peak plasma aspartate concentrations were significantly higher 26.2 +/- 16.3 v 10.4 +/- 5.0 mumol/L) and were reached significantly earlier (30 +/- 14 v 106 +/- 61.3 min) when aspartame was administered in solution.",Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3574137/),[μM] / [l],10.4,98717,DB00120,L-Phenylalanine
,3574137,peak plasma aspartate concentrations,"Similarly, peak plasma aspartate concentrations were significantly higher 26.2 +/- 16.3 v 10.4 +/- 5.0 mumol/L) and were reached significantly earlier (30 +/- 14 v 106 +/- 61.3 min) when aspartame was administered in solution.",Plasma amino acid concentrations in normal adults administered aspartame in capsules or solution: lack of bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3574137/),,106,98718,DB00120,L-Phenylalanine
,32277364,time to reach maximum concentration (Tmax),Bentysrepinine was rapidly absorbed and metabolised with a mean time to reach maximum concentration (Tmax) between 1-2 h and a mean terminal elimination half-life (t1/2) of approximately 1-3 h.,"Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),h,1-2,99864,DB00120,L-Phenylalanine
,32277364,terminal elimination half-life (t1/2),Bentysrepinine was rapidly absorbed and metabolised with a mean time to reach maximum concentration (Tmax) between 1-2 h and a mean terminal elimination half-life (t1/2) of approximately 1-3 h.,"Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),h,1-3,99865,DB00120,L-Phenylalanine
,32277364,urinary excretion,"The urinary excretion and faecal excretion of unchanged bentysrepinine were 2.98% and 4.58% of the total dose, respectively.","Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),%,2.98,99866,DB00120,L-Phenylalanine
,32277364,f,"The urinary excretion and faecal excretion of unchanged bentysrepinine were 2.98% and 4.58% of the total dose, respectively.","Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),%,2.98,99867,DB00120,L-Phenylalanine
,32277364,f,"The urinary excretion and faecal excretion of unchanged bentysrepinine were 2.98% and 4.58% of the total dose, respectively.","Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32277364/),%,4,99868,DB00120,L-Phenylalanine
,8327732,minimum effective tumor boron concentration,"The proposed minimum effective tumor boron concentration of 15 ppm was achieved in both tumor models for the three compounds tested, although only for L-BPA in the melanoma was this achieved when tumor-plasma ratios were above 1.","Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8327732/),ppm,15,100245,DB00120,L-Phenylalanine
above,8327732,tumor-plasma ratios,"The proposed minimum effective tumor boron concentration of 15 ppm was achieved in both tumor models for the three compounds tested, although only for L-BPA in the melanoma was this achieved when tumor-plasma ratios were above 1.","Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8327732/),,1,100246,DB00120,L-Phenylalanine
,8327732,maximum tumor concentrations,"In the RIF1 model, maximum tumor concentrations of 44 and 31 ppm B were reached after administration of 50 micrograms B/g body weight for boric acid and BSH, respectively.","Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8327732/),b·ppm,44,100247,DB00120,L-Phenylalanine
,8327732,maximum tumor concentrations,"In the RIF1 model, maximum tumor concentrations of 44 and 31 ppm B were reached after administration of 50 micrograms B/g body weight for boric acid and BSH, respectively.","Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8327732/),b·ppm,31,100248,DB00120,L-Phenylalanine
,8327732,maximum concentrations,"After administration of 12.5 micrograms B/g of L-BPA, maximum concentrations of 15 and 21 ppm were found in the RIF1 and B16 models, respectively.","Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8327732/),ppm,15,100249,DB00120,L-Phenylalanine
,8327732,maximum concentrations,"After administration of 12.5 micrograms B/g of L-BPA, maximum concentrations of 15 and 21 ppm were found in the RIF1 and B16 models, respectively.","Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8327732/),ppm,21,100250,DB00120,L-Phenylalanine
greater,8327732,tumor-brain ratios,"Brain levels of BSH were very low, however, leading to tumor-brain ratios markedly greater than 1 at all times.","Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8327732/),,1,100251,DB00120,L-Phenylalanine
,6840181,plasma t0.5 alpha,"After intravenous administration, mean plasma t0.5 alpha was 8.0 +/- 2.3 min, t0,5 beta was 63.3 +/- 8.7 min, and total systemic clearance was 510.4 +/- 57.9 ml/min.",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),min,8.0,100328,DB00120,L-Phenylalanine
,6840181,"t0,5 beta","After intravenous administration, mean plasma t0.5 alpha was 8.0 +/- 2.3 min, t0,5 beta was 63.3 +/- 8.7 min, and total systemic clearance was 510.4 +/- 57.9 ml/min.",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),min,63.3,100329,DB00120,L-Phenylalanine
,6840181,total systemic clearance,"After intravenous administration, mean plasma t0.5 alpha was 8.0 +/- 2.3 min, t0,5 beta was 63.3 +/- 8.7 min, and total systemic clearance was 510.4 +/- 57.9 ml/min.",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),[ml] / [min],510.4,100330,DB00120,L-Phenylalanine
,6840181,lag-time,"After oral administration, the drug was rapidly absorbed (lag-time = 18.4 +/- 3.7 min, absorption rate constant = 0.0547 +/- 0.0166 min-1, Tmax = 59.3 +/- 6.6 min), but there was considerable variation in its bioavailability (61.5 - 102.0% mean 78.3 +/- 6.3%).",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),min,18.4,100331,DB00120,L-Phenylalanine
,6840181,absorption rate constant,"After oral administration, the drug was rapidly absorbed (lag-time = 18.4 +/- 3.7 min, absorption rate constant = 0.0547 +/- 0.0166 min-1, Tmax = 59.3 +/- 6.6 min), but there was considerable variation in its bioavailability (61.5 - 102.0% mean 78.3 +/- 6.3%).",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),1/[min],0.0547,100332,DB00120,L-Phenylalanine
,6840181,Tmax,"After oral administration, the drug was rapidly absorbed (lag-time = 18.4 +/- 3.7 min, absorption rate constant = 0.0547 +/- 0.0166 min-1, Tmax = 59.3 +/- 6.6 min), but there was considerable variation in its bioavailability (61.5 - 102.0% mean 78.3 +/- 6.3%).",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),min,59.3,100333,DB00120,L-Phenylalanine
,6840181,bioavailability,"After oral administration, the drug was rapidly absorbed (lag-time = 18.4 +/- 3.7 min, absorption rate constant = 0.0547 +/- 0.0166 min-1, Tmax = 59.3 +/- 6.6 min), but there was considerable variation in its bioavailability (61.5 - 102.0% mean 78.3 +/- 6.3%).",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),%,61.5 - 102.0,100334,DB00120,L-Phenylalanine
,6840181,bioavailability,"After oral administration, the drug was rapidly absorbed (lag-time = 18.4 +/- 3.7 min, absorption rate constant = 0.0547 +/- 0.0166 min-1, Tmax = 59.3 +/- 6.6 min), but there was considerable variation in its bioavailability (61.5 - 102.0% mean 78.3 +/- 6.3%).",The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840181/),%,78.3,100335,DB00120,L-Phenylalanine
,2453234,area under the concentration curve,"In this patient, melphalan pharmacokinetics was different from that of patients without important renal dysfunction for the area under the concentration curve (1,324 mg.l-1.min).",[Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453234/),[mg·min] / [l],"1,324",100874,DB00120,L-Phenylalanine
,2453234,elimination half-life,"However, with a melphalan elimination half-life of 80 min, ABMG could be performed, as usually, 24 h after melphalan administration.",[Pharmacokinetics of high-dose melphalan (200 mg/m2) in a case of total renal insufficiency]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2453234/),min,80,100875,DB00120,L-Phenylalanine
,24433449,absorption,"The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),%,97,101991,DB00120,L-Phenylalanine
,24433449,"first order elimination, bioavailability","The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),%,97,101992,DB00120,L-Phenylalanine
,24433449,first order transit absorption rate constants,"The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC-oral, different first order transit absorption rate constants (LCIG = 9.2 h(-1) vs.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),1/[h],9.2,101993,DB00120,L-Phenylalanine
,24433449,mean absorption time,"LC-oral = 2.4 h(-1) ; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC-oral) and different residual (intra-subject) variability for LCIG (15% proportional error, 0.3 μg ml(-1) additive error) vs. LC-oral (29% proportional error, 0.59 μg ml(-1) additive error).",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),min,7,101994,DB00120,L-Phenylalanine
,24433449,mean absorption time,"LC-oral = 2.4 h(-1) ; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC-oral) and different residual (intra-subject) variability for LCIG (15% proportional error, 0.3 μg ml(-1) additive error) vs. LC-oral (29% proportional error, 0.59 μg ml(-1) additive error).",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),min,25,101995,DB00120,L-Phenylalanine
,24433449,oral clearance,"Estimated oral clearance and steady-state volume of distribution for levodopa were 24.8 l h(-1) and 131 l, respectively.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),[l] / [h],24.8,101996,DB00120,L-Phenylalanine
,24433449,steady-state volume of distribution,"Estimated oral clearance and steady-state volume of distribution for levodopa were 24.8 l h(-1) and 131 l, respectively.",Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433449/),l,131,101997,DB00120,L-Phenylalanine
,22722022,maximal plasma concentration of L-DOPA (C(max)),The maximal plasma concentration of L-DOPA (C(max)) was 18.2 ± 3.8 nmol/ml and was achieved 1.6 ± 0.3 h after administration (t(max)).,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),[nM] / [ml],18.2,103432,DB00120,L-Phenylalanine
,22722022,t(max),The maximal plasma concentration of L-DOPA (C(max)) was 18.2 ± 3.8 nmol/ml and was achieved 1.6 ± 0.3 h after administration (t(max)).,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),h,1.6,103433,DB00120,L-Phenylalanine
,22722022,Half-life,Half-life was 58.8 ± 22.7 min.,L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22722022/),min,58.8,103434,DB00120,L-Phenylalanine
,14642830,t(max),"With a clinically therapeutic dosage of L-dopa/benserazide (20/5 mg/kg, p.o.), the t(max) of L-dopa was 30 min in plasma and 60-90 min in ECF of striatum.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),min,30,104250,DB00120,L-Phenylalanine
,14642830,t(max),"With a clinically therapeutic dosage of L-dopa/benserazide (20/5 mg/kg, p.o.), the t(max) of L-dopa was 30 min in plasma and 60-90 min in ECF of striatum.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),min,60-90,104251,DB00120,L-Phenylalanine
,14642830,C(max),"Mean C(max) was 20.3 microM in plasma and 442.9 nM in ECF of striatum, which is about 2.2% of that in plasma.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),μM,20.3,104252,DB00120,L-Phenylalanine
,14642830,C(max),"Mean C(max) was 20.3 microM in plasma and 442.9 nM in ECF of striatum, which is about 2.2% of that in plasma.",Pharmacokinetics of L-dopa in plasma and extracellular fluid of striatum in common marmosets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14642830/),nM,442.9,104253,DB00120,L-Phenylalanine
,22301424,shelf life,The shelf life of the formulation was found to be 1.30 years.,"Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22301424/),years,1.30,104599,DB00120,L-Phenylalanine
,12495285,overall median survival,The overall median survival was 45 +/- 43 months after diagnosis.,Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12495285/),month,45,105070,DB00120,L-Phenylalanine
,18850046,C(max),"After 7 days of treatment, the levodopa AUC increased by 12.6% from day 1 (range: 114.2-150.7 microg.min/ml) to day 7 (range: 131.1-166.0 microg.min/ml) and C(max) increased by 9.6% (range: 1.90-2.86 microg/ml on day 1 and 2.12-3.13 microg/ml on day 7).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],1.90-2.86,105132,DB00120,L-Phenylalanine
,18850046,C(max),"After 7 days of treatment, the levodopa AUC increased by 12.6% from day 1 (range: 114.2-150.7 microg.min/ml) to day 7 (range: 131.1-166.0 microg.min/ml) and C(max) increased by 9.6% (range: 1.90-2.86 microg/ml on day 1 and 2.12-3.13 microg/ml on day 7).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.12-3.13,105133,DB00120,L-Phenylalanine
,18850046,C(max),"After 14 days of treatment, the increase in AUC was 17.0% (range: 119.6-160.1 microg.min/ml on day 1 and 142.9-172.7 microg.min/ml on day 14) and C(max) increased by 6.5% (range: 2.29-2.96 microg/ml on day 1 and 2.41-3.07 microg/ml on day 14).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.29-2.96,105134,DB00120,L-Phenylalanine
,18850046,C(max),"After 14 days of treatment, the increase in AUC was 17.0% (range: 119.6-160.1 microg.min/ml on day 1 and 142.9-172.7 microg.min/ml on day 14) and C(max) increased by 6.5% (range: 2.29-2.96 microg/ml on day 1 and 2.41-3.07 microg/ml on day 14).",Evolution of the bioavailability and other pharmacokinetic parameters of levodopa (with carbidopa) in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18850046/),[μg] / [ml],2.41-3.07,105135,DB00120,L-Phenylalanine
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,83.5,105136,DB00120,L-Phenylalanine
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,78.3,105137,DB00120,L-Phenylalanine
,25855267,Bioavailability,"Bioavailability of LD from ER CD-LD was 83.5%, 78.3%, and 58.8% relative to IR CD-LD, CR CD-LD, and CD-LD-entacapone, respectively.","Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25855267/),%,58.8,105138,DB00120,L-Phenylalanine
,34075614,area under the concentration-time curve (AUC),"Patients received standard full-dose melphalan in 17 transplants, with median area under the concentration-time curve (AUC) of 5.5 mg*h/L (range, 3.0-9.5 mg*h/L).",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],5.5,105196,DB00120,L-Phenylalanine
,34075614,AUC,Patients received test-dose melphalan in 23 transplants with a test-dose PK predicted full-dose AUC range of 2.9-16.8 mg*h/L.,Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],2.9-16.8,105197,DB00120,L-Phenylalanine
,34075614,AUC,"In seven transplants where patients had baseline organ impairment, test-dose PK predicted higher exposure for standard full-dose (median AUC 13.8 mg*h/L).",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],13.8,105198,DB00120,L-Phenylalanine
,34075614,AUC,"Melphalan full-dose was adjusted in these patients, with achievement of desired target AUC (3.6-5.4 mg*h/L) and no excess toxicity.",Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34075614/),[h·mg] / [l],3.6-5.4,105199,DB00120,L-Phenylalanine
,9066587,terminal half-life,Plasma levels of melphalan declined in a biexponential fashion with a mean terminal half-life of 83 minutes (range 52-168 minutes).,Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9066587/),min,83,105219,DB00120,L-Phenylalanine
,9066587,peak plasma concentrations,Estimated peak plasma concentrations ranged from 1.65 to 14.5 micrograms/ml.,Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9066587/),[μg] / [ml],1.65 to 14.5,105220,DB00120,L-Phenylalanine
,9066587,volume of distribution,"The average volume of distribution and total clearance were 317 ml/min/m2 (range 127-797 ml/min/m2) and 37.9 l/m2 (range 15.4-108 l/m2), respectively.",Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9066587/),[ml] / [m2·min],317,105221,DB00120,L-Phenylalanine
,9066587,total clearance,"The average volume of distribution and total clearance were 317 ml/min/m2 (range 127-797 ml/min/m2) and 37.9 l/m2 (range 15.4-108 l/m2), respectively.",Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9066587/),[l] / [m2],37.9,105222,DB00120,L-Phenylalanine
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,1.26,105533,DB00120,L-Phenylalanine
,22762460,FI,"FI for dose 2-5 was on average 1.26 for levodopa in LC-5, and 2.23 for dose 1-2 of LCE.",Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22762460/),,2.23,105534,DB00120,L-Phenylalanine
,2124159,clearance,Normal rats had a rapid gludopa clearance of 50.9 +/- 9.6 ml min-1 kg-1 and elimination rate constant of 2.99 +/- 0.27 h-1.,The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124159/),[ml] / [kg·min],50.9,106212,DB00120,L-Phenylalanine
,2124159,elimination rate constant,Normal rats had a rapid gludopa clearance of 50.9 +/- 9.6 ml min-1 kg-1 and elimination rate constant of 2.99 +/- 0.27 h-1.,The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124159/),1/[h],2.99,106213,DB00120,L-Phenylalanine
,2124159,mean residence time,"The mean residence time and half-life were 20.9 +/- 1.4 and 14.4 +/- 1.0 min, respectively.",The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124159/),min,20.9,106214,DB00120,L-Phenylalanine
,2124159,half-life,"The mean residence time and half-life were 20.9 +/- 1.4 and 14.4 +/- 1.0 min, respectively.",The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124159/),min,14.4,106215,DB00120,L-Phenylalanine
,2124159,apparent volume of distribution at steady state,The apparent volume of distribution at steady state was 1.05 +/- 0.18 l kg-1.,The pharmacokinetics of gamma-glutamyl-L-dopa in normal and anephric rats and rats with glycerol-induced acute renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124159/),[l] / [kg],1.05,106216,DB00120,L-Phenylalanine
,21854909,peak plasma enrichment levels,"Plasma L-[1-(13)C]phenylalanine enrichments increased during the first 90 min following beef ingestion, reaching peak plasma enrichment levels of 0.61±0.04 MPE.",The production of intrinsically labeled milk and meat protein is feasible and provides functional tools for human nutrition research. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21854909/),Mpe,0.61,106451,DB00120,L-Phenylalanine
,21854909,net protein balance,"Whole-body net protein balance, assessed by continuous infusion of L-[ring-(2)H(5)]phenylalanine and L-[ring-(2)H(2)]tyrosine, was higher in the postprandial period compared with basal values (6.4±0.1 vs. -4.5±0.1 μmol/kg per h).",The production of intrinsically labeled milk and meat protein is feasible and provides functional tools for human nutrition research. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21854909/),[μM] / [h·kg],6.4,106452,DB00120,L-Phenylalanine
,21854909,net protein balance,"Whole-body net protein balance, assessed by continuous infusion of L-[ring-(2)H(5)]phenylalanine and L-[ring-(2)H(2)]tyrosine, was higher in the postprandial period compared with basal values (6.4±0.1 vs. -4.5±0.1 μmol/kg per h).",The production of intrinsically labeled milk and meat protein is feasible and provides functional tools for human nutrition research. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21854909/),[μM] / [h·kg],-4.5,106453,DB00120,L-Phenylalanine
,31650410,T/N ratios,"Median T/N ratios at 60 min after 18F-FBPA and BPA injections were 3.5 and 3.43, respectively.",Similar T/N ratio between 18F-FBPA diagnostic and BPA therapeutic dosages for boron neutron capture therapy in orthotropic tongue cancer model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31650410/),,3.5,106658,DB00120,L-Phenylalanine
,31650410,T/N ratios,"Median T/N ratios at 60 min after 18F-FBPA and BPA injections were 3.5 and 3.43, respectively.",Similar T/N ratio between 18F-FBPA diagnostic and BPA therapeutic dosages for boron neutron capture therapy in orthotropic tongue cancer model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31650410/),,3.43,106659,DB00120,L-Phenylalanine
,31650410,T/N ratio,Median value of the T/N ratio between them was 3.49 at 60 min.,Similar T/N ratio between 18F-FBPA diagnostic and BPA therapeutic dosages for boron neutron capture therapy in orthotropic tongue cancer model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31650410/),,3.49,106660,DB00120,L-Phenylalanine
,31650410,tumor-to-blood (T/B) boron ratios,"However, median tumor-to-blood (T/B) boron ratios of 18F-FBPA and BPA at 60 min were 1.63 and 3.35, respectively.",Similar T/N ratio between 18F-FBPA diagnostic and BPA therapeutic dosages for boron neutron capture therapy in orthotropic tongue cancer model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31650410/),,1.63,106661,DB00120,L-Phenylalanine
,31650410,tumor-to-blood (T/B) boron ratios,"However, median tumor-to-blood (T/B) boron ratios of 18F-FBPA and BPA at 60 min were 1.63 and 3.35, respectively.",Similar T/N ratio between 18F-FBPA diagnostic and BPA therapeutic dosages for boron neutron capture therapy in orthotropic tongue cancer model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31650410/),,3.35,106662,DB00120,L-Phenylalanine
,7655188,half-life,"In comparison to NAPAP, 10 exhibited improved tolerability and a longer half-life in vivo, i.e., 20 +/- 5 min.",Preparation and evaluation of PEG-bound thrombin inhibitors based on 4-amidinophenylalanine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7655188/),min,20,107862,DB00120,L-Phenylalanine
,7655188,half-life,In rats the half-life of Mtr-Asn (PEG10000-OMe)-D-Adf-Pip 14 was determined to be 63 min.,Preparation and evaluation of PEG-bound thrombin inhibitors based on 4-amidinophenylalanine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7655188/),min,63,107863,DB00120,L-Phenylalanine
,7655188,half-life,Mtr-Asn(PEG10000-OMe)-D-Adf-Pip 14 showed a half-life of 120 min in pigs.,Preparation and evaluation of PEG-bound thrombin inhibitors based on 4-amidinophenylalanine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7655188/),min,120,107864,DB00120,L-Phenylalanine
,7712674,time to maximal activity,"The mathematic analysis of the effects of ciprofloxacin showed that time to maximal activity was between 10.4 hours (PAF-dependent [Ca2+]i increase), and 15 hours (fMLP-induced superoxide anion and chemiluminescence production).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,10.4,108356,DB00120,L-Phenylalanine
,7712674,time to maximal activity,"The mathematic analysis of the effects of ciprofloxacin showed that time to maximal activity was between 10.4 hours (PAF-dependent [Ca2+]i increase), and 15 hours (fMLP-induced superoxide anion and chemiluminescence production).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,15,108357,DB00120,L-Phenylalanine
,7712674,time to maximal activity,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,4.66,108358,DB00120,L-Phenylalanine
,7712674,time to maximal activity,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,1.90,108359,DB00120,L-Phenylalanine
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,1.90,108360,DB00120,L-Phenylalanine
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,13.03,108361,DB00120,L-Phenylalanine
,7712674,half-life,"In addition, time to maximal activity and half-life differed in PMNs and in plasma (4.66 versus 1.90 hours and 13.03 versus 7.28 hours, respectively).",Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7712674/),h,7.28,108362,DB00120,L-Phenylalanine
,31522098,flow rate,"The derivatives resolved with good baseline separation on an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with mobile phase composed of methanol with 0.2% formic acid in water at a flow rate of 0.2 mL/min.",Analysis of endogenous epinephrine and norepinephrine enantiomers in rat plasma and application to a stereoselective pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31522098/),[ml] / [min],0.2,108604,DB00120,L-Phenylalanine
more,31522098,Recoveries,Recoveries for all the analytes were more than 80.3%.,Analysis of endogenous epinephrine and norepinephrine enantiomers in rat plasma and application to a stereoselective pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31522098/),%,80.3,108605,DB00120,L-Phenylalanine
,11767066,peak times,"The peak times (the time expressed in minutes at which 13CO2 excretion was maximal) were 20 min in both breath tests, but 13C-TyrBT gave a higher peak than 13C-PheBT.",Evaluation of 13C-phenylalanine and 13C-tyrosine breath tests for the measurement of hepatocyte functional capacity in patients with liver cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11767066/),min,20,109429,DB00120,L-Phenylalanine
,7047042,bioavailability,Absorption of methyldopa from the gastrointestinal tract is incomplete and variable; bioavailability after oral administration is about 25% (range 8 to 62%).,Clinical pharmacokinetics of methyldopa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),%,25,109570,DB00120,L-Phenylalanine
,7047042,time to reach maximum plasma concentration (tmax),"The average time to reach maximum plasma concentration (tmax) [chemically determined] is 2 hours, when the maximum plasma concentration of active drug accounts for 50% of the radioactivity, the remainder representing various metabolites.",Clinical pharmacokinetics of methyldopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),h,2,109571,DB00120,L-Phenylalanine
,7047042,half-life of,"Physicochemical determination of methyldopa shows that bi-phasic elimination occurs after both intravenous and oral administration, the half-life of the alpha-phase being 0.21 hours (range 0.16 to 0.26 hours) and of the beta-phase 1.28 hours (range 1.02 to 1.69 hours) in normal subjects.",Clinical pharmacokinetics of methyldopa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),h,0.21,109572,DB00120,L-Phenylalanine
,7047042,half-life of,"Physicochemical determination of methyldopa shows that bi-phasic elimination occurs after both intravenous and oral administration, the half-life of the alpha-phase being 0.21 hours (range 0.16 to 0.26 hours) and of the beta-phase 1.28 hours (range 1.02 to 1.69 hours) in normal subjects.",Clinical pharmacokinetics of methyldopa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),h,1.28,109573,DB00120,L-Phenylalanine
,7047042,apparent volume of distribution in the central compartment,"The apparent volume of distribution in the central compartment is about 0.23L/kg (range 0.19 to 0.32L/kg), and the total volume of distribution (calculated as Vdarea) is about 0.60L/kg (range 0.41 to 0.72L/kg) in healthy volunteers.",Clinical pharmacokinetics of methyldopa. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),[l] / [kg],0.23,109574,DB00120,L-Phenylalanine
,7047042,total volume of distribution (,"The apparent volume of distribution in the central compartment is about 0.23L/kg (range 0.19 to 0.32L/kg), and the total volume of distribution (calculated as Vdarea) is about 0.60L/kg (range 0.41 to 0.72L/kg) in healthy volunteers.",Clinical pharmacokinetics of methyldopa. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),[l] / [kg],0.60,109575,DB00120,L-Phenylalanine
,7047042,Vdarea),"The apparent volume of distribution in the central compartment is about 0.23L/kg (range 0.19 to 0.32L/kg), and the total volume of distribution (calculated as Vdarea) is about 0.60L/kg (range 0.41 to 0.72L/kg) in healthy volunteers.",Clinical pharmacokinetics of methyldopa. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),[l] / [kg],0.60,109576,DB00120,L-Phenylalanine
,7047042,renal clearance,The renal clearance of methyldopa (95 ml/min/m2) is more than 50% higher than the endogenous creatinine clearance.,Clinical pharmacokinetics of methyldopa. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047042/),[ml] / [m2·min],95,109577,DB00120,L-Phenylalanine
,11243717,clearance (Cl),"Abdominal aortic coarctation produced significant differences in the estimates of clearance (Cl) and the elimination rate constant from the dialysate (K(ed)) after the administration of 50 mg kg(-1)of methyldopa (K(ed)SO, 0.31 +/- 0.09; ACo, 0.66 +/- 0.09(*)h(-1): Cl SO, 30.8 +/- 10.1; ACo, 78.6 +/- 13.3(*)mlkg(-1)min(-1);n= 6,(*)P< 0.05 vs SO).",Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243717/),1/[h],0.31,109914,DB00120,L-Phenylalanine
,11243717,elimination rate constant,"Abdominal aortic coarctation produced significant differences in the estimates of clearance (Cl) and the elimination rate constant from the dialysate (K(ed)) after the administration of 50 mg kg(-1)of methyldopa (K(ed)SO, 0.31 +/- 0.09; ACo, 0.66 +/- 0.09(*)h(-1): Cl SO, 30.8 +/- 10.1; ACo, 78.6 +/- 13.3(*)mlkg(-1)min(-1);n= 6,(*)P< 0.05 vs SO).",Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243717/),1/[h],0.31,109915,DB00120,L-Phenylalanine
,11243717,K(ed),"Abdominal aortic coarctation produced significant differences in the estimates of clearance (Cl) and the elimination rate constant from the dialysate (K(ed)) after the administration of 50 mg kg(-1)of methyldopa (K(ed)SO, 0.31 +/- 0.09; ACo, 0.66 +/- 0.09(*)h(-1): Cl SO, 30.8 +/- 10.1; ACo, 78.6 +/- 13.3(*)mlkg(-1)min(-1);n= 6,(*)P< 0.05 vs SO).",Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243717/),1/[h],0.31,109916,DB00120,L-Phenylalanine
,11243717,K(ed),"Abdominal aortic coarctation produced significant differences in the estimates of clearance (Cl) and the elimination rate constant from the dialysate (K(ed)) after the administration of 50 mg kg(-1)of methyldopa (K(ed)SO, 0.31 +/- 0.09; ACo, 0.66 +/- 0.09(*)h(-1): Cl SO, 30.8 +/- 10.1; ACo, 78.6 +/- 13.3(*)mlkg(-1)min(-1);n= 6,(*)P< 0.05 vs SO).",Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243717/),1/[h],0.66,109917,DB00120,L-Phenylalanine
,11243717,Cl,"Abdominal aortic coarctation produced significant differences in the estimates of clearance (Cl) and the elimination rate constant from the dialysate (K(ed)) after the administration of 50 mg kg(-1)of methyldopa (K(ed)SO, 0.31 +/- 0.09; ACo, 0.66 +/- 0.09(*)h(-1): Cl SO, 30.8 +/- 10.1; ACo, 78.6 +/- 13.3(*)mlkg(-1)min(-1);n= 6,(*)P< 0.05 vs SO).",Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243717/),1/[mlkg],30.8,109918,DB00120,L-Phenylalanine
,11243717,Cl,"Abdominal aortic coarctation produced significant differences in the estimates of clearance (Cl) and the elimination rate constant from the dialysate (K(ed)) after the administration of 50 mg kg(-1)of methyldopa (K(ed)SO, 0.31 +/- 0.09; ACo, 0.66 +/- 0.09(*)h(-1): Cl SO, 30.8 +/- 10.1; ACo, 78.6 +/- 13.3(*)mlkg(-1)min(-1);n= 6,(*)P< 0.05 vs SO).",Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243717/),1/[mlkg],78.6,109919,DB00120,L-Phenylalanine
,19762796,protein synthesis rates,Skeletal muscle protein synthesis rates calculated over the entire 6-h period averaged 0.058 +/- 0.012%/h.,The production of intrinsically labeled milk protein provides a functional tool for human nutrition research. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19762796/),[%] / [h],0.058,110775,DB00120,L-Phenylalanine
,31595429,bioavailability,Both the ODE and the SDE models estimated bioavailability to be approximately 75%.,Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31595429/),%,75,111266,DB00120,L-Phenylalanine
,12844132,half-life,"Fluconazole raised the total area under the plasma concentration-time curve from time 0 to infinity of nateglinide by 48% (range, 20%-73%; P <.00001) and prolonged its half-life from 1.6 to 1.9 hours (P <.05), but the peak plasma nateglinide concentration remained unchanged.",Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844132/),h,1.6,111756,DB00120,L-Phenylalanine
,12844132,half-life,"Fluconazole raised the total area under the plasma concentration-time curve from time 0 to infinity of nateglinide by 48% (range, 20%-73%; P <.00001) and prolonged its half-life from 1.6 to 1.9 hours (P <.05), but the peak plasma nateglinide concentration remained unchanged.",Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844132/),h,1.9,111757,DB00120,L-Phenylalanine
,12844132,half-life,"The peak plasma concentration of the M7 metabolite of nateglinide was reduced by 34% by fluconazole (P <.001), and its half-life was prolonged from 2.2 to 3.5 hours (P <.05).",Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844132/),h,2.2,111758,DB00120,L-Phenylalanine
,12844132,half-life,"The peak plasma concentration of the M7 metabolite of nateglinide was reduced by 34% by fluconazole (P <.001), and its half-life was prolonged from 2.2 to 3.5 hours (P <.05).",Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844132/),h,3.5,111759,DB00120,L-Phenylalanine
,2645050,peak melphalan concentration,On day -7 the peak melphalan concentration was 1.64 +/- 0.89 (SD) microM with a terminal half-life of 1.56 +/- 0.86 h.,Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),μM,1.64,111933,DB00120,L-Phenylalanine
,2645050,terminal half-life,On day -7 the peak melphalan concentration was 1.64 +/- 0.89 (SD) microM with a terminal half-life of 1.56 +/- 0.86 h.,Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),h,1.56,111934,DB00120,L-Phenylalanine
,2645050,area under the plasma concentration time curve (AUC),The area under the plasma concentration time curve (AUC) and oral clearance were 217.9 +/- 115.1 microM/min and 30.2 +/- 14.2 ml/min/kg.,Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),[μM] / [min],217.9,111935,DB00120,L-Phenylalanine
,2645050,oral clearance,The area under the plasma concentration time curve (AUC) and oral clearance were 217.9 +/- 115.1 microM/min and 30.2 +/- 14.2 ml/min/kg.,Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),[ml] / [kg·min],30.2,111936,DB00120,L-Phenylalanine
,2645050,peak concentration,"Analysis of intrapatient pharmacokinetic variability in 8 patients showed a significant difference between the doses given on days -7 and -5 in the peak concentration (2.09 versus 1.07 microM, P = 0.02), AUC (264.9 versus 134.8 microM/min, P = 0.01), and oral clearance (25.1 versus 53.1 ml/min/kg, P = 0.05) but no significant difference in the time to peak and terminal half-life.",Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),μM,2.09,111937,DB00120,L-Phenylalanine
,2645050,peak concentration,"Analysis of intrapatient pharmacokinetic variability in 8 patients showed a significant difference between the doses given on days -7 and -5 in the peak concentration (2.09 versus 1.07 microM, P = 0.02), AUC (264.9 versus 134.8 microM/min, P = 0.01), and oral clearance (25.1 versus 53.1 ml/min/kg, P = 0.05) but no significant difference in the time to peak and terminal half-life.",Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),μM,1.07,111938,DB00120,L-Phenylalanine
,2645050,AUC,"Analysis of intrapatient pharmacokinetic variability in 8 patients showed a significant difference between the doses given on days -7 and -5 in the peak concentration (2.09 versus 1.07 microM, P = 0.02), AUC (264.9 versus 134.8 microM/min, P = 0.01), and oral clearance (25.1 versus 53.1 ml/min/kg, P = 0.05) but no significant difference in the time to peak and terminal half-life.",Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),[μM] / [min],264.9,111939,DB00120,L-Phenylalanine
,2645050,AUC,"Analysis of intrapatient pharmacokinetic variability in 8 patients showed a significant difference between the doses given on days -7 and -5 in the peak concentration (2.09 versus 1.07 microM, P = 0.02), AUC (264.9 versus 134.8 microM/min, P = 0.01), and oral clearance (25.1 versus 53.1 ml/min/kg, P = 0.05) but no significant difference in the time to peak and terminal half-life.",Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),[μM] / [min],134.8,111940,DB00120,L-Phenylalanine
,2645050,oral clearance,"Analysis of intrapatient pharmacokinetic variability in 8 patients showed a significant difference between the doses given on days -7 and -5 in the peak concentration (2.09 versus 1.07 microM, P = 0.02), AUC (264.9 versus 134.8 microM/min, P = 0.01), and oral clearance (25.1 versus 53.1 ml/min/kg, P = 0.05) but no significant difference in the time to peak and terminal half-life.",Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),[ml] / [kg·min],25.1,111941,DB00120,L-Phenylalanine
,2645050,oral clearance,"Analysis of intrapatient pharmacokinetic variability in 8 patients showed a significant difference between the doses given on days -7 and -5 in the peak concentration (2.09 versus 1.07 microM, P = 0.02), AUC (264.9 versus 134.8 microM/min, P = 0.01), and oral clearance (25.1 versus 53.1 ml/min/kg, P = 0.05) but no significant difference in the time to peak and terminal half-life.",Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2645050/),[ml] / [kg·min],53.1,111942,DB00120,L-Phenylalanine
,11879711,specific activities,Optimisation of several parameters such as the quantity of precursor applied and the duration of metabolism led to incorporation yields of 15% and to specific activities of 875 mu Ci g(-1) in stilbenes.,Carbon-14 biolabelling of wine polyphenols in Vitis vinifera cell suspension cultures. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879711/),[ci·mu] / [g],875,111943,DB00120,L-Phenylalanine
,11879711,specific activity,"Both trans- and cis-resveratrols were easily obtained by enzymatic hydrolysis of their corresponding glucosides, with specific activity of 1200-1400 mu Ci g(-1).",Carbon-14 biolabelling of wine polyphenols in Vitis vinifera cell suspension cultures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11879711/),[ci·mu] / [g],1200-1400,111944,DB00120,L-Phenylalanine
,11259325,maximal plasma concentrations,"The maximal plasma concentrations of radioactivity (6360 ngEq/ml) and nateglinide (5690 ng/ml) were comparable, and plasma radioactivity concentrations were about twice those of blood at all times.",Pharmacokinetics and metabolism of nateglinide in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259325/),[ngeq] / [ml],6360,112229,DB00120,L-Phenylalanine
,11259325,maximal plasma concentrations,"The maximal plasma concentrations of radioactivity (6360 ngEq/ml) and nateglinide (5690 ng/ml) were comparable, and plasma radioactivity concentrations were about twice those of blood at all times.",Pharmacokinetics and metabolism of nateglinide in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259325/),[ng] / [ml],5690,112230,DB00120,L-Phenylalanine
,11259325,Oral bioavailability,"Oral bioavailability was 72%, indicating only a modest first-pass effect.",Pharmacokinetics and metabolism of nateglinide in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259325/),%,72,112231,DB00120,L-Phenylalanine
,11259325,elimination half-lives,"After either dose, plasma nateglinide concentrations declined rapidly with elimination half-lives of 1.5 to 1.7 h and plasma clearance of 7.4 l/h.",Pharmacokinetics and metabolism of nateglinide in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259325/),h,1.5 to 1.7,112232,DB00120,L-Phenylalanine
,11259325,plasma clearance,"After either dose, plasma nateglinide concentrations declined rapidly with elimination half-lives of 1.5 to 1.7 h and plasma clearance of 7.4 l/h.",Pharmacokinetics and metabolism of nateglinide in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259325/),[l] / [h],7.4,112233,DB00120,L-Phenylalanine
,11259325,half-lives,"Plasma radioactivity was eliminated more slowly with half-lives of 52 and 35 h in plasma and blood, respectively, after the oral dose.",Pharmacokinetics and metabolism of nateglinide in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259325/),h,52,112234,DB00120,L-Phenylalanine
,11259325,half-lives,"Plasma radioactivity was eliminated more slowly with half-lives of 52 and 35 h in plasma and blood, respectively, after the oral dose.",Pharmacokinetics and metabolism of nateglinide in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11259325/),h,35,112235,DB00120,L-Phenylalanine
,21297456,mean absorption time,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,28.5,112475,DB00120,L-Phenylalanine
,21297456,lag time,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,2.9,112476,DB00120,L-Phenylalanine
,21297456,bioavailability,"Estimated population parameter values were a mean absorption time of 28.5 minutes, a lag time of 2.9 minutes, and a bioavailability of 88%.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),%,88,112477,DB00120,L-Phenylalanine
,21297456,half-life of effect delay,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),min,21,112478,DB00120,L-Phenylalanine
,21297456,concentration at 50% effect,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),[mg] / [l],1.55,112479,DB00120,L-Phenylalanine
,21297456,Emax,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),u,2.39,112480,DB00120,L-Phenylalanine
,21297456,Emax,"The pharmacodynamic model for motor ratings had the following population values: a half-life of effect delay of 21 minutes, a concentration at 50% effect of 1.55 mg/L, an Emax of 2.39 U on the treatment response scale, and a sigmoidicity of the Emax function of 11.6.",A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21297456/),,11,112481,DB00120,L-Phenylalanine
,15954175,S/N,"The instrumental detection limit of the method was determined to be 900 fg (S/N 3, pure standard).",First results of a quantitative study of DNA adducts of melphalan in the rat by isotope dilution mass spectrometry using capillary liquid chromatography coupled to electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954175/),,3,114661,DB00120,L-Phenylalanine
,28274234,tolerance,"At week 26 in the sapropterin plus diet group, mean phenylalanine tolerance was 30.5 (95% confidence interval 18.7-42.3) mg/kg/day higher than in the diet-only group (p < 0.001).","Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28274234/),[mg] / [d·kg],30.5,115093,DB00120,L-Phenylalanine
,2895212,half-life,G-CSF was rapidly cleared from the blood with a mean half-life of 110 min for the second phase.,Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895212/),min,110,115718,DB00120,L-Phenylalanine
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.42,115958,DB00120,L-Phenylalanine
,2611767,peak levels,"After loading of bromocriptine alone, we found mean peak levels at 60 min (1.42 ng/ml) and at 90 min (1.82 ng/ml).",The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611767/),[ng] / [ml],1.82,115959,DB00120,L-Phenylalanine
,8813223,time to peak plasma concentrations,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),min,49,117571,DB00120,L-Phenylalanine
,8813223,time to peak plasma concentrations,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),min,47,117572,DB00120,L-Phenylalanine
,8813223,peak plasma concentration,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[ng] / [ml],"1,273",117573,DB00120,L-Phenylalanine
,8813223,peak plasma concentration,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[ng] / [ml],"1,153",117574,DB00120,L-Phenylalanine
,8813223,area under the curve,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[μg] / [h·ml],"2,295",117575,DB00120,L-Phenylalanine
,8813223,area under the curve,"The mean time to peak plasma concentrations was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 micrograms/ml/h with Sinemet and 2,330 micrograms/ml/h with Atamet.",Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8813223/),[μg] / [h·ml],"2,330",117576,DB00120,L-Phenylalanine
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,4.1,117581,DB00120,L-Phenylalanine
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,2.9,117582,DB00120,L-Phenylalanine
,22732703,area-under-the-curve (AUC),"BU was infused daily for 4 days, either at a fixed dose of 130 mg/m² (5 patients) or using pharmacokinetic (PK) dose adjustment (42 patients), to target an average daily area-under-the-curve (AUC) of 5000 μmol/min, determined by a test dose of i.v. BU at 32 mg/m².","Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732703/),[μM] / [min],5000,117724,DB00120,L-Phenylalanine
,2479431,half-life (t1/2),Pharmacokinetic study of rhG-CSF showed a half-life (t1/2) of 114 min.,In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2479431/),min,114,118667,DB00120,L-Phenylalanine
,8175392,survival time,"Therapy experiments: Median survival time of untreated rats was 44 days compared to 76 days and 93 days for those receiving physical doses of 2.73 Gy and 3.64 Gy, respectively.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,44,118931,DB00120,L-Phenylalanine
,8175392,survival time,"Therapy experiments: Median survival time of untreated rats was 44 days compared to 76 days and 93 days for those receiving physical doses of 2.73 Gy and 3.64 Gy, respectively.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,76,118932,DB00120,L-Phenylalanine
,8175392,survival time,"Therapy experiments: Median survival time of untreated rats was 44 days compared to 76 days and 93 days for those receiving physical doses of 2.73 Gy and 3.64 Gy, respectively.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,93,118933,DB00120,L-Phenylalanine
,8175392,survival times,"Rats that had received both 10B-BPA and physical doses of 1.82, 2.73, or 3.64 Gy had median survival times of 170, 182, and 262 days, respectively.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,170,118934,DB00120,L-Phenylalanine
,8175392,survival times,"Rats that had received both 10B-BPA and physical doses of 1.82, 2.73, or 3.64 Gy had median survival times of 170, 182, and 262 days, respectively.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,182,118935,DB00120,L-Phenylalanine
,8175392,survival times,"Rats that had received both 10B-BPA and physical doses of 1.82, 2.73, or 3.64 Gy had median survival times of 170, 182, and 262 days, respectively.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,262,118936,DB00120,L-Phenylalanine
,8175392,survival times,"Animals that received 12 Gy in a single dose or 18 Gy fractionated (2 Gy x 9) of gamma photons from a 137Cs source had median survival times of 86 and 79 days, respectively, compared to 47 days for untreated animals.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,86,118937,DB00120,L-Phenylalanine
,8175392,survival times,"Animals that received 12 Gy in a single dose or 18 Gy fractionated (2 Gy x 9) of gamma photons from a 137Cs source had median survival times of 86 and 79 days, respectively, compared to 47 days for untreated animals.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,79,118938,DB00120,L-Phenylalanine
,8175392,survival times,"Animals that received 12 Gy in a single dose or 18 Gy fractionated (2 Gy x 9) of gamma photons from a 137Cs source had median survival times of 86 and 79 days, respectively, compared to 47 days for untreated animals.",A nude rat model for neutron capture therapy of human intracerebral melanoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8175392/),d,47,118939,DB00120,L-Phenylalanine
,2305718,Peak plasma melphalan concentrations,Peak plasma melphalan concentrations in the three patients ranged from 0.354 (patient 2) to 1.768 micrograms/ml (patient 1).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[μg] / [ml],0.354,119352,DB00120,L-Phenylalanine
,2305718,Peak plasma melphalan concentrations,Peak plasma melphalan concentrations in the three patients ranged from 0.354 (patient 2) to 1.768 micrograms/ml (patient 1).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[μg] / [ml],1.768,119353,DB00120,L-Phenylalanine
,2305718,concentration X time products (C x Ts),"Plasma melphalan concentration X time products (C x Ts) showed extreme variability in one patient (patient 2), ranging from 0.76 to 4.48 micrograms.h/ml.",Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),[h·μg] / [ml],0.76 to 4.48,119354,DB00120,L-Phenylalanine
,2305718,plasma C X T ratios,The p.o.:i.v. plasma C X T ratios for high-dose melphalan ranged between 0.09 (patient 3) and 0.58 (patient 2).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),,0.09,119355,DB00120,L-Phenylalanine
,2305718,plasma C X T ratios,The p.o.:i.v. plasma C X T ratios for high-dose melphalan ranged between 0.09 (patient 3) and 0.58 (patient 2).,Pharmacokinetics of very high-dose oral melphalan in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305718/),,0.58,119356,DB00120,L-Phenylalanine
,11712868,t(1/2),"Analysis of the arterial blood dialysates showed a lower half-life of MD in ACo rats (t(1/2): 1.5 +/- 0.3 h, n= 6, P< 0.05, 't' test) than in SO rats (t(1/2): 3.7 +/- 1.0 h, n= 6).",Pharmacokinetic and pharmacodynamic alterations of methyldopa in rats with aortic coarctation. A study using microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11712868/),h,1.5,121147,DB00120,L-Phenylalanine
,11712868,t(1/2),"Analysis of the arterial blood dialysates showed a lower half-life of MD in ACo rats (t(1/2): 1.5 +/- 0.3 h, n= 6, P< 0.05, 't' test) than in SO rats (t(1/2): 3.7 +/- 1.0 h, n= 6).",Pharmacokinetic and pharmacodynamic alterations of methyldopa in rats with aortic coarctation. A study using microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11712868/),h,3.7,121148,DB00120,L-Phenylalanine
,10510160,"AUC(0,tau)","The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively.",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0.39,121517,DB00120,L-Phenylalanine
,10510160,Cmax,"The mean AUC(0,tau) and Cmax values at baseline were 0.39 microg ml-1 h and 0. 14 microg ml-1, respectively.",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[μg] / [ml],0. 14,121518,DB00120,L-Phenylalanine
,10510160,"AUC(0,tau)","During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0.35,121519,DB00120,L-Phenylalanine
,10510160,"AUC(0,tau)","During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[h·μg] / [ml],0. 34,121520,DB00120,L-Phenylalanine
,10510160,Cmax,"During tolcapone treatment these values were on average 0.35 microg ml-1 h (AUC(0,tau), week 1-2), 0. 34 microg ml-1 h (AUC(0,tau), week 6 and 0.13 microg ml-1 (Cmax, weeks 1-2 and 6).",COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),[μg] / [ml],0.13,121521,DB00120,L-Phenylalanine
,10510160,tmax,tmax remained unchanged (approx. 2 h).,COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510160/),h,2,121522,DB00120,L-Phenylalanine
less,3948304,elimination half-life (t1/2,The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration.,Pharmacokinetics of high-dose melphalan in children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948304/),min,80,121683,DB00120,L-Phenylalanine
,3311444,half-life,"The elimination rate of melphalan from plasma was significantly increased by cimetidine (P less than 0.05), the half-life being reduced from 1.94 +/- 0.55 h to 1.57 +/- 0.53 h.",Interaction of cimetidine with oral melphalan. A pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311444/),h,1.94,122237,DB00120,L-Phenylalanine
,3311444,half-life,"The elimination rate of melphalan from plasma was significantly increased by cimetidine (P less than 0.05), the half-life being reduced from 1.94 +/- 0.55 h to 1.57 +/- 0.53 h.",Interaction of cimetidine with oral melphalan. A pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311444/),h,1.57,122238,DB00120,L-Phenylalanine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.9,122908,DB00120,L-Phenylalanine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.1,122909,DB00120,L-Phenylalanine
,1791629,EC50,"In the presence of ADO (1 microM), R 75,231 (EC50 = 1.9 +/- 0.3 x 10(-7) M) (n = 3) was almost as potent as dilazep (EC50 = 1.1 +/- 0.2 x 10(-7) M) (n = 3), but far more potent than dipyridamole (EC50 = 1.2 +/- 0.2 x 10(-6) M) (n = 3).",Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1791629/),M,1.2,122910,DB00120,L-Phenylalanine
,7479562,AUC0-->3,"The AUC0-->3 values for the non-protein bound L-DOPA did not differ significantly between the dialysis (141.3 +/- 16.0 nmol.h/ml) and traditional whole blood sampling (145.3 +/- 18.7 nmol.h/ml), confirming that microdialysis combined with accurate calibration is a reliable technique for studying the kinetics of drugs in vivo in different tissues.",Quantitative microdialysis for studying the in vivo L-DOPA kinetics in blood and skeletal muscle of the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479562/),[h·nM] / [ml],141.3,123322,DB00120,L-Phenylalanine
,7479562,AUC0-->3,"The AUC0-->3 values for the non-protein bound L-DOPA did not differ significantly between the dialysis (141.3 +/- 16.0 nmol.h/ml) and traditional whole blood sampling (145.3 +/- 18.7 nmol.h/ml), confirming that microdialysis combined with accurate calibration is a reliable technique for studying the kinetics of drugs in vivo in different tissues.",Quantitative microdialysis for studying the in vivo L-DOPA kinetics in blood and skeletal muscle of the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479562/),[h·nM] / [ml],145.3,123323,DB00120,L-Phenylalanine
,17950919,MTD,"The gemcitabine MTD was defined at 20 hours (total dose 12,000 mg/m2) on both schedules.","Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17950919/),h,20,124583,DB00120,L-Phenylalanine
,17950919,tumor response rate,"The tumor response rate was 91%, with 50% complete responses.","Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17950919/),%,91,124584,DB00120,L-Phenylalanine
greater,6960001,recoveries,Precisions are all less than 8% with recoveries greater than 80%.,"HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6960001/),%,80,125701,DB00120,L-Phenylalanine
,8324742,concentrations,"10B concentrations in the tumor, blood, and normal brain were 23.7, 9.4, and 8.4 micrograms/g, respectively, 6 h following administration.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),,9.4,127059,DB00120,L-Phenylalanine
,8324742,concentrations,"10B concentrations in the tumor, blood, and normal brain were 23.7, 9.4, and 8.4 micrograms/g, respectively, 6 h following administration.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),,8.4,127060,DB00120,L-Phenylalanine
,8324742,survival time,"The median survival time was 44 days for untreated rats, 76 days for those receiving a physical dose of 2.7 Gy, and 93 days for those receiving 3.6 Gy.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,44,127061,DB00120,L-Phenylalanine
,8324742,survival time,"The median survival time was 44 days for untreated rats, 76 days for those receiving a physical dose of 2.7 Gy, and 93 days for those receiving 3.6 Gy.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,76,127062,DB00120,L-Phenylalanine
,8324742,survival time,"The median survival time was 44 days for untreated rats, 76 days for those receiving a physical dose of 2.7 Gy, and 93 days for those receiving 3.6 Gy.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,93,127063,DB00120,L-Phenylalanine
,8324742,total tumor physical doses,"Animals receiving both 10B-L-boronophenylalanine and physical doses of 1.8, 2.7, or 3.6 Gy (total tumor physical doses of 5.0, 7.5, or 10.1 Gy) had median survival times of 170, 182, and 262 days, respectively.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),,5.0,127064,DB00120,L-Phenylalanine
,8324742,total tumor physical doses,"Animals receiving both 10B-L-boronophenylalanine and physical doses of 1.8, 2.7, or 3.6 Gy (total tumor physical doses of 5.0, 7.5, or 10.1 Gy) had median survival times of 170, 182, and 262 days, respectively.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),,7,127065,DB00120,L-Phenylalanine
,8324742,survival times,"Animals receiving both 10B-L-boronophenylalanine and physical doses of 1.8, 2.7, or 3.6 Gy (total tumor physical doses of 5.0, 7.5, or 10.1 Gy) had median survival times of 170, 182, and 262 days, respectively.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,170,127066,DB00120,L-Phenylalanine
,8324742,survival times,"Animals receiving both 10B-L-boronophenylalanine and physical doses of 1.8, 2.7, or 3.6 Gy (total tumor physical doses of 5.0, 7.5, or 10.1 Gy) had median survival times of 170, 182, and 262 days, respectively.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,182,127067,DB00120,L-Phenylalanine
,8324742,survival times,"Animals receiving both 10B-L-boronophenylalanine and physical doses of 1.8, 2.7, or 3.6 Gy (total tumor physical doses of 5.0, 7.5, or 10.1 Gy) had median survival times of 170, 182, and 262 days, respectively.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,262,127068,DB00120,L-Phenylalanine
,8324742,survival times,"In a parallel study, animals that were irradiated with gamma photons from a 137Cs source with 12 Gy or 2.0 Gy 9 delivered to the head had median survival times of 86 and 79 days, respectively, compared to 47 days for untreated animals.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,86,127069,DB00120,L-Phenylalanine
,8324742,survival times,"In a parallel study, animals that were irradiated with gamma photons from a 137Cs source with 12 Gy or 2.0 Gy 9 delivered to the head had median survival times of 86 and 79 days, respectively, compared to 47 days for untreated animals.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,79,127070,DB00120,L-Phenylalanine
,8324742,survival times,"In a parallel study, animals that were irradiated with gamma photons from a 137Cs source with 12 Gy or 2.0 Gy 9 delivered to the head had median survival times of 86 and 79 days, respectively, compared to 47 days for untreated animals.",Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324742/),d,47,127071,DB00120,L-Phenylalanine
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1599,127166,DB00120,L-Phenylalanine
,9579293,area under the curve,The area under the curve was 1599 +/- 615 ng.ml-1 h. (levodopa + saline) and 1821 +/- 625 ng.ml-1.h (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[h·ng] / [ml],1821,127167,DB00120,L-Phenylalanine
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1094,127168,DB00120,L-Phenylalanine
,9579293,Cmax,Cmax was 1094 +/- 476 ng.ml-1 (levodopa + saline) and 1129 +/- 435 ng.ml-1 (levodopa + apomorphine).,Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],1129,127169,DB00120,L-Phenylalanine
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),[ng] / [ml],430,127170,DB00120,L-Phenylalanine
,9579293,EC50,"Estimates of the EC50 of levodopa decreased significantly from 430 +/- 163 ng.ml-1 (levodopa + saline) to 315 +/- 123 ng+ml-1 (levodopa + apomorphine) (95% confidence interval [CI] 0.51 -0.98, point estimator 0.75).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),1/[ng+ml],315,127171,DB00120,L-Phenylalanine
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,1.9,127172,DB00120,L-Phenylalanine
,9579293,duration of the motor response,"The mean duration of the motor response rose from 1.9 +/- 0.5 h (levodopa + saline) to 3.0 +/- 0.9 h (levodopa + apomorphine (95% CI 1.23 to 2.06, point estimator 1.60).",Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579293/),h,3.0,127173,DB00120,L-Phenylalanine
,32935460,tmax,Solriamfetol median tmax was 2-3 hours; exposure was dose-proportional.,"A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935460/),h,2-3,128175,DB00120,L-Phenylalanine
,12193065,IC(50),"CGS 34226 is a thiol-containing, potent dual inhibitor of endothelin converting enzyme-1 (ECE-1) and neutral endopeptidase 24.11 (NEP) with IC(50) values of 11 and 5 nM respectively.",Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193065/),nM,11,128985,DB00120,L-Phenylalanine
,12193065,IC(50),"CGS 34226 is a thiol-containing, potent dual inhibitor of endothelin converting enzyme-1 (ECE-1) and neutral endopeptidase 24.11 (NEP) with IC(50) values of 11 and 5 nM respectively.",Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193065/),nM,5,128986,DB00120,L-Phenylalanine
,12193065,area under the curve,"Thirty and 120 min after the administration of vehicle, big ET-1 (0.3 nmol/kg, intravenously; i.v.) produced pressor responses of approximately 800 mmHg.min (area under the curve for change in MAPxtime).",Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12193065/),,800,128987,DB00120,L-Phenylalanine
,2089102,Ki,Ro 40-7592 was found to inhibit COMT in a competitive fashion both in the CNS and in the periphery (Ki for the liver enzyme = 30 nM).,Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2089102/),nM,30,131877,DB00120,L-Phenylalanine
,2076722,half-life,The disequilibrium half-life for development of effect after oral administration was calculated to be about 30 min.,Pharmacokinetics and effects of levodopa in advanced Parkinson's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076722/),min,30,133317,DB00120,L-Phenylalanine
,908178,overall elimination constant Ke1,"2. For intravenous administration the overall elimination constant Ke1 was 0.56 +/- 0.03 h-1, the volume of distribution of the central compartment 0.29 +/- 0.80 1 kg-1 and the plasma clearance rate 11.2 +/- 0.6 1 h-1.","Pharmacokinetics of methyldopa. Plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908178/),1/[h],0.56,134061,DB00120,L-Phenylalanine
,908178,volume of distribution of the central compartment,"2. For intravenous administration the overall elimination constant Ke1 was 0.56 +/- 0.03 h-1, the volume of distribution of the central compartment 0.29 +/- 0.80 1 kg-1 and the plasma clearance rate 11.2 +/- 0.6 1 h-1.","Pharmacokinetics of methyldopa. Plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908178/),[1] / [kg],0.29,134062,DB00120,L-Phenylalanine
,908178,plasma clearance rate,"2. For intravenous administration the overall elimination constant Ke1 was 0.56 +/- 0.03 h-1, the volume of distribution of the central compartment 0.29 +/- 0.80 1 kg-1 and the plasma clearance rate 11.2 +/- 0.6 1 h-1.","Pharmacokinetics of methyldopa. Plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908178/),[1] / [h],11.2,134063,DB00120,L-Phenylalanine
,908178,Plasma half-times,"3. Plasma half-times during the beta-phase of the methyldopa plasma decay curve following intravenous and oral administration were 2.8 +/- 1.3 and 2.1 +/- 0.7 h, respectively.","Pharmacokinetics of methyldopa. Plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908178/),h,2.8,134064,DB00120,L-Phenylalanine
,908178,Plasma half-times,"3. Plasma half-times during the beta-phase of the methyldopa plasma decay curve following intravenous and oral administration were 2.8 +/- 1.3 and 2.1 +/- 0.7 h, respectively.","Pharmacokinetics of methyldopa. Plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908178/),h,2.1,134065,DB00120,L-Phenylalanine
,908178,Maximal plasma levels,4. Maximal plasma levels in hypertensive out-patients show great variation and range from 0 to 1.9 microgram ml-1.,"Pharmacokinetics of methyldopa. Plasma levels following single intravenous, oral and multiple oral dosage in normotensive and hypertensive subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/908178/),[μg] / [ml],0 to 1.9,134066,DB00120,L-Phenylalanine
,7931323,k0D,"After intravenous injection, FDOPA in circulation was O-methylated (k0D = 0.055 min-1), and the metabolite (O-methyl-FDOPA) escaped from plasma with a rate constant (k-1M) of 0.01 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.055,134094,DB00120,L-Phenylalanine
,7931323,rate constant (k-1M),"After intravenous injection, FDOPA in circulation was O-methylated (k0D = 0.055 min-1), and the metabolite (O-methyl-FDOPA) escaped from plasma with a rate constant (k-1M) of 0.01 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.01,134095,DB00120,L-Phenylalanine
,7931323,initial clearance of FDOPA to striatum (K1D),"The initial clearance of FDOPA to striatum (K1D) was 0.07 ml g-1 min-1, and the equilibrium distribution volume (VeD) was 0.67 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g·min],0.07,134096,DB00120,L-Phenylalanine
,7931323,equilibrium distribution volume (VeD),"The initial clearance of FDOPA to striatum (K1D) was 0.07 ml g-1 min-1, and the equilibrium distribution volume (VeD) was 0.67 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g],0.67,134097,DB00120,L-Phenylalanine
,7931323,initial clearance,"The initial clearance of O-methyl-FDOPA to striatum (K1M) was 0.08 ml g-1 min-1, and the equilibrium distribution volume (VeM) was 0.75 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g·min],0.08,134098,DB00120,L-Phenylalanine
,7931323,equilibrium distribution volume (VeM),"The initial clearance of O-methyl-FDOPA to striatum (K1M) was 0.08 ml g-1 min-1, and the equilibrium distribution volume (VeM) was 0.75 ml g-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),[ml] / [g],0.75,134099,DB00120,L-Phenylalanine
,7931323,rate constant of FDOP,The rate constant of FDOPA decarboxylation (k3D) was 0.17 min-1 in striatum.,A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.17,134100,DB00120,L-Phenylalanine
,7931323,apparent rate constant,"The elimination of 6-[18F]fluorodopamine (FDA) from striatum suggested an apparent rate constant for monoamine oxidase activity (k7') of 0.055 min-1. 6-[18F]Fluorohomovanillic acid (FHVA) was formed from 6-[18F]fluoro-L-3,4-dihydroxyphenylacetic acid with a rate constant (k11) of 0.083 min-1, and FHVA was eliminated from striatum (k9) with a rate constant of 0.12 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.055,134101,DB00120,L-Phenylalanine
,7931323,rate constant (k11),"The elimination of 6-[18F]fluorodopamine (FDA) from striatum suggested an apparent rate constant for monoamine oxidase activity (k7') of 0.055 min-1. 6-[18F]Fluorohomovanillic acid (FHVA) was formed from 6-[18F]fluoro-L-3,4-dihydroxyphenylacetic acid with a rate constant (k11) of 0.083 min-1, and FHVA was eliminated from striatum (k9) with a rate constant of 0.12 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.083,134102,DB00120,L-Phenylalanine
,7931323,rate constant,"The elimination of 6-[18F]fluorodopamine (FDA) from striatum suggested an apparent rate constant for monoamine oxidase activity (k7') of 0.055 min-1. 6-[18F]Fluorohomovanillic acid (FHVA) was formed from 6-[18F]fluoro-L-3,4-dihydroxyphenylacetic acid with a rate constant (k11) of 0.083 min-1, and FHVA was eliminated from striatum (k9) with a rate constant of 0.12 min-1.",A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931323/),1/[min],0.12,134103,DB00120,L-Phenylalanine
,6705135,peak plasma levels,Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml).,Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705135/),[ng] / [ml],65,134966,DB00120,L-Phenylalanine
,6705135,peak plasma levels,Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml).,Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705135/),[ng] / [ml],195,134967,DB00120,L-Phenylalanine
,6705135,peak plasma levels,Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml).,Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705135/),h,2.8,134968,DB00120,L-Phenylalanine
,6705135,peak plasma levels,Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml).,Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705135/),h,1.3,134969,DB00120,L-Phenylalanine
,6705135,areas under the curve,Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml).,Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705135/),[min·μg] / [ml],10.8,134970,DB00120,L-Phenylalanine
,6705135,areas under the curve,Considerable differences were observed in the melphalan concentration curves between the 'PO fed' and 'PO fasting' days: on the PO fed days the delay before absorption started was longer (1.1 +/- 0.5 h as against 0.3 +/- 0.1 h); peak plasma levels were one-third the value (65 +/- 15 ng/ml; 195 +/- 80 ng/ml) and occurred at twice the time after administration (2.8 +/- 0.8 h; 1.3 +/- 0.3 h); and areas under the curve were smaller 10.8 +/- 4.7 min X micrograms/ml; 23.8 +/- 13.8 min X micrograms/ml).,Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705135/),[min·μg] / [ml],23.8,134971,DB00120,L-Phenylalanine
,3948305,area under the curve (AUC),"The median area under the curve (AUC) when taken fasting was 179 (range 95-336) ng X h X ml-1, and when taken with food, 122 (47-227) ng X h X ml-1, the median reduction being 39% (P less than 0.01).",The effect of food on oral melphalan absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),[h·ng] / [ml],179,135278,DB00120,L-Phenylalanine
,3948305,area under the curve (AUC),"The median area under the curve (AUC) when taken fasting was 179 (range 95-336) ng X h X ml-1, and when taken with food, 122 (47-227) ng X h X ml-1, the median reduction being 39% (P less than 0.01).",The effect of food on oral melphalan absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),[h·ng] / [ml],122,135279,DB00120,L-Phenylalanine
,3948305,terminal melphalan,"In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1).",The effect of food on oral melphalan absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),min,57,135280,DB00120,L-Phenylalanine
,3948305,half-life,"In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1).",The effect of food on oral melphalan absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),min,57,135281,DB00120,L-Phenylalanine
,3948305,oral half-life,"In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1).",The effect of food on oral melphalan absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),min,55,135282,DB00120,L-Phenylalanine
,3948305,oral half-life,"In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1).",The effect of food on oral melphalan absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),min,55,135283,DB00120,L-Phenylalanine
,3948305,bioavailability,In these patients bioavailability was 85% (26-96)% when the drug was taken fasting and 58% (7-99)% when taken with food (P less than 0.025).,The effect of food on oral melphalan absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),%,85,135284,DB00120,L-Phenylalanine
,3948305,bioavailability,In these patients bioavailability was 85% (26-96)% when the drug was taken fasting and 58% (7-99)% when taken with food (P less than 0.025).,The effect of food on oral melphalan absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),%,58,135285,DB00120,L-Phenylalanine
,3948305,clearance,Median clearance following IV administration was 362 ml/min/m2 (range 104-694).,The effect of food on oral melphalan absorption. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948305/),[ml] / [m2·min],362,135286,DB00120,L-Phenylalanine
,12879279,half-life,The half-life of PAA was 55+/-18 min at the 1.8 g/m2 dose and 77+/-22 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,55,135414,DB00120,L-Phenylalanine
,12879279,half-life,The half-life of PAA was 55+/-18 min at the 1.8 g/m2 dose and 77+/-22 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,77,135415,DB00120,L-Phenylalanine
,12879279,half-life,The half-life of PAG was 112+/-53 min at the 1.8 g/m2 dose and 135+/-75 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,112,135416,DB00120,L-Phenylalanine
,12879279,half-life,The half-life of PAG was 112+/-53 min at the 1.8 g/m2 dose and 135+/-75 min at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),min,135,135417,DB00120,L-Phenylalanine
,12879279,clearance,The clearance of PAA was 66+/-33 ml/min per m2 at the 1.8 g/m2 dose and 60+/-24 ml/min per m2 at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[ml] / [m2·min],66,135418,DB00120,L-Phenylalanine
,12879279,clearance,The clearance of PAA was 66+/-33 ml/min per m2 at the 1.8 g/m2 dose and 60+/-24 ml/min per m2 at the 2.5 g/m2 dose.,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[ml] / [m2·min],60,135419,DB00120,L-Phenylalanine
,12879279,Vm,"The Michaelis-Menten constants describing the conversion of PAA to PAG in the model (Vm and Km) were (means+/-SD) 18.4+/-13.8 mg/m2 per min and 152+/-155 microg/ml, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[mg] / [m2·min],18.4,135420,DB00120,L-Phenylalanine
,12879279,Km,"The Michaelis-Menten constants describing the conversion of PAA to PAG in the model (Vm and Km) were (means+/-SD) 18.4+/-13.8 mg/m2 per min and 152+/-155 microg/ml, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[μg] / [ml],152,135421,DB00120,L-Phenylalanine
,12879279,V(d-PAA),"The volumes of distribution for PAA and PAG (V(d-PAA) and V(d-PAG)) were 7.9+/-3.4 l/m2 and 34.4+/-16.1 l/m2, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[l] / [m2],7.9,135422,DB00120,L-Phenylalanine
,12879279,V(d-PA,"The volumes of distribution for PAA and PAG (V(d-PAA) and V(d-PAG)) were 7.9+/-3.4 l/m2 and 34.4+/-16.1 l/m2, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[l] / [m2],7.9,135423,DB00120,L-Phenylalanine
,12879279,V(d-PA,"The volumes of distribution for PAA and PAG (V(d-PAA) and V(d-PAG)) were 7.9+/-3.4 l/m2 and 34.4+/-16.1 l/m2, respectively.",Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),[l] / [m2],34.4,135424,DB00120,L-Phenylalanine
,12879279,first-order elimination rate constant,The first-order elimination rate constant for PAG (k(e-PAG)) was 0.0091+/-0.0039 min(-1).,Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12879279/),1/[min],0.0091,135425,DB00120,L-Phenylalanine
,26366963,peak plasma LD concentration (Cmax),"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],2.0,135959,DB00120,L-Phenylalanine
,26366963,peak plasma LD concentration (Cmax),"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],1.0,135960,DB00120,L-Phenylalanine
,26366963,area under the plasma concentration time curve,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l·min],137,135961,DB00120,L-Phenylalanine
,26366963,area under the plasma concentration time curve,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l·min],33.6,135962,DB00120,L-Phenylalanine
,26366963,Cmax,"Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna.",Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26366963/),[mg] / [l],0.7,135963,DB00120,L-Phenylalanine
,8925804,Cmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),[μg] / [ml],3.87,136534,DB00120,L-Phenylalanine
,8925804,Cmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),[μg] / [ml],5.28,136535,DB00120,L-Phenylalanine
,8925804,Tmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),h,3.9,136536,DB00120,L-Phenylalanine
,8925804,Tmax,"Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal.",Effect of a high-protein meal on gabapentin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925804/),h,2.8,136537,DB00120,L-Phenylalanine
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"2,169",136647,DB00120,L-Phenylalanine
,12865145,steady-state levodopa concentrations,"At higher doses (target steady-state levodopa concentrations of 2,169 and 1,200 ng/ml), treatment-naive volunteers had unacceptably frequent side effects.",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],"1,200",136648,DB00120,L-Phenylalanine
,12865145,steady-state concentration,"The final infusion protocol, with a target steady-state concentration of 600 ng/ml, was well-tolerated (mild nausea in 11% of subjects was the only side effect occurring significantly more than in single-blind saline infusions), produced the desired plasma levodopa concentration (612+/-187 ng/ml, mean+/-S.D.), and produced statistically significant antiparkinsonian benefit (16% mean reduction in a standard rating of parkinsonian motor signs, P<0.0005).",Rapid intravenous loading of levodopa for human research: clinical results. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865145/),[ng] / [ml],600,136649,DB00120,L-Phenylalanine
,32010367,Bioavailability,"Bioavailability of the drug - nasal drops were 244.4% compared with the drug ""Madopar 125"".",Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32010367/),%,244.4,138331,DB00120,L-Phenylalanine
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.30,140754,DB00120,L-Phenylalanine
,8730980,total AUC,Benzhexol administration did not affect the total AUC of levodopa (7.30 +/- 1.09 vs 7.19 +/- 1.26 micrograms ml-1 h; means +/- s.d.).,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],7.19,140755,DB00120,L-Phenylalanine
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],39.4,140756,DB00120,L-Phenylalanine
,8730980,total AUC,The total AUC of paracetamol was not affected by benzhexol administration (39.4 +/- 8.2 vs 40.0 +/- 8.9 micrograms ml-1 h; mean +/- s.d.) 4.,The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8730980/),[h·μg] / [ml],40.0,140757,DB00120,L-Phenylalanine
,11313680,AUC,The melphalan AUC ranged from 177 to 475 microg small middle dotmin/ml (no difference between C1 and C2).,Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313680/),[dotmin·middle·small·μg] / [ml],177 to 475,142971,DB00120,L-Phenylalanine
,25862515,half-life,"Uox-HSA had a half-life of 8.8 h in mice, while wild-type Uox had a half-life of 1.3 h.",Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862515/),h,8.8,143100,DB00120,L-Phenylalanine
,25862515,half-life,"Uox-HSA had a half-life of 8.8 h in mice, while wild-type Uox had a half-life of 1.3 h.",Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862515/),h,1.3,143101,DB00120,L-Phenylalanine
,25862515,AUC,The AUC increased 5.5-fold (1657 vs. 303 mU/mL x h).,Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862515/),[mu] / [h·ml],1657,143102,DB00120,L-Phenylalanine
,25862515,AUC,The AUC increased 5.5-fold (1657 vs. 303 mU/mL x h).,Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862515/),[mu] / [h·ml],303,143103,DB00120,L-Phenylalanine
,7739350,concentrations,"When carbidopa was given intraperitoneally at a dose of 2.5 and 5 mg/kg and intravenously at 5 mg/kg, plasma carbidopa concentrations at the time of Fdopa injection were 0.95 +/- 0.26, 2.22 +/- 0.23 and 2.79 +/- 0.26 micrograms/ml, respectively.",Routes of administration and effect of carbidopa pretreatment on 6-[18F]fluoro-L-dopa/PET scans in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739350/),,2.22,143672,DB00120,L-Phenylalanine
,7739350,concentrations,"When carbidopa was given intraperitoneally at a dose of 2.5 and 5 mg/kg and intravenously at 5 mg/kg, plasma carbidopa concentrations at the time of Fdopa injection were 0.95 +/- 0.26, 2.22 +/- 0.23 and 2.79 +/- 0.26 micrograms/ml, respectively.",Routes of administration and effect of carbidopa pretreatment on 6-[18F]fluoro-L-dopa/PET scans in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739350/),,2.79,143673,DB00120,L-Phenylalanine
,7956740,terminal half-life,"Plasma concentrations of unchanged MK-852 in five rats declined with a mean terminal half-life of 0.92 hr after a 2.5 mg/kg i.v. dose of MK-852; plasma clearance and Vd were 23.1 ml/min/kg and 1.81 liters/kg, respectively.","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),h,0.92,145043,DB00120,L-Phenylalanine
,7956740,plasma clearance,"Plasma concentrations of unchanged MK-852 in five rats declined with a mean terminal half-life of 0.92 hr after a 2.5 mg/kg i.v. dose of MK-852; plasma clearance and Vd were 23.1 ml/min/kg and 1.81 liters/kg, respectively.","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),[ml] / [kg·min],23.1,145044,DB00120,L-Phenylalanine
,7956740,Vd,"Plasma concentrations of unchanged MK-852 in five rats declined with a mean terminal half-life of 0.92 hr after a 2.5 mg/kg i.v. dose of MK-852; plasma clearance and Vd were 23.1 ml/min/kg and 1.81 liters/kg, respectively.","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),[l] / [kg],1.81,145045,DB00120,L-Phenylalanine
,7956740,half-life,"Following a 0.6 mg/kg i.v. dose, the half-life, plasma clearance, and Vd of MK-852 in four dogs were 0.84 hr, 3.93 ml/min/kg, and 0.28 liters/kg, respectively.","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),h,0.84,145046,DB00120,L-Phenylalanine
,7956740,plasma clearance,"Following a 0.6 mg/kg i.v. dose, the half-life, plasma clearance, and Vd of MK-852 in four dogs were 0.84 hr, 3.93 ml/min/kg, and 0.28 liters/kg, respectively.","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),[ml] / [kg·min],3.93,145047,DB00120,L-Phenylalanine
,7956740,Vd,"Following a 0.6 mg/kg i.v. dose, the half-life, plasma clearance, and Vd of MK-852 in four dogs were 0.84 hr, 3.93 ml/min/kg, and 0.28 liters/kg, respectively.","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),[l] / [kg],0.28,145048,DB00120,L-Phenylalanine
,7956740,urinary recoveries,"In dogs, the excretion patterns of radioactivity were similar to those of rats, except that 14C urinary recoveries (79%) were higher than 3H (63%).","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),%,79,145049,DB00120,L-Phenylalanine
,7956740,urinary recoveries,"In dogs, the excretion patterns of radioactivity were similar to those of rats, except that 14C urinary recoveries (79%) were higher than 3H (63%).","Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7956740/),%,63,145050,DB00120,L-Phenylalanine
,15541426,Ki,"CR3465 (L-Tyrosine, N-[(2-quinolinyl)carbonyl]-O-(7-fluoro-2-quinolinylmethyl) sodium salt) is a potent antagonist of [3H]leukotriene D4 ([3H]LTD4) binding to guinea pig lung preparations, its Ki (4.7+/-0.7 nM) being comparable with that of montelukast (5.6+/-0.6 nM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),nM,4.7,145628,DB00120,L-Phenylalanine
,15541426,Ki,"CR3465 (L-Tyrosine, N-[(2-quinolinyl)carbonyl]-O-(7-fluoro-2-quinolinylmethyl) sodium salt) is a potent antagonist of [3H]leukotriene D4 ([3H]LTD4) binding to guinea pig lung preparations, its Ki (4.7+/-0.7 nM) being comparable with that of montelukast (5.6+/-0.6 nM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),nM,5.6,145629,DB00120,L-Phenylalanine
,15541426,ED50,"Intravenous (i.v.) administration of the agent both antagonized (ED50, 9.9+/-1.9 microg/kg) and reverted LTD4 -induced bronchoconstriction of anesthetized guinea pigs.","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),[μg] / [kg],9.9,145630,DB00120,L-Phenylalanine
,15541426,IC50,"CR3465 reduced inflammatory infiltrates in the bronchoalveolar lavage fluid after antigen challenge of sensitized animals, and proved also active in inhibiting phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) activities exhibited by human platelets and neutrophils (IC50, 2.01+/-0.07 and 4.7+/-0.5 microM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),μM,2.01,145631,DB00120,L-Phenylalanine
,15541426,IC50,"CR3465 reduced inflammatory infiltrates in the bronchoalveolar lavage fluid after antigen challenge of sensitized animals, and proved also active in inhibiting phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) activities exhibited by human platelets and neutrophils (IC50, 2.01+/-0.07 and 4.7+/-0.5 microM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),μM,4.7,145632,DB00120,L-Phenylalanine
,15541426,IC50,"In line with properties shown by phosphodiesterase inhibitors, CR3465 reduced the contractile response of guinea pig airways to histamine and decreased N-formyl-Met-Leu-Phe (fMLP)-induced degranulation of human neutrophils (IC50, 13.8 microM).","Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),μM,13.8,145633,DB00120,L-Phenylalanine
,15541426,bioavailability,Pharmacokinetic data in the rat demonstrated approximately 100% bioavailability of the agent.,"Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15541426/),%,100,145634,DB00120,L-Phenylalanine
,2766304,half-life,The initial phase of the plasma concentration versus time curve had a half-life of 4.9 min and accounted for 94% of the total area under the curve.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),min,4.9,146324,DB00120,L-Phenylalanine
,2766304,half-life of the terminal phase of the curve,The half-life of the terminal phase of the curve was 36.7 min and the area accounted for only 6% of the total area under the curve.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),min,36.7,146325,DB00120,L-Phenylalanine
,2766304,Plasma clearance,Plasma clearance of BSO was 28.1 ml/min/kg and the steady state volume of distribution was 280 ml/kg.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),[ml] / [kg·min],28.1,146326,DB00120,L-Phenylalanine
,2766304,steady state volume of distribution,Plasma clearance of BSO was 28.1 ml/min/kg and the steady state volume of distribution was 280 ml/kg.,Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766304/),[ml] / [kg],280,146327,DB00120,L-Phenylalanine
,3427559,Time to peak plasma levodopa concentration,"Time to peak plasma levodopa concentration increased threefold (from 45 +/- 23 to 134 +/- 76 min, p less than 0.001), when levodopa was administered after meals.",Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427559/),min,45,146617,DB00120,L-Phenylalanine
,3427559,Time to peak plasma levodopa concentration,"Time to peak plasma levodopa concentration increased threefold (from 45 +/- 23 to 134 +/- 76 min, p less than 0.001), when levodopa was administered after meals.",Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427559/),min,134,146618,DB00120,L-Phenylalanine
,32003299,drug loading capacity,DTX was successfully encapsulated in the hydrophobic micellar core with a high encapsulation efficiency (> 95%) and a high drug loading capacity (4.81 ± 0.08%).,Drug-interactive mPEG-b-PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32003299/),%,4.81,146624,DB00120,L-Phenylalanine
lower,2587414,half-life,The nonapeptide [Arg8]vasopressin was rapidly degraded with a half-life of lower than 1 minute after local administration into the hippocampus.,In vivo conversion of vasopressin after microinjection into limbic brain areas of rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2587414/),min,1,146917,DB00120,L-Phenylalanine
,3723361,minimum effective dose,It was found from these results that DL-phenylalanine acted as a competing agent in the GI tract and the minimum effective dose required of DL-phenylalanine might be 1 g for 50 mg of cinnarizine in the cinnarizine-beta-cyclodextrin complex.,Enhancement of bioavailability of cinnarizine from its beta-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723361/),g,1,147149,DB00120,L-Phenylalanine
,25649051,Maximum COMT inhibition (Emax),Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).,"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649051/),%,52,147219,DB00120,L-Phenylalanine
,25649051,Maximum COMT inhibition (Emax),Maximum COMT inhibition (Emax) ranged from 52% (5 mg OPC) to 80% (30 mg OPC).,"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649051/),%,80,147220,DB00120,L-Phenylalanine
less,7127659,t1/2,"Uptake of label in most tissues was rapid, with a t1/2 of less than 1 h.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,1,147278,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues of the gastrointestinal tract showed the most rapid rates of elimination, with t1/2 beta of 13, 24, 18, and 19 h for stomach, duodenum, and small and large intestines, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,13,147279,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues of the gastrointestinal tract showed the most rapid rates of elimination, with t1/2 beta of 13, 24, 18, and 19 h for stomach, duodenum, and small and large intestines, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,24,147280,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues of the gastrointestinal tract showed the most rapid rates of elimination, with t1/2 beta of 13, 24, 18, and 19 h for stomach, duodenum, and small and large intestines, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,18,147281,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues of the gastrointestinal tract showed the most rapid rates of elimination, with t1/2 beta of 13, 24, 18, and 19 h for stomach, duodenum, and small and large intestines, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,19,147282,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Bone marrow also showed a fast rate of elimination of radioactivity, with a t1/2 beta of 30 h.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,30,147283,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues with the slowest rates of elimination were skin, eye, spleen, pancreas, and lung, with t1/2 beta of 333, 241, 149, 122, and 109 h, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,333,147284,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues with the slowest rates of elimination were skin, eye, spleen, pancreas, and lung, with t1/2 beta of 333, 241, 149, 122, and 109 h, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,241,147285,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues with the slowest rates of elimination were skin, eye, spleen, pancreas, and lung, with t1/2 beta of 333, 241, 149, 122, and 109 h, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,149,147286,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues with the slowest rates of elimination were skin, eye, spleen, pancreas, and lung, with t1/2 beta of 333, 241, 149, 122, and 109 h, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,122,147287,DB00120,L-Phenylalanine
,7127659,t1/2 beta,"Tissues with the slowest rates of elimination were skin, eye, spleen, pancreas, and lung, with t1/2 beta of 333, 241, 149, 122, and 109 h, respectively.",Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7127659/),h,109,147288,DB00120,L-Phenylalanine
,781212,fraction reaching the systemic circulation,The mean fraction reaching the systemic circulation as methyldopa was estimated to be 0.25 (range 0.08-0.62 for n = 11).,Pharmacokinetics of methyldopa in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/781212/),,0.25,148453,DB00120,L-Phenylalanine
,15048586,AUC ratios (AUC peritoneal fluid/AUC plasma),AUC ratios (AUC peritoneal fluid/AUC plasma) were 12.1 for the NT group and 12.3 for the HT group.,Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15048586/),,12.1,148853,DB00120,L-Phenylalanine
,15048586,AUC ratios (AUC peritoneal fluid/AUC plasma),AUC ratios (AUC peritoneal fluid/AUC plasma) were 12.1 for the NT group and 12.3 for the HT group.,Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15048586/),,12.3,148854,DB00120,L-Phenylalanine
,29478239,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7.,"A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),h,3.35,149136,DB00120,L-Phenylalanine
,29478239,Maximum plasma concentrations (Cmax),Maximum plasma concentrations (Cmax) of PF-06669571 were reached 3.35 and 3.19 h post-dose on day 1 and day 7.,"A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),h,3.19,149137,DB00120,L-Phenylalanine
,29478239,Cmax,"Geometric mean Cmax and area under the plasma concentration-time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively.","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),[ng] / [ml],92.51,149138,DB00120,L-Phenylalanine
,29478239,area under the plasma concentration-time profile from time 0 to 24 h,"Geometric mean Cmax and area under the plasma concentration-time profile from time 0 to 24 h post-dose on day 7 were 92.51 ng/mL and 1626 ng·h/mL, respectively.","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29478239/),[h·ng] / [ml],1626,149139,DB00120,L-Phenylalanine
,19721250,diameter,"The weight, the diameter and the hardness of the obtained tablet were 416.1 mg, 10 mmpsi, about 60 N, respectively.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),mmpsi,10,149179,DB00120,L-Phenylalanine
,19721250,hardness,"The weight, the diameter and the hardness of the obtained tablet were 416.1 mg, 10 mmpsi, about 60 N, respectively.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),,60,149180,DB00120,L-Phenylalanine
,19721250,bioavailability,"An in vivo single oral administration study using normal beagle dogs showed the bioavailability value of the obtained nateglinide dry coated tablets against nateglinide immediate release tablets was 73.6%, although the value of nateglinide controlled release tablets containing enteric coated granules was 57.2-60.8%.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),%,73.6,149181,DB00120,L-Phenylalanine
,19721250,bioavailability,"An in vivo single oral administration study using normal beagle dogs showed the bioavailability value of the obtained nateglinide dry coated tablets against nateglinide immediate release tablets was 73.6%, although the value of nateglinide controlled release tablets containing enteric coated granules was 57.2-60.8%.",Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19721250/),%,57.2-60.8,149182,DB00120,L-Phenylalanine
,2920496,peak levodopa levels,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[nM] / [ml],3.6,149240,DB00120,L-Phenylalanine
,2920496,peak levodopa levels,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[nM] / [ml],1.6,149241,DB00120,L-Phenylalanine
,2920496,AUC,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[min·nM] / [ml],257,149242,DB00120,L-Phenylalanine
,2920496,AUC,When levodopa was taken with ferrous sulfate there was a 55% decrease in peak levodopa levels (3.6 +/- 2.6 vs 1.6 +/- 0.82 nmol/ml; p less than 0.05) and a 51% decrease in AUC (257 +/- 133 vs 125 +/- 51 nmol.min/ml; p less than 0.01).,Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920496/),[min·nM] / [ml],125,149243,DB00120,L-Phenylalanine
,15375519,Tumor response rate (complete + partial response),"Tumor response rate (complete + partial response) and time to local disease progression were significantly different in group A and B (9% vs 58% and 7 vs 13 months, respectively).",Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15375519/),%,9,149755,DB00120,L-Phenylalanine
,15375519,Tumor response rate (complete + partial response),"Tumor response rate (complete + partial response) and time to local disease progression were significantly different in group A and B (9% vs 58% and 7 vs 13 months, respectively).",Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15375519/),%,58,149756,DB00120,L-Phenylalanine
,15375519,time to local disease progression,"Tumor response rate (complete + partial response) and time to local disease progression were significantly different in group A and B (9% vs 58% and 7 vs 13 months, respectively).",Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15375519/),%,58,149757,DB00120,L-Phenylalanine
,15375519,time to local disease progression,"Tumor response rate (complete + partial response) and time to local disease progression were significantly different in group A and B (9% vs 58% and 7 vs 13 months, respectively).",Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15375519/),month,7,149758,DB00120,L-Phenylalanine
,15375519,time to local disease progression,"Tumor response rate (complete + partial response) and time to local disease progression were significantly different in group A and B (9% vs 58% and 7 vs 13 months, respectively).",Hypoxic antiblastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings of a novel treatment for in transit melanoma metastases. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15375519/),month,13,149759,DB00120,L-Phenylalanine
,1974290,t 1/2 alpha,"By the i.v. route, elimination followed apparent first order kinetics and was biphasic with a t 1/2 alpha of 7 min and terminal half-life of 67 min.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,7,150493,DB00120,L-Phenylalanine
,1974290,terminal half-life,"By the i.v. route, elimination followed apparent first order kinetics and was biphasic with a t 1/2 alpha of 7 min and terminal half-life of 67 min.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,67,150494,DB00120,L-Phenylalanine
,1974290,t 1/2 ab,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,6,150495,DB00120,L-Phenylalanine
,1974290,terminal half-life,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),min,65,150496,DB00120,L-Phenylalanine
,1974290,bioavailability,"After i.p. administration absorption was rapid (t 1/2 ab 6 min), elimination was monophasic with a terminal half-life almost identical following i.v. dosing (65 min), and bioavailability was 40%.","Pharmacokinetics, bioavailability, metabolism, tissue distribution and urinary excretion of gamma-L-glutamyl-L-dopa in the rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974290/),%,40,150497,DB00120,L-Phenylalanine
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[min·ng] / [ml],"639,490",150783,DB00120,L-Phenylalanine
,19412946,area-under-the-concentration-curve,"PK analysis revealed the anticipated near-equivalent mean L-dopa area-under-the-concentration-curve values (639,490 ng min/mL for two doses of CLE, and 662,577 for CL-CR, P = 0.86).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"662,577",150784,DB00120,L-Phenylalanine
,19412946,maximal concentration,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),[ng] / [ml],"1,926",150785,DB00120,L-Phenylalanine
,19412946,CL-CR,"The mean maximal concentration for the first CLE dose was 1,926 +/- 760 ng/mL and for CL-CR, 1,840 +/- 889 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,"1,840",150786,DB00120,L-Phenylalanine
,19412946,CL-CR,"During the PK studies, the mean time that L-dopa concentration was > or =1,000 ng/mL for CLE was 291 +/- 88 minutes and for CL-CR, 306 +/- 86 (P = 0.33).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),,306,150787,DB00120,L-Phenylalanine
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,18,150788,DB00120,L-Phenylalanine
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,28,150789,DB00120,L-Phenylalanine
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,64,150790,DB00120,L-Phenylalanine
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,65,150791,DB00120,L-Phenylalanine
,19412946,percent-time,"The mean percent-time in ""off"" state was 18% for CLE and 28% for CL-CR (P = 0.017), ""on state without dyskinesia"" was 64% for CLE and 65% for CL-CR (P = 0.803), and ""on state with nontroublesome dyskinesia"" was 18% for CLE and 7% for CL-CR (P = 0.03).",Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19412946/),%,7,150792,DB00120,L-Phenylalanine
,1761075,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[min·μM] / [l],547,150795,DB00120,L-Phenylalanine
,1761075,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[min·μM] / [l],428,150796,DB00120,L-Phenylalanine
,1761075,apparent oral clearance,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[ml] / [kg·min],8.1,150797,DB00120,L-Phenylalanine
,1761075,apparent oral clearance,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),[ml] / [kg·min],10.7,150798,DB00120,L-Phenylalanine
,1761075,plasma elimination half-life,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),min,67.6,150799,DB00120,L-Phenylalanine
,1761075,plasma elimination half-life,"The area under the plasma concentration-time curve (AUC) of levodopa was significantly greater in the older group (547 versus 428 mumol.l-1.min in Group B), coupled with a reduced apparent oral clearance (8.1 versus 10.7 ml.min-1.kg-1) and a longer plasma elimination half-life (67.6 versus 54.6 min).",Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1761075/),min,54.6,150800,DB00120,L-Phenylalanine
,1355542,systemic extraction ratio,"When L-dopa was administered into the vascular perfusate, a systemic extraction ratio of 0.38 was found, the major part being decarboxylated to dopamine.",Decarboxylation of L-dopa in the rat isolated vascularly perfused small intestine: contribution to systemic elimination and dose-dependent first pass effect. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355542/),,0.38,150936,DB00120,L-Phenylalanine
,1355542,clearance,The intestinal L-dopa clearance was estimated to be 17.1 mL min-1 kg-1.,Decarboxylation of L-dopa in the rat isolated vascularly perfused small intestine: contribution to systemic elimination and dose-dependent first pass effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1355542/),[ml] / [kg·min],17.1,150937,DB00120,L-Phenylalanine
,28430745,overall response rate,A total of 35 patients with complete data were analyzed and the overall response rate was 91.4%.,Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430745/),%,91.4,151188,DB00120,L-Phenylalanine
,8150874,extraction yield,The extraction yield of pentamidine was 82%.,High-performance liquid chromatographic determination of pentamidine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150874/),%,82,152422,DB00120,L-Phenylalanine
,8150874,limit of detection,The limit of detection was 8.6 ng/ml with a sample size of 100 microliters.,High-performance liquid chromatographic determination of pentamidine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150874/),[ng] / [ml],8.6,152423,DB00120,L-Phenylalanine
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],928.07,153188,DB00120,L-Phenylalanine
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],1055.99,153189,DB00120,L-Phenylalanine
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],137.25,153190,DB00120,L-Phenylalanine
,22057087,AUC(0→∞),"The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively.","Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057087/),[ngh] / [ml],467.15,153191,DB00120,L-Phenylalanine
,7296753,activation energy,The HPTLC method was used to determine the activation energy for in vitro melphalan hydrolysis: this was 14.5 kcal/mole.,Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7296753/),[kcal] / [mole],14.5,153346,DB00120,L-Phenylalanine
,7296753,t1/2,The mean t1/2 in four animals was 32.6 +/- 10.3 (S.D.) min and following IV administration to two animals the apparent volumes of distribution were 2.20 and 1.73 l/kg.,Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7296753/),min,32.6,153347,DB00120,L-Phenylalanine
,7296753,apparent volumes of distribution,The mean t1/2 in four animals was 32.6 +/- 10.3 (S.D.) min and following IV administration to two animals the apparent volumes of distribution were 2.20 and 1.73 l/kg.,Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7296753/),[l] / [kg],2.20,153348,DB00120,L-Phenylalanine
,7296753,apparent volumes of distribution,The mean t1/2 in four animals was 32.6 +/- 10.3 (S.D.) min and following IV administration to two animals the apparent volumes of distribution were 2.20 and 1.73 l/kg.,Melphalan estimation by quantitative thin-layer chromatography. Observations on melphalan hydrolysis in vitro and pharmacokinetics in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7296753/),[l] / [kg],1.73,153349,DB00120,L-Phenylalanine
,17400422,flow rate,During melphalan administration in the hepatic inflow cannula a mean flow rate of 121.3 mL/min and mean pressure of 62.5mm Hg were achieved.,Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17400422/),[ml] / [min],121.3,153547,DB00120,L-Phenylalanine
,17400422,pressure,During melphalan administration in the hepatic inflow cannula a mean flow rate of 121.3 mL/min and mean pressure of 62.5mm Hg were achieved.,Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17400422/),hg·mm,62.5,153548,DB00120,L-Phenylalanine
,8223831,relative bioavailability,The relative bioavailability of levodopa in the solid preparation compared to the dispersion was in all patients 100%.,Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223831/),%,100,153859,DB00120,L-Phenylalanine
less,2747308,Absorption lag-time,Absorption lag-time was less than 1 h.,Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747308/),h,1,154035,DB00120,L-Phenylalanine
,2747308,time for attaining the peak concentration,"The median time for attaining the peak concentration was 1.12 h (97% confidence interval: 0.68-1.55), 1.21 h (0.85-1.43) and 1.08 h (0.84-1.29) after doses of 5, 10 and 20 mg.",Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747308/),h,1.12,154036,DB00120,L-Phenylalanine
,2747308,time for attaining the peak concentration,"The median time for attaining the peak concentration was 1.12 h (97% confidence interval: 0.68-1.55), 1.21 h (0.85-1.43) and 1.08 h (0.84-1.29) after doses of 5, 10 and 20 mg.",Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747308/),h,1.21,154037,DB00120,L-Phenylalanine
,2747308,time for attaining the peak concentration,"The median time for attaining the peak concentration was 1.12 h (97% confidence interval: 0.68-1.55), 1.21 h (0.85-1.43) and 1.08 h (0.84-1.29) after doses of 5, 10 and 20 mg.",Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2747308/),h,1.08,154038,DB00120,L-Phenylalanine
,32285957,AUC,The day -2 range in AUC (4.95-11.28 mg h/L) confirmed significant interpatient variability.,Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32285957/),[h·mg] / [l],4.95-11.28,154051,DB00120,L-Phenylalanine
,3701643,Perfused tissue volumes,Perfused tissue volumes ranged from 2.1 to 16 liters as measured by water displacement.,Pharmacokinetics of melphalan in isolated perfusion of the limbs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701643/),l,2.1 to 16,154099,DB00120,L-Phenylalanine
,3701643,half-lives,"Mean half-lives of 4.7 +/- 0.3 and 53.0 +/- 1.6 min were obtained for the alpha and beta phase, respectively.",Pharmacokinetics of melphalan in isolated perfusion of the limbs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701643/),min,4.7,154100,DB00120,L-Phenylalanine
,3701643,half-lives,"Mean half-lives of 4.7 +/- 0.3 and 53.0 +/- 1.6 min were obtained for the alpha and beta phase, respectively.",Pharmacokinetics of melphalan in isolated perfusion of the limbs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701643/),min,53.0,154101,DB00120,L-Phenylalanine
,10508450,area under the curve (AUC,The serum samples gave a significantly higher mean area under the curve (AUC; 491 +/- 139 micromol.,"Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508450/),μM,491,154333,DB00120,L-Phenylalanine
,10508450,protein binding,"min/L), suggesting a protein binding of 50%.","Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10508450/),%,50,154334,DB00120,L-Phenylalanine
,15007638,CL,Melphalan CL was higher in male patients (14.3+/-4.5 l/h per m2) than in female patients (12.3+/-4.5 l/h per m2).,"Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15007638/),[l] / [h·m2],14.3,154798,DB00120,L-Phenylalanine
,15007638,CL,Melphalan CL was higher in male patients (14.3+/-4.5 l/h per m2) than in female patients (12.3+/-4.5 l/h per m2).,"Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15007638/),[l] / [h·m2],12.3,154799,DB00120,L-Phenylalanine
,15007638,CL,Large interindividual variability in pharmacokinetic parameters occurred (CL varied from 4.4 to 30.6 l/h per m2).,"Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15007638/),[l] / [h·m2],4.4 to 30.6,154800,DB00120,L-Phenylalanine
,17091341,Maximal BH(4) concentrations,Maximal BH(4) concentrations (median 22.69 nmol/g Hb) were measured 4 h after BH(4) administration in 63 out of 71 patients.,Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091341/),[nM] / [g·hb],22.69,155460,DB00120,L-Phenylalanine
,17091341,t (max),"The following pharmacokinetic parameters were calculated for BH(4) in blood: t (max) = 4 h, AUC (T(0-32)) = 370 nmol x h/g Hb, and t (1/2) for absorption (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases.",Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091341/),h,4,155461,DB00120,L-Phenylalanine
,17091341,AUC (T(0-32)),"The following pharmacokinetic parameters were calculated for BH(4) in blood: t (max) = 4 h, AUC (T(0-32)) = 370 nmol x h/g Hb, and t (1/2) for absorption (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases.",Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091341/),[h·nM] / [g·hb],370,155462,DB00120,L-Phenylalanine
,17091341,t (1/2),"The following pharmacokinetic parameters were calculated for BH(4) in blood: t (max) = 4 h, AUC (T(0-32)) = 370 nmol x h/g Hb, and t (1/2) for absorption (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases.",Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091341/),h,1.1,155463,DB00120,L-Phenylalanine
,17091341,t (1/2),"The following pharmacokinetic parameters were calculated for BH(4) in blood: t (max) = 4 h, AUC (T(0-32)) = 370 nmol x h/g Hb, and t (1/2) for absorption (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases.",Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091341/),h,2.5,155464,DB00120,L-Phenylalanine
,17091341,t (1/2),"The following pharmacokinetic parameters were calculated for BH(4) in blood: t (max) = 4 h, AUC (T(0-32)) = 370 nmol x h/g Hb, and t (1/2) for absorption (1.1 h), distribution (2.5 h), and elimination (46.0 h) phases.",Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091341/),h,46.0,155465,DB00120,L-Phenylalanine
,1327609,bio-availability,"Actual total daily levodopa dosage in patients treated with Sinemet CR was increased by 33%; however, the plasma level of this dosage is calculated to be similar to that of the previous dosage of Sinemet-STD (bio-availability of Sinemet CR is 71%).","Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1327609/),%,71,155796,DB00120,L-Phenylalanine
,27164062,area under the concentration-time curve,"BU was administered i.v. daily for 4 days to achieve a target area under the concentration-time curve total of 20,000 mM·min based on pharmacokinetic analysis after the first dose.","Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27164062/),mM·min,"20,000",156740,DB00120,L-Phenylalanine
,7756097,dose-corrected AUC,3. The dose-corrected AUC of levodopa after the IR-formulation was 27.5 (+/- 9.1 s.d.) ng ml-1 h per mg and 23.2 (+/- 4.6 s.d.) ng ml-1 h per mg after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[h·ng] / [mg·ml],27.5,157739,DB00120,L-Phenylalanine
,7756097,dose-corrected AUC,3. The dose-corrected AUC of levodopa after the IR-formulation was 27.5 (+/- 9.1 s.d.) ng ml-1 h per mg and 23.2 (+/- 4.6 s.d.) ng ml-1 h per mg after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[h·ng] / [mg·ml],23.2,157740,DB00120,L-Phenylalanine
,7756097,Cmax,Cmax was 1714 (+/- 1027 s.d.) ng ml-1 after the IR-formulation and 1494 (+/- 383 s.d.) ng ml-1 after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],1714,157741,DB00120,L-Phenylalanine
,7756097,Cmax,Cmax was 1714 (+/- 1027 s.d.) ng ml-1 after the IR-formulation and 1494 (+/- 383 s.d.) ng ml-1 after the CR-formulation.,Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],1494,157742,DB00120,L-Phenylalanine
,7756097,EC50,"Estimates of the EC50 of levodopa were 495 (+/- 144 s.d.) ng ml-1 (IR) and 1024 (+/- 502 s.d.) ng ml-1 (CR), respectively (95%-CI: 1.51-2.66, point estimator 1.95).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],495,157743,DB00120,L-Phenylalanine
,7756097,EC50,"Estimates of the EC50 of levodopa were 495 (+/- 144 s.d.) ng ml-1 (IR) and 1024 (+/- 502 s.d.) ng ml-1 (CR), respectively (95%-CI: 1.51-2.66, point estimator 1.95).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),[ng] / [ml],1024,157744,DB00120,L-Phenylalanine
,7756097,duration of the motor response,"The mean duration of the motor response was 1.9 (+/- 0.5 s.d.) h (IR) and 2.8 (+/- 0.7 s.d.) h (CR), respectively (95%-CI: 1.12-2.04, point estimator 1.53).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),h,1.9,157745,DB00120,L-Phenylalanine
,7756097,duration of the motor response,"The mean duration of the motor response was 1.9 (+/- 0.5 s.d.) h (IR) and 2.8 (+/- 0.7 s.d.) h (CR), respectively (95%-CI: 1.12-2.04, point estimator 1.53).",Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756097/),h,2.8,157746,DB00120,L-Phenylalanine
,29959802,Cmax,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,88.4,157833,DB00120,L-Phenylalanine
,29959802,AUC0-t,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.5,157834,DB00120,L-Phenylalanine
,29959802,AUC0-inf,"L-DOPA for Cmax , AUC0-t , and AUC0-inf were 88.4 (75.9-103.1), 89.5 (84.1-95.3), and 89.6 (84.2-95.4), respectively.","Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959802/),,89.6,157835,DB00120,L-Phenylalanine
,3995475,Peak perfusate melphalan concentrations,"Peak perfusate melphalan concentrations were 6.1 to 115 mg/ml, which was one to two logs higher than peak systemic concentratives of melphalan.",A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3995475/),[mg] / [ml],6.1 to 115,161515,DB00120,L-Phenylalanine
,12383865,maximum level,"In the blood, ""CMP-immunoreactive material"" appeared rapidly, reaching a maximum level of 5.5 microg/ml at 60 min.",Peptide fragments released from Phe-caseinomacropeptide in vivo in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383865/),[μg] / [ml],5.5,161999,DB00120,L-Phenylalanine
,9316692,plasma half-life,"As predicted from the plasma half-life (1.7 +/- 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily.",Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9316692/),h,1.7,163196,DB00120,L-Phenylalanine
,14728990,T(max),"Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated.",Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),h,1-4,164954,DB00120,L-Phenylalanine
,14728990,C(max),"Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated.",Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),[nM] / [l],258.7-259.0,164955,DB00120,L-Phenylalanine
,14728990,area under the curve (AUC,"Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated.",Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),[)h·nmol(] / [l],1708-1958,164956,DB00120,L-Phenylalanine
,14728990,elimination half-life time,The elimination half-life time was calculated to be 3.3-5.1h.,Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14728990/),h,3.3-5.1,164957,DB00120,L-Phenylalanine
,8392486,residence half-life,First PET studies with [68Ga]-DFO-SMS showed a rapid accumulation in the tumor and a residence half-life at the tumor site of about 6 hours.,New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392486/),h,6,165002,DB00120,L-Phenylalanine
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1001,165310,DB00120,L-Phenylalanine
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1082,165311,DB00120,L-Phenylalanine
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1549,165312,DB00120,L-Phenylalanine
,17654694,C(max),"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[ng] / [ml],1663,165313,DB00120,L-Phenylalanine
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],1661,165314,DB00120,L-Phenylalanine
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],1665,165315,DB00120,L-Phenylalanine
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],2462,165316,DB00120,L-Phenylalanine
,17654694,AUC,"ANOVA showed the C(max) values for levodopa were not significantly different with or without sarizotan after single doses (1001 vs 1082 ng/ml; point estimate [PE] 1.10, 90% confidence intervals [CI] 0.83-1.45) or at steady-state (1549 vs 1663 ng/ml; PE 1.06, 90% CI 0.89-1.27); nor were AUC values for single doses (1661 vs 1665 ng h/ml; PE 1.01, 90% CI 0.91-1.11) or at steady-state (2462 vs 2482 ng h/ml; PE 1.01, 90% CI 0.97-1.05).",Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654694/),[h·ng] / [ml],2482,165317,DB00120,L-Phenylalanine
,7225283,neutrophil counts,"The lowest neutrophil counts following i.v. melphalan (1 mg/kg) averaged 4.9 x 10(3)/mm3 pre-nephrectomy and 0.9 x 10(3)/mm3 post-nephrectomy, respectively (P = 0.002).",Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225283/),1/[mm3],4.9 x 10(3),166521,DB00120,L-Phenylalanine
,7225283,neutrophil counts,"The lowest neutrophil counts following i.v. melphalan (1 mg/kg) averaged 4.9 x 10(3)/mm3 pre-nephrectomy and 0.9 x 10(3)/mm3 post-nephrectomy, respectively (P = 0.002).",Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225283/),,0.9 x 10(3),166522,DB00120,L-Phenylalanine
,7225283,platelet counts,"The mean lowest recorded platelet counts after melphalan (1 mg/kg) were 115 x 10(3)/mm3 in the pre-nephrectomized dogs, and 9.7 x 10(3/mm3 in those who had been nephrectomized (P = 0.002).",Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225283/),,115 x 10(3),166523,DB00120,L-Phenylalanine
,7225283,platelet counts,"The mean lowest recorded platelet counts after melphalan (1 mg/kg) were 115 x 10(3)/mm3 in the pre-nephrectomized dogs, and 9.7 x 10(3/mm3 in those who had been nephrectomized (P = 0.002).",Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225283/),,9.7 x 10(3,166524,DB00120,L-Phenylalanine
,11012557,apparent elimination half-life,The mean apparent elimination half-life from plasma was approximately 12 h.,"A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012557/),h,12,166718,DB00120,L-Phenylalanine
greater,2778650,oral LD50,It was also noted that the oral LD50 value of 1 was greater than 6 g/kg in mice.,A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778650/),[g] / [kg],6,167319,DB00120,L-Phenylalanine
,7735207,peak concentration,"The dopamine concentration in the striatum increased immediately after L-dopa injection, with the peak concentration (15.9 +/- 0.5 micrograms/g) occurring at 3 min; then it returned to the pre-medication level until 2 h at 100 mg/kg dosing.",Pharmacokinetic and pharmacodynamic studies of L-dopa in rats. Effect of L-dopa on dopamine and dopamine metabolite concentration in rat striatum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735207/),[μg] / [g],15.9,167895,DB00120,L-Phenylalanine
,1617631,peak plasma concentration,"Pharmacokinetic studies indicated a rapid clearance of L-histidinol following a bolus dose (250 mg/kg i.p.), peak plasma concentration of 200 micrograms/ml (1.4 mM), and beta phase t1/2 of 12.6 min.",L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),[μg] / [ml],200,168290,DB00120,L-Phenylalanine
,1617631,beta phase t1/2,"Pharmacokinetic studies indicated a rapid clearance of L-histidinol following a bolus dose (250 mg/kg i.p.), peak plasma concentration of 200 micrograms/ml (1.4 mM), and beta phase t1/2 of 12.6 min.",L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),min,12.6,168291,DB00120,L-Phenylalanine
no greater,1617631,Maximum tolerable plasma steady state concentrations,Maximum tolerable plasma steady state concentrations with a 24-h infusion (2000 mg/kg/24 h) were no greater than 25 micrograms/ml (0.18 mM).,L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),[μg] / [ml],25,168292,DB00120,L-Phenylalanine
,1617631,Maximum tolerable plasma steady state concentrations,Maximum tolerable plasma steady state concentrations with a 24-h infusion (2000 mg/kg/24 h) were no greater than 25 micrograms/ml (0.18 mM).,L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617631/),mM,0.18,168293,DB00120,L-Phenylalanine
,2129121,oral bioavailability,4. The oral bioavailability of gludopa is only 1 to 2% and this rules out the dipeptide as an effective dopaminergic prodrug.,Five years' experience with gamma-L-glutamyl-L-dopa: a relatively renally specific dopaminergic prodrug in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2129121/),%,1 to 2,168601,DB00120,L-Phenylalanine
,33367562,limit of detection,"A precised (96.7%) and accurate (95.0%) HPLC method was validated at low UltraViolet (UV) wavelength of 208 nm that showed limit of detection and limit of quantitation of 59 and 177 ng/mL, respectively.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),[ng] / [ml],59,168960,DB00120,L-Phenylalanine
,33367562,limit of quantitation,"A precised (96.7%) and accurate (95.0%) HPLC method was validated at low UltraViolet (UV) wavelength of 208 nm that showed limit of detection and limit of quantitation of 59 and 177 ng/mL, respectively.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),[ng] / [ml],177,168961,DB00120,L-Phenylalanine
,33367562,bioavailability,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),%,75,168962,DB00120,L-Phenylalanine
,33367562,bioavailability,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),%,85,168963,DB00120,L-Phenylalanine
,33367562,mean residence time,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),min,78,168964,DB00120,L-Phenylalanine
,33367562,mean residence time,"Pharmacokinetic parameters including bioavailability of 75 and 85% with mean residence time of 78 and 94 min were estimated for intranasal solution and thermosensitive gel using the validated HPLC method, which indicated that levodopa nasal gel may be a good alternative with appropriate pharmacokinetic outcome.",Rapid High-Performance Liquid Chromatography Method for Levodopa Quantitation at Low UV Wavelength: Application of Pharmacokinetics Study in Rat Following Intranasal Delivery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33367562/),min,94,168965,DB00120,L-Phenylalanine
,10379864,peak systemic TNF-alpha level,"For 18 patients without leakage, the mean peak systemic TNF-alpha level was 2.8 ng/ml at 10 minutes after ILP.",Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379864/),[ng] / [ml],2.8,169536,DB00120,L-Phenylalanine
,10379864,peak systemic TNF-alpha levels,"After leakage, the peak systemic TNF-alpha levels were 31.9 and 88.3 ng/ml at 5 minutes.",Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379864/),[ng] / [ml],31.9,169537,DB00120,L-Phenylalanine
,10379864,peak systemic TNF-alpha levels,"After leakage, the peak systemic TNF-alpha levels were 31.9 and 88.3 ng/ml at 5 minutes.",Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379864/),[ng] / [ml],88.3,169538,DB00120,L-Phenylalanine
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,6,170488,DB00120,L-Phenylalanine
,15090932,Time to return to baseline,"Time to return to baseline COMT activity ranged from 6 (50 mg) to 18 hours (400 mg), following the same dose-dependent tendency.","Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15090932/),h,18,170489,DB00120,L-Phenylalanine
,16536473,T(1/2),TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000.,Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536473/),h,36.9,170969,DB00120,L-Phenylalanine
up to,16536473,tumor/plasma ratios,TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000.,Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536473/),,1000,170970,DB00120,L-Phenylalanine
,2197852,area under the plasma concentration-time curve (AUC),"Evaluation of the area under the plasma concentration-time curve (AUC) for phenylalanine also showed no significant difference between groups (197 +/- 49.1 vs 182 +/- 28.3 mumol.L-1.h for aspartame alone and aspartame plus sucrose, respectively).",Effect of sucrose on the metabolic disposition of aspartame. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197852/),[h·μM] / [l],197,171432,DB00120,L-Phenylalanine
,2197852,area under the plasma concentration-time curve (AUC),"Evaluation of the area under the plasma concentration-time curve (AUC) for phenylalanine also showed no significant difference between groups (197 +/- 49.1 vs 182 +/- 28.3 mumol.L-1.h for aspartame alone and aspartame plus sucrose, respectively).",Effect of sucrose on the metabolic disposition of aspartame. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197852/),[h·μM] / [l],182,171433,DB00120,L-Phenylalanine
,30087157,EC50,Outcomes from each of the species evaluated indicate that the EC50 of amantadine for reducing dyskinesia range from 1025 to 1633 ng/ml (1367 ng/ml for an all-species model).,Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087157/),[ng] / [ml],1025 to 1633,172850,DB00120,L-Phenylalanine
,30087157,EC50,Outcomes from each of the species evaluated indicate that the EC50 of amantadine for reducing dyskinesia range from 1025 to 1633 ng/ml (1367 ng/ml for an all-species model).,Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30087157/),[ng] / [ml],1367,172851,DB00120,L-Phenylalanine
,32823081,half-lives,"The 10B concentration in the blood peaked at the end of intravenous infusion of BPA, followed by a biphasic-decreasing curve with half-lives for the first and second components of the curve being 0.7-3.7 and 7.2-12.0 h, respectively.",Pharmacokinetics of 10B-p-boronophenylalanine (BPA) in the blood and tumors in human patients: A critical review with special reference to tumor-to-blood (T/B) ratios using resected tumor samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32823081/),h,0.7-3.7,173091,DB00120,L-Phenylalanine
,32823081,half-lives,"The 10B concentration in the blood peaked at the end of intravenous infusion of BPA, followed by a biphasic-decreasing curve with half-lives for the first and second components of the curve being 0.7-3.7 and 7.2-12.0 h, respectively.",Pharmacokinetics of 10B-p-boronophenylalanine (BPA) in the blood and tumors in human patients: A critical review with special reference to tumor-to-blood (T/B) ratios using resected tumor samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32823081/),h,7.2-12.0,173092,DB00120,L-Phenylalanine
,32823081,tumor-to-blood (T/B) ratio,The mean tumor-to-blood (T/B) ratio obtained from resected tumor samples was 3.40 ± 0.83 for melanoma and the ratio ranged from 1.4 to 4.7 for glioblastoma.,Pharmacokinetics of 10B-p-boronophenylalanine (BPA) in the blood and tumors in human patients: A critical review with special reference to tumor-to-blood (T/B) ratios using resected tumor samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32823081/),,3.40,173093,DB00120,L-Phenylalanine
,15812395,MTD,"The docetaxel MTD was defined as 400 mg/m 2 , combined with melphalan (150 mg/m2 ) and carboplatin (1000 mg/m2 ).","Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15812395/),[mg] / [2·m],400,173178,DB00120,L-Phenylalanine
,15812395,response rate,"The response rate among 38 patients with measurable disease was 95%, with 47% complete responses.","Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15812395/),%,95,173179,DB00120,L-Phenylalanine
,1587963,renal clearance,"There was also a significant increase in renal clearance of unmetabolized methyldopa (62.7 +/- 13.6 vs. 99.3 +/- 29.1 mL/min, P less than .01) and a decrease in the plasma half-life of methyldopa at day 56 (2.22 +/- 0.91 vs. 1.56 +/- 0.68 hr, P less than .05).",Increases in methyldopa absorption and renal excretion after multiple doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587963/),[ml] / [min],62.7,174247,DB00120,L-Phenylalanine
,1587963,renal clearance,"There was also a significant increase in renal clearance of unmetabolized methyldopa (62.7 +/- 13.6 vs. 99.3 +/- 29.1 mL/min, P less than .01) and a decrease in the plasma half-life of methyldopa at day 56 (2.22 +/- 0.91 vs. 1.56 +/- 0.68 hr, P less than .05).",Increases in methyldopa absorption and renal excretion after multiple doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587963/),[ml] / [min],99.3,174248,DB00120,L-Phenylalanine
,1587963,plasma half-life,"There was also a significant increase in renal clearance of unmetabolized methyldopa (62.7 +/- 13.6 vs. 99.3 +/- 29.1 mL/min, P less than .01) and a decrease in the plasma half-life of methyldopa at day 56 (2.22 +/- 0.91 vs. 1.56 +/- 0.68 hr, P less than .05).",Increases in methyldopa absorption and renal excretion after multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587963/),h,2.22,174249,DB00120,L-Phenylalanine
,1587963,plasma half-life,"There was also a significant increase in renal clearance of unmetabolized methyldopa (62.7 +/- 13.6 vs. 99.3 +/- 29.1 mL/min, P less than .01) and a decrease in the plasma half-life of methyldopa at day 56 (2.22 +/- 0.91 vs. 1.56 +/- 0.68 hr, P less than .05).",Increases in methyldopa absorption and renal excretion after multiple doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587963/),h,1.56,174250,DB00120,L-Phenylalanine
,12551706,C(max),The parameter C(max) of levodopa was significantly lower and t(max) longer under postprandial conditions than under fasting conditions (mean C(max) 1.41 vs.,Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551706/),,1.41,174655,DB00120,L-Phenylalanine
,12551706,t(max),2.09 mg l(-1); mean t(max) 3.1 vs. 1.0 h).,Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551706/),h,3.1,174656,DB00120,L-Phenylalanine
,12551706,t(max),2.09 mg l(-1); mean t(max) 3.1 vs. 1.0 h).,Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12551706/),h,1.0,174657,DB00120,L-Phenylalanine
,21083061,T(1/2),"In this mouse study, the T(1/2) of BH4 in plasma was approximately 1.2 h.",Detection of tetrahydrobiopterin by LC-MS/MS in plasma from multiple species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083061/),h,1.2,175144,DB00120,L-Phenylalanine
,9241095,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of exogenously administered levodopa increased from 1.2 in the control group to 5.9 mg l(-1) h at benserazide doses of 100-200 mg three times daily.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],1.2,176234,DB00120,L-Phenylalanine
,9241095,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of exogenously administered levodopa increased from 1.2 in the control group to 5.9 mg l(-1) h at benserazide doses of 100-200 mg three times daily.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],5.9,176235,DB00120,L-Phenylalanine
,9241095,AUC,Benserazide caused a dose-dependent increase in the AUC of 3-OMD from 7.4 to 106 mg l(-1) h at doses of 200 mg.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],7,176236,DB00120,L-Phenylalanine
,9241095,AUC,Benserazide caused a dose-dependent increase in the AUC of 3-OMD from 7.4 to 106 mg l(-1) h at doses of 200 mg.,Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241095/),[h·mg] / [l],106,176237,DB00120,L-Phenylalanine
,3124856,Km,"Determination of the Michaelis-Menten kinetic constants for aromatic amino acid decarboxylase AADC, EC 4.1.1.26) indicated that the Km for L-2-18F-DOPA (982 +/- 115 microM) was considerably higher than that for L-6-18F-DOPA (101 +/- 22 microM).",Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3124856/),μM,982,176242,DB00120,L-Phenylalanine
,3124856,Km,"Determination of the Michaelis-Menten kinetic constants for aromatic amino acid decarboxylase AADC, EC 4.1.1.26) indicated that the Km for L-2-18F-DOPA (982 +/- 115 microM) was considerably higher than that for L-6-18F-DOPA (101 +/- 22 microM).",Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3124856/),μM,101,176243,DB00120,L-Phenylalanine
,17091250,area-under-the-curve ratio,The area-under-the-curve ratio of peritoneal fluid to plasma was 33.3 +/- 11.8 with an average peak plasma concentration of 0.82 +/- 0.24 microg/ml occurring at 28.5 +/- 13.1 min.,Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091250/),,33.3,176591,DB00120,L-Phenylalanine
,17091250,peak plasma concentration,The area-under-the-curve ratio of peritoneal fluid to plasma was 33.3 +/- 11.8 with an average peak plasma concentration of 0.82 +/- 0.24 microg/ml occurring at 28.5 +/- 13.1 min.,Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091250/),[μg] / [ml],0.82,176592,DB00120,L-Phenylalanine
,17091250,peak concentration,Concentrations of melphalan in tumor nodules on the peritoneal surface were approximately ten times higher than in plasma with an average peak concentration of 7.2 +/- 4.2 microg/gm.,Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17091250/),[μg] / [gm],7.2,176593,DB00120,L-Phenylalanine
,22779444,solubility,The modification allowed overcoming the known melphalan aqueous solubility problem (0.1 µg/ml) leading us to obtain a polymer-drug bioconjugate more suitable for oral and parental administration.,"Synthesis, characterization and in vitro studies of pegylated melphalan conjugates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779444/),[μg] / [ml],0.1,176994,DB00120,L-Phenylalanine
higher,22779444,LD50 concentration,"It shows that LD50 concentration was higher 1.14 and 2 µm for M-PEG 2000 and M-PEG 5000, respectively in comparison to pure melphalan (0.74 µm).","Synthesis, characterization and in vitro studies of pegylated melphalan conjugates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779444/),µm,1.14,176995,DB00120,L-Phenylalanine
higher,22779444,LD50 concentration,"It shows that LD50 concentration was higher 1.14 and 2 µm for M-PEG 2000 and M-PEG 5000, respectively in comparison to pure melphalan (0.74 µm).","Synthesis, characterization and in vitro studies of pegylated melphalan conjugates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779444/),µm,2,176996,DB00120,L-Phenylalanine
,22779444,LD50 concentration,"It shows that LD50 concentration was higher 1.14 and 2 µm for M-PEG 2000 and M-PEG 5000, respectively in comparison to pure melphalan (0.74 µm).","Synthesis, characterization and in vitro studies of pegylated melphalan conjugates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22779444/),µm,0.74,176997,DB00120,L-Phenylalanine
,7791104,elimination half-life,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,2.66,177336,DB00120,L-Phenylalanine
,7791104,volume of distribution by area,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177337,DB00120,L-Phenylalanine
,7791104,AUC,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177338,DB00120,L-Phenylalanine
,7791104,t1/2,"In addition, the elimination half-life (2.66 hr) and volume of distribution by area of L-dopa in blood plasma and its AUC and t1/2 in muscle ECF (1.80 hr) were enhanced substantially.",The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791104/),h,1.80,177339,DB00120,L-Phenylalanine
,22751085,maximum plasma concentration (Cmax),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],14.1,177975,DB00120,L-Phenylalanine
,22751085,maximum plasma concentration (Cmax),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],9.7,177976,DB00120,L-Phenylalanine
,22751085,plasma concentration at 30 min (C30 min),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],13.7,177977,DB00120,L-Phenylalanine
,22751085,plasma concentration at 30 min (C30 min),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [l],8.1,177978,DB00120,L-Phenylalanine
,22751085,area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [h·l],15.9,177979,DB00120,L-Phenylalanine
,22751085,area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr),"Mean ± SEM levodopa maximum plasma concentration (Cmax) (14.1 ± 2.9 vs 9.7 ± 1.6 μmol/L; P < 0.01), plasma concentration at 30 min (C30 min) (13.7 ± 3.0 vs 8.1 ± 2.0 μmol/L; P < 0.01), and area under the plasma concentration-time curve from 0 to 3 hours (AUC0-3 hr) (15.9 ± 3.1 vs 12.1 ± 2.4 μmol/L · hour; P < 0.05) were significantly higher after coadministration of levodopa with domperidone compared to levodopa alone.",Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22751085/),[μM] / [h·l],12.1,177980,DB00120,L-Phenylalanine
,20573084,total,"A two compartment model generated population mean estimates for total and unbound melphalan clearance (CL) of 27.8 and 128 l h(-1), respectively.",Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),[l] / [h],27.8,178560,DB00120,L-Phenylalanine
,20573084,unbound,"A two compartment model generated population mean estimates for total and unbound melphalan clearance (CL) of 27.8 and 128 l h(-1), respectively.",Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),[l] / [h],27.8,178561,DB00120,L-Phenylalanine
,20573084,clearance (CL),"A two compartment model generated population mean estimates for total and unbound melphalan clearance (CL) of 27.8 and 128 l h(-1), respectively.",Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),[l] / [h],128,178562,DB00120,L-Phenylalanine
,20573084,Total AUC,Total AUC (range 4.9-24.4 mg l(-1) h) and unbound AUC (range 1.0-6.5 mg l(-1) h) were significantly higher in patients who had oral mucositis (>or=grade 3) and long hospital admissions (P < 0.01).,Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),[h·mg] / [l],4.9-24.4,178563,DB00120,L-Phenylalanine
,20573084,unbound AUC,Total AUC (range 4.9-24.4 mg l(-1) h) and unbound AUC (range 1.0-6.5 mg l(-1) h) were significantly higher in patients who had oral mucositis (>or=grade 3) and long hospital admissions (P < 0.01).,Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),[h·mg] / [l],1.0-6.5,178564,DB00120,L-Phenylalanine
,20573084,unbound AUC,Patients who responded well had significantly higher unbound AUC (median 3.2 vs.,Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),,3.2,178565,DB00120,L-Phenylalanine
,20573084,total AUC,"2.8 mg l(-1) h, P < 0.05) when assessed from diagnosis to post-melphalan and higher total AUC (median 21.3 vs. 13.4 mg l(-1) h, P= 0.06), when assessed from pre- to post-melphalan.",Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),[h·mg] / [l],21.3,178566,DB00120,L-Phenylalanine
,20573084,total AUC,"2.8 mg l(-1) h, P < 0.05) when assessed from diagnosis to post-melphalan and higher total AUC (median 21.3 vs. 13.4 mg l(-1) h, P= 0.06), when assessed from pre- to post-melphalan.",Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20573084/),[h·mg] / [l],13.4,178567,DB00120,L-Phenylalanine
,27378394,extinction coefficients,Highly fluorescent nanocapsules with hydrodynamic diameters of 122 nm and 68 nm and extinction coefficients of 1.3 × 10(9) M(-1) cm(-1) and 1.5 × 10(8) M(-1) cm(-1) respectively were prepared by varying the reaction conditions.,Highly fluorescent resorcinarene cavitand nanocapsules with efficient renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378394/),1/[M·cm],1.3 × 10(9),180905,DB00120,L-Phenylalanine
,27378394,extinction coefficients,Highly fluorescent nanocapsules with hydrodynamic diameters of 122 nm and 68 nm and extinction coefficients of 1.3 × 10(9) M(-1) cm(-1) and 1.5 × 10(8) M(-1) cm(-1) respectively were prepared by varying the reaction conditions.,Highly fluorescent resorcinarene cavitand nanocapsules with efficient renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27378394/),1/[M·cm],1.5 × 10(8),180906,DB00120,L-Phenylalanine
,7139852,plasma half-life,The mean plasma half-life of unchanged melphalan was 0.9 +/- 0.5 (SD) h.,Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),h,0.9,181486,DB00120,L-Phenylalanine
,7139852,',"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),h,1 to 4,181487,DB00120,L-Phenylalanine
,7139852,lag-time,"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),h,1 to 4,181488,DB00120,L-Phenylalanine
,7139852,peak concentration,"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),[ng] / [ml],96,181489,DB00120,L-Phenylalanine
,7139852,area under the plasma concentration by time curve,"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),[h·ng] / [ml],160,181490,DB00120,L-Phenylalanine
,3428308,tmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.4,183143,DB00120,L-Phenylalanine
,3428308,tmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.8,183144,DB00120,L-Phenylalanine
,3428308,tmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,0.8,183145,DB00120,L-Phenylalanine
,3428308,Cmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.25,183146,DB00120,L-Phenylalanine
,3428308,Cmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.56,183147,DB00120,L-Phenylalanine
,3428308,Cmax,"The mean values for tmax were 2.4, 2.8 and 0.8 h, whereas those for Cmax were 0.25, 0.56 and 1.38 micrograms/ml for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],1.38,183148,DB00120,L-Phenylalanine
,3428308,relative bioavailability,"The mean relative bioavailability (versus standard Madopar) was 58 and 67% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,58,183149,DB00120,L-Phenylalanine
,3428308,relative bioavailability,"The mean relative bioavailability (versus standard Madopar) was 58 and 67% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,67,183150,DB00120,L-Phenylalanine
,3428308,half-value duration,"The parameter of half-value duration (= time span where plasma concentrations are equal to or higher than the half Cmax) was on average 3.5, 3.8 and 0.8 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,3.5,183151,DB00120,L-Phenylalanine
,3428308,half-value duration,"The parameter of half-value duration (= time span where plasma concentrations are equal to or higher than the half Cmax) was on average 3.5, 3.8 and 0.8 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,3.8,183152,DB00120,L-Phenylalanine
,3428308,half-value duration,"The parameter of half-value duration (= time span where plasma concentrations are equal to or higher than the half Cmax) was on average 3.5, 3.8 and 0.8 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,0.8,183153,DB00120,L-Phenylalanine
,3428308,tmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.8,183154,DB00120,L-Phenylalanine
,3428308,tmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,2.3,183155,DB00120,L-Phenylalanine
,3428308,tmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,0.8,183156,DB00120,L-Phenylalanine
,3428308,Cmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.35,183157,DB00120,L-Phenylalanine
,3428308,Cmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],0.60,183158,DB00120,L-Phenylalanine
,3428308,Cmax,"Following benserazide pretreatment the mean tmax values for levodopa were 2.8, 2.3 and 0.8 h and the mean Cmax values were 0.35, 0.60 and 1.33 micrograms/ml, respectively, for one HBS capsule, two HBS capsules and standard Madopar.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),[μg] / [ml],1.33,183159,DB00120,L-Phenylalanine
,3428308,relative bioavailability,"The relative bioavailability (versus standard Madopar) was 57 +/- 14 and 63 +/- 21% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,57,183160,DB00120,L-Phenylalanine
,3428308,relative bioavailability,"The relative bioavailability (versus standard Madopar) was 57 +/- 14 and 63 +/- 21% (value normalized to dose) for one and two HBS capsules, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,63,183161,DB00120,L-Phenylalanine
,3428308,half-value duration,"The mean values of the half-value duration were 3.6, 4.2 and 1.3 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,3.6,183162,DB00120,L-Phenylalanine
,3428308,half-value duration,"The mean values of the half-value duration were 3.6, 4.2 and 1.3 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,4.2,183163,DB00120,L-Phenylalanine
,3428308,half-value duration,"The mean values of the half-value duration were 3.6, 4.2 and 1.3 h for one HBS capsule, two HBS capsules and standard Madopar, respectively.",Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),h,1.3,183164,DB00120,L-Phenylalanine
,3428308,bioavailability,The reduced bioavailability of the HBS form (60% of that of the standard form) suggests that a higher daily dose of Madopar HBS should be used for clinical practice.,Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428308/),%,60,183165,DB00120,L-Phenylalanine
,9221827,elimination half-lives,"The elimination half-lives of OA, OP-OA, O alpha, OA-OH, OB, and OC were 103+/-16, 50.5+/-2.8, 9.6+/-2.3, 6+/-0.9, 4.2+/-1.2, and 0.6+/-0.2 hr, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),h,103,183209,DB00120,L-Phenylalanine
,9221827,elimination half-lives,"The elimination half-lives of OA, OP-OA, O alpha, OA-OH, OB, and OC were 103+/-16, 50.5+/-2.8, 9.6+/-2.3, 6+/-0.9, 4.2+/-1.2, and 0.6+/-0.2 hr, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),h,50.5,183210,DB00120,L-Phenylalanine
,9221827,elimination half-lives,"The elimination half-lives of OA, OP-OA, O alpha, OA-OH, OB, and OC were 103+/-16, 50.5+/-2.8, 9.6+/-2.3, 6+/-0.9, 4.2+/-1.2, and 0.6+/-0.2 hr, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),h,9.6,183211,DB00120,L-Phenylalanine
,9221827,elimination half-lives,"The elimination half-lives of OA, OP-OA, O alpha, OA-OH, OB, and OC were 103+/-16, 50.5+/-2.8, 9.6+/-2.3, 6+/-0.9, 4.2+/-1.2, and 0.6+/-0.2 hr, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),h,6,183212,DB00120,L-Phenylalanine
,9221827,elimination half-lives,"The elimination half-lives of OA, OP-OA, O alpha, OA-OH, OB, and OC were 103+/-16, 50.5+/-2.8, 9.6+/-2.3, 6+/-0.9, 4.2+/-1.2, and 0.6+/-0.2 hr, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),h,4.2,183213,DB00120,L-Phenylalanine
,9221827,elimination half-lives,"The elimination half-lives of OA, OP-OA, O alpha, OA-OH, OB, and OC were 103+/-16, 50.5+/-2.8, 9.6+/-2.3, 6+/-0.9, 4.2+/-1.2, and 0.6+/-0.2 hr, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),h,0.6,183214,DB00120,L-Phenylalanine
,9221827,Total body clearance,"Total body clearance of OA, OP-OA, O alpha, OA-OH, and OB via the bile, urine, and metabolic routes were 3.1, 3.6, 40, 65, and 43 ml/hr kg, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),[ml] / [h·kg],3.1,183215,DB00120,L-Phenylalanine
,9221827,Total body clearance,"Total body clearance of OA, OP-OA, O alpha, OA-OH, and OB via the bile, urine, and metabolic routes were 3.1, 3.6, 40, 65, and 43 ml/hr kg, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),[ml] / [h·kg],3.6,183216,DB00120,L-Phenylalanine
,9221827,Total body clearance,"Total body clearance of OA, OP-OA, O alpha, OA-OH, and OB via the bile, urine, and metabolic routes were 3.1, 3.6, 40, 65, and 43 ml/hr kg, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),[ml] / [h·kg],40,183217,DB00120,L-Phenylalanine
,9221827,Total body clearance,"Total body clearance of OA, OP-OA, O alpha, OA-OH, and OB via the bile, urine, and metabolic routes were 3.1, 3.6, 40, 65, and 43 ml/hr kg, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),[ml] / [h·kg],65,183218,DB00120,L-Phenylalanine
,9221827,Total body clearance,"Total body clearance of OA, OP-OA, O alpha, OA-OH, and OB via the bile, urine, and metabolic routes were 3.1, 3.6, 40, 65, and 43 ml/hr kg, respectively.",Pharmacokinetics of ochratoxin A and its metabolites in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9221827/),[ml] / [h·kg],43,183219,DB00120,L-Phenylalanine
,3322837,relative bioavailability,The clinical response to Madopar HBS was delayed and brief; the relative bioavailability was only 50%.,Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3322837/),%,50,183669,DB00120,L-Phenylalanine
,11554430,relative bioavailability,The relative bioavailability of Dopegyt (test preparation) and Presinol (reference preparation) calculated from the AUC0-infinity values was 116.7+/-56.7% that also confirmed bioequivalence.,Comparative bioavailability of alpha-methyldopa normal and film tablet formulations after single oral administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11554430/),%,116.7,185624,DB00120,L-Phenylalanine
,2475185,half-life (t 1/2) of elimination,"The half-life (t 1/2) of elimination of G-CSF was in the range 1.3 to 4.2 hours and was prolonged at higher doses, suggesting that one clearance mechanism becomes saturated at doses greater than 10 micrograms/kg, When a continuous subcutaneous (SC) infusion was administered for five days, a rapid reduction in serum G-CSF levels occurred during the last two days of the infusion, indicating that an additional clearance mechanism was induced.",Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475185/),h,1.3 to 4.2,185783,DB00120,L-Phenylalanine
,30261554,AUC,"The final model was used to simulate whether target carboplatin AUC (16.4 mg ml-1 ·min) would be achieved using the paediatric Newell formula, modified Calvert formula and weight-based dosing.","Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30261554/),[mg·min] / [ml],16.4,185909,DB00120,L-Phenylalanine
,22122189,rate,Phe disappeared from plasma at a mean rate of 2.8%/min.,Oral and intravenous l-[1-13 C]phenylalanine delivery measure similar rates of elimination when gastric emptying and splanchnic extraction are accounted for in adult mixed hounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122189/),[%] / [min],2.8,187132,DB00120,L-Phenylalanine
,22122189,half-life for gastric emptying,"The half-life for gastric emptying was 18 min, and first-pass Phe extraction by the splanchnic bed was 24% of the dietary Phe.",Oral and intravenous l-[1-13 C]phenylalanine delivery measure similar rates of elimination when gastric emptying and splanchnic extraction are accounted for in adult mixed hounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122189/),min,18,187133,DB00120,L-Phenylalanine
,3085927,peak plasma Dopa concentrations,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),[ng] / [ml],"1,893",187197,DB00120,L-Phenylalanine
,3085927,peak plasma Dopa concentrations,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),[ng] / [ml],"2,733",187198,DB00120,L-Phenylalanine
,3085927,time to peak plasma concentration,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),h,0.7,187199,DB00120,L-Phenylalanine
,3085927,time to peak plasma concentration,"Increasing carbidopa from a mean of 145 to 290 mg/day caused a mean increase in peak plasma Dopa concentrations from 1,893 +/- 476 to 2,733 +/- 607 ng/ml and area under the Dopa plasma concentration versus time curve of 24.6 +/- 10.0%, as well as a decrease in the time to peak plasma concentration to 0.7 +/- 0.2 versus 1.2 +/- 0.3 h.",Effect of supplemental carbidopa on bioavailability of L-dopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3085927/),h,1.2,187200,DB00120,L-Phenylalanine
,9795070,tmax,"The levodopa pharmacokinetics of the new DRF showed rapid absorption (tmax=1.1 h), followed by sustained levodopa plasma concentrations, similar to the SRF.",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),h,1.1,188844,DB00120,L-Phenylalanine
,9795070,Cmax,"Following multi-dose administration, the peak plasma concentration of the new DRF was 90% higher compared to the SFR (Cmax=2.1 and 1.1 microg/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[μg] / [ml],2.1,188845,DB00120,L-Phenylalanine
,9795070,Cmax,"Following multi-dose administration, the peak plasma concentration of the new DRF was 90% higher compared to the SFR (Cmax=2.1 and 1.1 microg/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[μg] / [ml],1.1,188846,DB00120,L-Phenylalanine
,9795070,AUC0-infinity,"The bioavailability was significantly increased by 40% (AUC0-infinity=6.1 and 4.3 microg x h/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[h·μg] / [ml],6.1,188847,DB00120,L-Phenylalanine
,9795070,AUC0-infinity,"The bioavailability was significantly increased by 40% (AUC0-infinity=6.1 and 4.3 microg x h/ml, respectively).",Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795070/),[h·μg] / [ml],4.3,188848,DB00120,L-Phenylalanine
,909609,half life,The fourth phase of elimination is the slowest with a half life of 4 days.,Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/909609/),d,4,189107,DB00120,L-Phenylalanine
,26785130,maximum,"Model-predicted melphalan maximum vitreous, aqueous, and retina concentrations were 7.8 μg/mL, 0.024 μg/mL, and 9.8 μg/g tissue, respectively, attained immediately and at 0.8 and 0.25 h after intravitreal injection.",Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26785130/),[μg] / [ml],7.8,190160,DB00120,L-Phenylalanine
,26785130,elimination half-life,"The elimination half-life from the vitreous, aqueous humor, and retina was 1.0, 0.2, and 1.2 h, respectively.",Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26785130/),h,1.0,190161,DB00120,L-Phenylalanine
,26785130,elimination half-life,"The elimination half-life from the vitreous, aqueous humor, and retina was 1.0, 0.2, and 1.2 h, respectively.",Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26785130/),h,0.2,190162,DB00120,L-Phenylalanine
,26785130,elimination half-life,"The elimination half-life from the vitreous, aqueous humor, and retina was 1.0, 0.2, and 1.2 h, respectively.",Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26785130/),h,1.2,190163,DB00120,L-Phenylalanine
,8670556,maximum concentration (Cmax),Baseline concentrations of phenylalanine (the main metabolite of aspartame) rose after ingestion with a significantly higher maximum concentration (Cmax) (81.3 vs.,Aspartame pharmacokinetics - the effect of ageing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8670556/),,81.3,190467,DB00120,L-Phenylalanine
,8670556,area under the plasma concentration-time curve extrapolated to infinity AUC 9(0-infinity),"63.3 micromol/1, p<0.01) and area under the plasma concentration-time curve extrapolated to infinity AUC 9(0-infinity)(518.7 vs. 353.5 micromol . h/l, p<0.01) in the elderly group.",Aspartame pharmacokinetics - the effect of ageing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8670556/),[h·μM] / [l],518.7,190468,DB00120,L-Phenylalanine
,8670556,area under the plasma concentration-time curve extrapolated to infinity AUC 9(0-infinity),"63.3 micromol/1, p<0.01) and area under the plasma concentration-time curve extrapolated to infinity AUC 9(0-infinity)(518.7 vs. 353.5 micromol . h/l, p<0.01) in the elderly group.",Aspartame pharmacokinetics - the effect of ageing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8670556/),[h·μM] / [l],353.5,190469,DB00120,L-Phenylalanine
,8670556,volume of distribution (V),The higher concentrations reflected a significant fall in volume of distribution (V) from 2.03 to 1.59 1/kg (p <0.05) and clearance (CL) from 7.3 to 4.9 ml/min/kg (p <0.005) in the elderly group.,Aspartame pharmacokinetics - the effect of ageing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8670556/),[1] / [kg],2.03 to 1.59,190470,DB00120,L-Phenylalanine
,8670556,clearance (CL),The higher concentrations reflected a significant fall in volume of distribution (V) from 2.03 to 1.59 1/kg (p <0.05) and clearance (CL) from 7.3 to 4.9 ml/min/kg (p <0.005) in the elderly group.,Aspartame pharmacokinetics - the effect of ageing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8670556/),[ml] / [kg·min],7.3 to 4.9,190471,DB00120,L-Phenylalanine
,8670556,elimination half life,The greater effect on CL than on V resulted in a small but non-significant rise in elimination half life (3.5 to 3.9 hours).,Aspartame pharmacokinetics - the effect of ageing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8670556/),h,3.5 to 3.9,190472,DB00120,L-Phenylalanine
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.3,190584,DB00120,L-Phenylalanine
,10492060,t1/2,"The mean t1/2 values of entacapone were 1.3 h and 1.8 h during the first and sixth days, respectively; the difference was not significant.",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.8,190585,DB00120,L-Phenylalanine
,10492060,Cmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190586,DB00120,L-Phenylalanine
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.4,190587,DB00120,L-Phenylalanine
,10492060,t1/2,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,2.3,190588,DB00120,L-Phenylalanine
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,0.8,190589,DB00120,L-Phenylalanine
,10492060,tmax,"There were no between-day differences in Cmax, t1/2 (2.4 h on days 1-2 and 2.3 h on days 6-7) or AUC of levodopa, whereas tmax occurred at 0.8 h on day 1 and at 1.2 h on day 6 (P = 0.03).",Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492060/),h,1.2,190590,DB00120,L-Phenylalanine
,9765344,area under the curve,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],9.4,191639,DB00120,L-Phenylalanine
,9765344,area under the curve,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],102,191640,DB00120,L-Phenylalanine
,9765344,oral plasma clearance,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],3810,191641,DB00120,L-Phenylalanine
,9765344,oral plasma clearance,Ketoconazole markedly raised the area under the curve of orally administered K02 from 9.4 +/- 4.4 to 102 +/- 24 mg . min/liter and decreased K02 oral plasma clearance from 3810 +/- 1620 to 306 +/- 60 ml/min/kg.,"Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],306,191642,DB00120,L-Phenylalanine
,9765344,AUC,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],94,191643,DB00120,L-Phenylalanine
,9765344,AUC,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[mg·min] / [l],107,191644,DB00120,L-Phenylalanine
,9765344,clearance,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],110,191645,DB00120,L-Phenylalanine
,9765344,clearance,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),[ml] / [kg·min],95,191646,DB00120,L-Phenylalanine
,9765344,oral bioavailability,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),%,2.9,191647,DB00120,L-Phenylalanine
,9765344,oral bioavailability,"With concomitant ketoconazole dosing, the changes of AUC of i.v. administered K02 (from 94 +/- 17 to 107 +/- 14 mg . min/liter) and clearance (from 110 +/- 22 to 95 +/- 13 ml/min/kg) were not significant, although K02 oral bioavailability increased from 2.9 +/- 1.4 to 31.0 +/- 7.5% (P < .001).","Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765344/),%,31.0,191648,DB00120,L-Phenylalanine
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.95,194693,DB00120,L-Phenylalanine
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.78,194694,DB00120,L-Phenylalanine
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.80,194695,DB00120,L-Phenylalanine
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.65,194696,DB00120,L-Phenylalanine
,12616669,t1/2,Nateglinide was eliminated rapidly in all groups (t1/2 = 1.9-2.8 h).,Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,1.9-2.8,194697,DB00120,L-Phenylalanine
,12616669,renal excretion,There was a low extent of renal excretion of nateglinide in healthy subjects (11%) and diabetic patients with IRF (3%).,Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),%,11,194698,DB00120,L-Phenylalanine
,12616669,renal excretion,There was a low extent of renal excretion of nateglinide in healthy subjects (11%) and diabetic patients with IRF (3%).,Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),%,3,194699,DB00120,L-Phenylalanine
,9609732,half-life (t1/2),"nSP-C and rSP-C were cleared from rabbit lungs similarly to DPC, each with a half-life (t1/2) of approximately 11 h.",Clearance of SP-C and recombinant SP-C in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9609732/),h,11,195692,DB00120,L-Phenylalanine
,9609732,t1/2,"In mice, the clearance of rSP-C from the lungs was slower (t1/2 28 h) than the clearance of DPC (t1/2 12 h).",Clearance of SP-C and recombinant SP-C in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9609732/),h,28,195693,DB00120,L-Phenylalanine
,9609732,t1/2,"In mice, the clearance of rSP-C from the lungs was slower (t1/2 28 h) than the clearance of DPC (t1/2 12 h).",Clearance of SP-C and recombinant SP-C in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9609732/),h,12,195694,DB00120,L-Phenylalanine
,2650527,response duration,"Six of 14 patients achieved a partial response, and the median response duration was 4 months (range 3-10 months).","High-dose melphalan, misonidazole, and autologous bone marrow transplantation for the treatment of metastatic colorectal carcinoma. A phase I study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2650527/),,4,195719,DB00120,L-Phenylalanine
,2650527,peak serum concentrations,"Mean peak serum concentrations ranged from 81.8 micrograms/ml to 115.2 micrograms/ml at the second and third misonidazole dose levels, which approximate those known to provide effective chemosensitization with melphalan in animal models.","High-dose melphalan, misonidazole, and autologous bone marrow transplantation for the treatment of metastatic colorectal carcinoma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2650527/),[μg] / [ml],81.8,195720,DB00120,L-Phenylalanine
,2650527,peak serum concentrations,"Mean peak serum concentrations ranged from 81.8 micrograms/ml to 115.2 micrograms/ml at the second and third misonidazole dose levels, which approximate those known to provide effective chemosensitization with melphalan in animal models.","High-dose melphalan, misonidazole, and autologous bone marrow transplantation for the treatment of metastatic colorectal carcinoma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2650527/),[μg] / [ml],115.2,195721,DB00120,L-Phenylalanine
,11249051,progression-free,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,37.,199261,DB00120,L-Phenylalanine
,11249051,overall survival,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,65,199262,DB00120,L-Phenylalanine
,10338337,peak values,"The peak values at the end of administration were 9.4 2.6 microg 10B/g blood, and half-lives for the initial and second components of the blood clearance were 2.8 and 9.2 h, respectively.","Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10338337/),[10b·μg] / [blood·g],9.4,199676,DB00120,L-Phenylalanine
,10338337,peak values,"The peak values at the end of administration were 9.4 2.6 microg 10B/g blood, and half-lives for the initial and second components of the blood clearance were 2.8 and 9.2 h, respectively.","Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10338337/),[10b·μg] / [blood·g],2.6,199677,DB00120,L-Phenylalanine
,10338337,half-lives,"The peak values at the end of administration were 9.4 2.6 microg 10B/g blood, and half-lives for the initial and second components of the blood clearance were 2.8 and 9.2 h, respectively.","Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10338337/),h,2.8,199678,DB00120,L-Phenylalanine
,10338337,half-lives,"The peak values at the end of administration were 9.4 2.6 microg 10B/g blood, and half-lives for the initial and second components of the blood clearance were 2.8 and 9.2 h, respectively.","Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10338337/),h,9.2,199679,DB00120,L-Phenylalanine
,10338337,skin-to-blood ratios,"Skin concentrations in the 10 patients varied from case to case; however, skin-to-blood ratios were relatively constant at 1.31+/-0.22 during the 6 h after the end of administration.","Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10338337/),,1.31,199680,DB00120,L-Phenylalanine
,10338337,tumour-to-blood ratio,"Boron concentrations in the tumours resected from the seven patients who were operated on decreased in parallel to the blood values, the tumour-to-blood ratio being relatively constant at 3.40+/-0.83.","Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10338337/),,3.40,199681,DB00120,L-Phenylalanine
,23548675,run time,"To our knowledge, this is the first UHPLC-MS/MS based method that utilizes derivatization with fluorescamine and provides adequate sensitivity for both levodopa and carbidopa with 50 μL of sample and a run time of 3.5 min.",Development and validation of a simple and sensitive method for quantification of levodopa and carbidopa in rat and monkey plasma using derivatization and UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23548675/),min,3.5,200291,DB00120,L-Phenylalanine
,8527287,tmax,"5. Tolcapone was rapidly absorbed and eliminated with, on average, a tmax of 1.5 h and a t1/2 of 2.3 h.",Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527287/),h,1.5,200415,DB00120,L-Phenylalanine
,8527287,t1/2,"5. Tolcapone was rapidly absorbed and eliminated with, on average, a tmax of 1.5 h and a t1/2 of 2.3 h.",Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527287/),h,2.3,200416,DB00120,L-Phenylalanine
,10868314,Cmax,"Mean +/- SD pharmacokinetic parameters in cirrhotic versus healthy subjects were slightly different (Cmax, 7.7 +/- 4.9 vs. 5.6 +/- 1.3 micrograms/ml; AUC(0-t), 18.5 +/- 7.5 vs. 14.2 +/- 2.1 micrograms.h/ml, respectively).",Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868314/),[μg] / [ml],7.7,200481,DB00120,L-Phenylalanine
,10868314,Cmax,"Mean +/- SD pharmacokinetic parameters in cirrhotic versus healthy subjects were slightly different (Cmax, 7.7 +/- 4.9 vs. 5.6 +/- 1.3 micrograms/ml; AUC(0-t), 18.5 +/- 7.5 vs. 14.2 +/- 2.1 micrograms.h/ml, respectively).",Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868314/),[μg] / [ml],5.6,200482,DB00120,L-Phenylalanine
,10868314,AUC(0-t),"Mean +/- SD pharmacokinetic parameters in cirrhotic versus healthy subjects were slightly different (Cmax, 7.7 +/- 4.9 vs. 5.6 +/- 1.3 micrograms/ml; AUC(0-t), 18.5 +/- 7.5 vs. 14.2 +/- 2.1 micrograms.h/ml, respectively).",Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868314/),[h·μg] / [ml],18.5,200483,DB00120,L-Phenylalanine
,10868314,AUC(0-t),"Mean +/- SD pharmacokinetic parameters in cirrhotic versus healthy subjects were slightly different (Cmax, 7.7 +/- 4.9 vs. 5.6 +/- 1.3 micrograms/ml; AUC(0-t), 18.5 +/- 7.5 vs. 14.2 +/- 2.1 micrograms.h/ml, respectively).",Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868314/),[h·μg] / [ml],14.2,200484,DB00120,L-Phenylalanine
,3342460,half-life,"Chlorambucil demonstrated a monophasic disappearance from plasma, with a half-life of 26 min.",Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342460/),min,26,200940,DB00120,L-Phenylalanine
,3342460,brain:plasma concentration integral ratios,"Calculated from the areas under the concentration-time curves, the brain:plasma concentration integral ratios of chlorambucil and phenylacetic mustard were 0.021 and 0.013, respectively.",Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342460/),,0.021,200941,DB00120,L-Phenylalanine
,3342460,brain:plasma concentration integral ratios,"Calculated from the areas under the concentration-time curves, the brain:plasma concentration integral ratios of chlorambucil and phenylacetic mustard were 0.021 and 0.013, respectively.",Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342460/),,0.013,200942,DB00120,L-Phenylalanine
,3342460,half-lives,"Melphalan demonstrated a biphasic disappearance from plasma, with half-lives of 1.9 and 78 min.",Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342460/),min,1.9,200943,DB00120,L-Phenylalanine
,3342460,half-lives,"Melphalan demonstrated a biphasic disappearance from plasma, with half-lives of 1.9 and 78 min.",Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342460/),min,78,200944,DB00120,L-Phenylalanine
,3342460,brain:plasma ratio,"Low concentrations of melphalan were detected in the brain, and its brain:plasma ratio was 0.13.",Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342460/),,0.13,200945,DB00120,L-Phenylalanine
,7092953,T1/2 alpha,The decline of radioactivity from the blood was biphasic with T1/2 alpha = 7 hr and T1/2 beta = 75 hr.,Macromolecular interactions of [14C-ring]melphalan in blood. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7092953/),h,7,203344,DB00120,L-Phenylalanine
,7092953,T1/2 beta,The decline of radioactivity from the blood was biphasic with T1/2 alpha = 7 hr and T1/2 beta = 75 hr.,Macromolecular interactions of [14C-ring]melphalan in blood. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7092953/),h,75,203345,DB00120,L-Phenylalanine
,7608316,half-life,"Pharmacokinetic parameters were recorded as follows: half-life was 2.0 +/- 0.7 hours; total body and renal clearance were 268 +/- 72 and 107 +/- 35 mL/min, respectively; and volume of distribution at steady-state was 33 +/- 11 L.",Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608316/),h,2.0,203411,DB00120,L-Phenylalanine
,7608316,total body,"Pharmacokinetic parameters were recorded as follows: half-life was 2.0 +/- 0.7 hours; total body and renal clearance were 268 +/- 72 and 107 +/- 35 mL/min, respectively; and volume of distribution at steady-state was 33 +/- 11 L.",Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608316/),[ml] / [min],268,203412,DB00120,L-Phenylalanine
,7608316,renal clearance,"Pharmacokinetic parameters were recorded as follows: half-life was 2.0 +/- 0.7 hours; total body and renal clearance were 268 +/- 72 and 107 +/- 35 mL/min, respectively; and volume of distribution at steady-state was 33 +/- 11 L.",Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608316/),[ml] / [min],107,203413,DB00120,L-Phenylalanine
,7608316,volume of distribution at steady-state,"Pharmacokinetic parameters were recorded as follows: half-life was 2.0 +/- 0.7 hours; total body and renal clearance were 268 +/- 72 and 107 +/- 35 mL/min, respectively; and volume of distribution at steady-state was 33 +/- 11 L.",Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608316/),l,33,203414,DB00120,L-Phenylalanine
,7608316,absolute bioavailability,The absolute bioavailability of the drug was 42 +/- 16%.,Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608316/),%,42,203415,DB00120,L-Phenylalanine
,6480880,AUC(0-24),"Although assay sensitivity did not allow an adequate assessment of serum AUC(0-infinity) after intravenous administration, mean digoxin AUC(0-24) was 10.2 +/- 3.5 and 10.0 +/- 1.8 ng/ml X hr with placebo and methyldopa, respectively (P greater than 0.05).",Methyldopa does not alter the disposition of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480880/),[ng] / [h·ml],10.2,203635,DB00120,L-Phenylalanine
,6480880,AUC(0-24),"Although assay sensitivity did not allow an adequate assessment of serum AUC(0-infinity) after intravenous administration, mean digoxin AUC(0-24) was 10.2 +/- 3.5 and 10.0 +/- 1.8 ng/ml X hr with placebo and methyldopa, respectively (P greater than 0.05).",Methyldopa does not alter the disposition of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480880/),[ng] / [h·ml],10.0,203636,DB00120,L-Phenylalanine
,6480880,urinary excretion,"Mean urinary excretion after digoxin with or without methyldopa treatment was 0.204 +/- 0.34 and 0.197 +/- 0.38 mg, respectively.",Methyldopa does not alter the disposition of digoxin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480880/),mg,0.204,203637,DB00120,L-Phenylalanine
,6480880,urinary excretion,"Mean urinary excretion after digoxin with or without methyldopa treatment was 0.204 +/- 0.34 and 0.197 +/- 0.38 mg, respectively.",Methyldopa does not alter the disposition of digoxin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480880/),mg,0.197,203638,DB00120,L-Phenylalanine
,6480880,steady-state serum concentrations of oral digoxin (AUC(0-24)/zeta),"The mean steady-state serum concentrations of oral digoxin (AUC(0-24)/zeta) with and without methyldopa were 0.65 +/- 0.2 and 0.62 +/- 0.3 ng/ml, respectively.",Methyldopa does not alter the disposition of digoxin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480880/),[ng] / [ml],0.65,203639,DB00120,L-Phenylalanine
,6480880,steady-state serum concentrations of oral digoxin (AUC(0-24)/zeta),"The mean steady-state serum concentrations of oral digoxin (AUC(0-24)/zeta) with and without methyldopa were 0.65 +/- 0.2 and 0.62 +/- 0.3 ng/ml, respectively.",Methyldopa does not alter the disposition of digoxin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480880/),[ng] / [ml],0.62,203640,DB00120,L-Phenylalanine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],389,203783,DB00120,L-Phenylalanine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],346,203784,DB00120,L-Phenylalanine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],543,203785,DB00120,L-Phenylalanine
,9728899,concentration at half-maximal effect,"The mean concentration at half-maximal effect estimated for the different groups was as follows (mean value +/- SD): group 1, 389 +/- 138 ng x ml(-1); group 2, 346 +/- 203 ng x ml(-1); group 3, 543 +/- 245 ng x ml(-1); group 4, 711 +/- 215 ng x ml(-1).",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),[ng] / [ml],711,203786,DB00120,L-Phenylalanine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,10,203787,DB00120,L-Phenylalanine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,12,203788,DB00120,L-Phenylalanine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,24,203789,DB00120,L-Phenylalanine
,9728899,maximal response,"Estimate of the maximal response was determined to be the following: group 1, 10 +/- 3; group 2, 12 +/- 5; group 3, 24 +/- 13; group 4, 18 +/- 7.",Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9728899/),,18,203790,DB00120,L-Phenylalanine
,445964,plasma t1/2alpha,Composite plasma t1/2alpha was 7.7 +/- 3.3 and t1/2beta was 108 +/- 20.8 min for 8 of the patients.,Kinetics of intravenous melphalan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445964/),,7.7,204122,DB00120,L-Phenylalanine
,445964,t1/2beta,Composite plasma t1/2alpha was 7.7 +/- 3.3 and t1/2beta was 108 +/- 20.8 min for 8 of the patients.,Kinetics of intravenous melphalan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/445964/),min,108,204123,DB00120,L-Phenylalanine
,445964,urinary excretion,The mean 24-hr urinary excretion of melphalan was 13.0 +/- 5.4% of the administered dose.,Kinetics of intravenous melphalan. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/445964/),%,13.0,204124,DB00120,L-Phenylalanine
,16327247,C(max),"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[μg] / [ml],17.4,204397,DB00120,L-Phenylalanine
,16327247,C(max),"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[μg] / [ml],8.6,204398,DB00120,L-Phenylalanine
,16327247,AUC,"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[min·μg] / [ml],1882.8,204399,DB00120,L-Phenylalanine
,16327247,AUC,"When a levodopa preparation (EC-Doparl tablets) was orally administered with banana juice made by mixing with a fresh banana and water, there were significant decreases in C(max) (17.4+/-2.5 vs. 8.6+/-3.1 microg/ml; alpha=0.05) and AUC (1882.8+/-49.2 vs. 933.5+/-286.6 microg.min/ml; alpha=0.05) for levodopa.",Banana juice reduces bioavailability of levodopa preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327247/),[min·μg] / [ml],933.5,204400,DB00120,L-Phenylalanine
,16759103,IC(50),"Optimization of the metabolic profile of early analogues led to the discovery of (2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]pyridin-6-ylphenyl)butanamide (6), a potent, orally active DPP-4 inhibitor (IC(50) = 6.3 nM) with excellent selectivity, oral bioavailability in preclinical species, and in vivo efficacy in animal models.","(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759103/),nM,6.3,204739,DB00120,L-Phenylalanine
,32482490,Tmax,Median Tmax values with CVT-301 and oral CD/LD were 15 and 120 min (P < 0.001).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),min,15,205209,DB00120,L-Phenylalanine
,32482490,Tmax,Median Tmax values with CVT-301 and oral CD/LD were 15 and 120 min (P < 0.001).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),min,120,205210,DB00120,L-Phenylalanine
,32482490,Cmax,Cmax with CVT-301 was lower than with oral CD/LD (590.3 vs 844.3 ng/mL).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],590.3,205211,DB00120,L-Phenylalanine
,32482490,Cmax,Cmax with CVT-301 was lower than with oral CD/LD (590.3 vs 844.3 ng/mL).,Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],844.3,205212,DB00120,L-Phenylalanine
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],522.9,205213,DB00120,L-Phenylalanine
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],531.5,205214,DB00120,L-Phenylalanine
,32482490,C10min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],247.3,205215,DB00120,L-Phenylalanine
,32482490,C30min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],531.5,205216,DB00120,L-Phenylalanine
,32482490,C30min,"C10min and C30min values with CVT-301 were approximately twice those with CD/LD (522.9 and 531.5 ng/mL vs 247.3 and 300.9 ng/mL, respectively).",Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482490/),[ng] / [ml],300.9,205217,DB00120,L-Phenylalanine
,1450671,half-life,"A unique in vivo approach to assessing the concentrations of 4-[10B]borono-L-phenylalanine (L-BPA), a melanoma targeting compound for boron neutron capture therapy (BNCT), was investigated using L-BPA labelled with positron-emitting 18F (half-life = 110 min), i.e., 4-[10B]borono-2-[18F]fluoro-L-phenylalanine (L-[18F]FBPA).",A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450671/),min,110,205258,DB00120,L-Phenylalanine
less,2116808,oral bioavailability,In a second study the oral bioavailability of gludopa was estimated in normal subjects and found to be low (less than 2%).,Effect of prolonged intravenous infusion of gludopa in humans and a preliminary study of its oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2116808/),%,2,208091,DB00120,L-Phenylalanine
,8558205,half-lives,"Harmonic mean half-lives were 1.39 hours and 1.89 hours for R-BSO and S-BSO, respectively.",Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558205/),h,1.39,208766,DB00120,L-Phenylalanine
,8558205,half-lives,"Harmonic mean half-lives were 1.39 hours and 1.89 hours for R-BSO and S-BSO, respectively.",Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558205/),h,1.89,208767,DB00120,L-Phenylalanine
,3815357,permeability-surface area product,The permeability-surface area product was concentration dependent and decreased from 10.8 +/- 0.6 (+/- SE) X 10(-4)S-1 at 0.02 mumol/ml melphalan to 5.4 +/- 0.3 X 10(-4)S-1 at 16.3 mumol/ml.,Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815357/),1/[s],10.8,210137,DB00120,L-Phenylalanine
,3815357,permeability-surface area product,The permeability-surface area product was concentration dependent and decreased from 10.8 +/- 0.6 (+/- SE) X 10(-4)S-1 at 0.02 mumol/ml melphalan to 5.4 +/- 0.3 X 10(-4)S-1 at 16.3 mumol/ml.,Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815357/),1/[s],5.4,210138,DB00120,L-Phenylalanine
,3815357,Vmax,"The Michaelis-Menten parameters Vmax and Km, determined by nonlinear regression analysis of the permeability-surface area product data, equaled 0.9 +/- 0.3 X 10(-4) mumol/s/g and 0.15 +/- 0.06 mumol/ml, respectively, for the saturable component of melphalan's brain uptake.",Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815357/),[μM] / [g·s],0.9,210139,DB00120,L-Phenylalanine
,3815357,Km,"The Michaelis-Menten parameters Vmax and Km, determined by nonlinear regression analysis of the permeability-surface area product data, equaled 0.9 +/- 0.3 X 10(-4) mumol/s/g and 0.15 +/- 0.06 mumol/ml, respectively, for the saturable component of melphalan's brain uptake.",Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815357/),[μM] / [ml],0.15,210140,DB00120,L-Phenylalanine
,3815357,Kd,The Kd of the nonsaturable component was 5.3 +/- 0.03 X 10(-4)S-1.,Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815357/),1/[s],5.3,210141,DB00120,L-Phenylalanine
,7916491,clearance rate (K1),"In striatum, the unidirectional clearance rate (K1) for L-[3H]tyrosine (6.2 ml hg-1 min-1) was significantly greater than the rates for L-[14C]AMPT (2.8 ml hg-1 min-1) and D-[14C]AMPT (0.8 ml hg-1 min-1).",Brain uptake of alpha-[14C]methyl-para-tyrosine in the rat. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7916491/),[ml] / [hg·min],6.2,210210,DB00120,L-Phenylalanine
,7916491,clearance rate (K1),"In striatum, the unidirectional clearance rate (K1) for L-[3H]tyrosine (6.2 ml hg-1 min-1) was significantly greater than the rates for L-[14C]AMPT (2.8 ml hg-1 min-1) and D-[14C]AMPT (0.8 ml hg-1 min-1).",Brain uptake of alpha-[14C]methyl-para-tyrosine in the rat. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7916491/),[ml] / [hg·min],2.8,210211,DB00120,L-Phenylalanine
,7916491,clearance rate (K1),"In striatum, the unidirectional clearance rate (K1) for L-[3H]tyrosine (6.2 ml hg-1 min-1) was significantly greater than the rates for L-[14C]AMPT (2.8 ml hg-1 min-1) and D-[14C]AMPT (0.8 ml hg-1 min-1).",Brain uptake of alpha-[14C]methyl-para-tyrosine in the rat. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7916491/),[ml] / [hg·min],0.8,210212,DB00120,L-Phenylalanine
,7916491,apparent volume of distribution (Vf),The apparent volume of distribution (Vf) for L-[14C]AMPT in striatum (72.5 +/- 4.0 ml hg-1) did not differ from the Vf in other brain regions.,Brain uptake of alpha-[14C]methyl-para-tyrosine in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7916491/),[ml] / [hg],72.5,210213,DB00120,L-Phenylalanine
,12844325,elimination half-life,The elimination half-life of cabergoline estimated from urinary data of healthy subjects ranges between 63 and 109 hours.,Clinical pharmacokinetics of cabergoline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844325/),h,63 and 109,210629,DB00120,L-Phenylalanine
,1515240,AUC,"AUC, standardised to 1 mg/m2, ranged between 4.3 and 8.9 (mg/l) min.",Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515240/),min,4.3 and 8.9,210661,DB00120,L-Phenylalanine
,1515240,AUC,"Myelosuppression appeared at 47 (mg/l) min and grade 3 or 4 haematological toxicities were observed in 4 cycles, associated with AUC values ranging between 86 and 112 (mg/l) min.",Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1515240/),[mg] / [l)·min],86 and 112,210662,DB00120,L-Phenylalanine
,29751116,Cmax,"Median Cmax was 7380 ng/mL (interquartile range [IQR], 6522 to 8027).",Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29751116/),[ng] / [ml],7380,212044,DB00120,L-Phenylalanine
,29751116,AUC,"Similarly, median AUC was 533,552 ng/mL∙min (IQR, 450,850 to 662,936).",Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29751116/),[ng] / [ml∙min],"533,552",212045,DB00120,L-Phenylalanine
,29751116,overall response rate,"PG-Free Mel had an acceptable safety profile regardless of the exposure, with no mortality and an overall response rate of 96% and a very good partial response rate of 75%.",Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29751116/),%,96,212046,DB00120,L-Phenylalanine
,6160601,terminal-phase plasma half-life,"Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose.","The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,5.5,212050,DB00120,L-Phenylalanine
,6160601,terminal-phase plasma half-life,"Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose.","The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,4.0,212051,DB00120,L-Phenylalanine
,6160601,terminal-phase half-life,IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration.,"The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,1.3,212052,DB00120,L-Phenylalanine
,26153275,oral bioavailability,"The oral bioavailability of CT7758 was 4% in mice, 2% in rats, 7-55% in dogs, and 0.2% in cynomolgus monkeys.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),%,4,213311,DB00120,L-Phenylalanine
,26153275,oral bioavailability,"The oral bioavailability of CT7758 was 4% in mice, 2% in rats, 7-55% in dogs, and 0.2% in cynomolgus monkeys.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),%,2,213312,DB00120,L-Phenylalanine
,26153275,oral bioavailability,"The oral bioavailability of CT7758 was 4% in mice, 2% in rats, 7-55% in dogs, and 0.2% in cynomolgus monkeys.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),%,7-55,213313,DB00120,L-Phenylalanine
,26153275,oral bioavailability,"The oral bioavailability of CT7758 was 4% in mice, 2% in rats, 7-55% in dogs, and 0.2% in cynomolgus monkeys.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),%,0.2,213314,DB00120,L-Phenylalanine
,26153275,fraction absorbed,"The low bioavailability in rodents and monkey results from low intestinal absorption as evidenced by a low fraction absorbed in the rat portal vein model (3%), low-to-medium permeability in Caco-2 cells (≤1.3 × 10(-6) cm/s) with evidences of polarized efflux, and high polar surface area (104 Å).","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),%,3,213315,DB00120,L-Phenylalanine
≤,26153275,permeability,"The low bioavailability in rodents and monkey results from low intestinal absorption as evidenced by a low fraction absorbed in the rat portal vein model (3%), low-to-medium permeability in Caco-2 cells (≤1.3 × 10(-6) cm/s) with evidences of polarized efflux, and high polar surface area (104 Å).","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),[cm] / [s],1.3 × 10(-6),213316,DB00120,L-Phenylalanine
,26153275,polar,"The low bioavailability in rodents and monkey results from low intestinal absorption as evidenced by a low fraction absorbed in the rat portal vein model (3%), low-to-medium permeability in Caco-2 cells (≤1.3 × 10(-6) cm/s) with evidences of polarized efflux, and high polar surface area (104 Å).","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),å,104,213317,DB00120,L-Phenylalanine
≤,26153275,elimination half-life,"In rodents and cynomolgus monkeys, the total plasma clearance was moderate to high (≥50% hepatic blood flow QH) and associated with a short elimination half-life (≤1 hour).","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),h,1,213318,DB00120,L-Phenylalanine
,26153275,t1/2,This contrast with the dog data which showed a much lower clearance (6% QH) and a longer t1/2 (2.4 hours).,"Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),h,2.4,213319,DB00120,L-Phenylalanine
,26153275,volume of distribution (Vz),"The volume of distribution (Vz) also varied significantly across species with value of 5.5, 2.8, 0.24, and 0.93 l/kg in mouse, rat, dog, and cynomolgus monkey, respectively.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),[l] / [kg],5.5,213320,DB00120,L-Phenylalanine
,26153275,volume of distribution (Vz),"The volume of distribution (Vz) also varied significantly across species with value of 5.5, 2.8, 0.24, and 0.93 l/kg in mouse, rat, dog, and cynomolgus monkey, respectively.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),[l] / [kg],2.8,213321,DB00120,L-Phenylalanine
,26153275,volume of distribution (Vz),"The volume of distribution (Vz) also varied significantly across species with value of 5.5, 2.8, 0.24, and 0.93 l/kg in mouse, rat, dog, and cynomolgus monkey, respectively.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),[l] / [kg],0.24,213322,DB00120,L-Phenylalanine
,26153275,volume of distribution (Vz),"The volume of distribution (Vz) also varied significantly across species with value of 5.5, 2.8, 0.24, and 0.93 l/kg in mouse, rat, dog, and cynomolgus monkey, respectively.","Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26153275/),[l] / [kg],0.93,213323,DB00120,L-Phenylalanine
,3416297,g,In vitro mean glutathione-S-transferase values were 91.52 nmol/min/mg protein in TE-671 and 50.31 nmol/min/mg protein in Daoy.,"Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[nM] / [mg·min],91.52,214176,DB00120,L-Phenylalanine
,3416297,g,In vitro mean glutathione-S-transferase values were 91.52 nmol/min/mg protein in TE-671 and 50.31 nmol/min/mg protein in Daoy.,"Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[nM] / [mg·min],50.31,214177,DB00120,L-Phenylalanine
,3416297,Km,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),μM,108.3,214178,DB00120,L-Phenylalanine
,3416297,Vmax,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[pM] / [10(6)·cells·min],363.1,214179,DB00120,L-Phenylalanine
,3416297,Km,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),μM,111.7,214180,DB00120,L-Phenylalanine
,3416297,Vmax,"Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),[pM] / [10(6)·cells·min],180.6,214181,DB00120,L-Phenylalanine
,3416297,half-life,"The mean plasma concentration in mice given a 10% lethal dose (71.3 mg/m2) of melphalan i.p. was 50.3 microM at 10 min, with the half-life of 29.9 min.","Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3416297/),min,29.9,214182,DB00120,L-Phenylalanine
,14741071,area under the concentration-time curve (AUC(0-t)),"The mean (coefficient of variation (CV%)) area under the concentration-time curve (AUC(0-t)) of R-acenocoumarol in the presence and absence of nateglinide was 4217 (23%) and 3831 (24%) ng.h/ml, respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),[h·ng] / [ml],4217,214948,DB00120,L-Phenylalanine
,14741071,area under the concentration-time curve (AUC(0-t)),"The mean (coefficient of variation (CV%)) area under the concentration-time curve (AUC(0-t)) of R-acenocoumarol in the presence and absence of nateglinide was 4217 (23%) and 3831 (24%) ng.h/ml, respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),[h·ng] / [ml],3831,214949,DB00120,L-Phenylalanine
,14741071,AUC,"The corresponding AUC(INR) values were 104 (13%) and 99 (10%), respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),,104,214950,DB00120,L-Phenylalanine
,14741071,AUC,"The corresponding AUC(INR) values were 104 (13%) and 99 (10%), respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),,99,214951,DB00120,L-Phenylalanine
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],2.10,215026,DB00120,L-Phenylalanine
,1773422,area under the curve [AUC],On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.96,215027,DB00120,L-Phenylalanine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],4.05,215028,DB00120,L-Phenylalanine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],1.94,215029,DB00120,L-Phenylalanine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.91,215030,DB00120,L-Phenylalanine
,1773422,AUC,On the basis of this influence we have been able to differentiate between three groups of patients: (a) in six patients (five of them with frequent off episodes) LD values were significantly lower (p less than 0.05) when both drugs were given together (area under the curve [AUC] +/- SE 2.10 +/- 0.42 micrograms/ml/h vs. 4.96 +/- 1.10 micrograms/ml/h); (b) in eight patients (one with frequent akinesia) LD levels were significantly higher (p less than 0.003) when both drugs were given together (AUC +/- SE 4.05 +/- 0.51 micrograms/ml/h vs. 1.94 +/- 0.19 micrograms/ml/h); (c) in six patients (without motor fluctuations) no difference in LD levels was noted (AUC +/- SE 3.91 + 0.62 micrograms/ml/h vs. 3.81 +/- 0.70 micrograms/ml/h).,The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1773422/),[μg] / [h·ml],3.81,215031,DB00120,L-Phenylalanine
,4053270,half-lives,"Melphalan levels in the plasma decreased biphasically, with mean half-lives of 6.6 min and 3.0 h.",High dose melphalan in children with advanced malignant disease. A pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053270/),min,6.6,215256,DB00120,L-Phenylalanine
,4053270,half-lives,"Melphalan levels in the plasma decreased biphasically, with mean half-lives of 6.6 min and 3.0 h.",High dose melphalan in children with advanced malignant disease. A pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4053270/),h,3.0,215257,DB00120,L-Phenylalanine
,12968988,half-life (t(1/2)),"Rifampicin decreased the mean AUC(0,7 h) of nateglinide by 24% (range 5-53%; P = 0.0009) and shortened its half-life (t(1/2)) from 1.6 to 1.3 h (P = 0.001).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,1.6,215471,DB00120,L-Phenylalanine
,12968988,half-life (t(1/2)),"Rifampicin decreased the mean AUC(0,7 h) of nateglinide by 24% (range 5-53%; P = 0.0009) and shortened its half-life (t(1/2)) from 1.6 to 1.3 h (P = 0.001).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,1.3,215472,DB00120,L-Phenylalanine
,12968988,t(1/2),"The AUC(0,7 h) of the M7 metabolite of nateglinide was decreased by 19% (P = 0.002) and its t(1/2) was shortened from 2.1 to 1.6 h by rifampicin (P = 0.008).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,2.1,215473,DB00120,L-Phenylalanine
,12968988,t(1/2),"The AUC(0,7 h) of the M7 metabolite of nateglinide was decreased by 19% (P = 0.002) and its t(1/2) was shortened from 2.1 to 1.6 h by rifampicin (P = 0.008).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,1.6,215474,DB00120,L-Phenylalanine
,3978649,half-life (t1/2),The initial loss with a half-life (t1/2) of approximately 5 to 10 min is interpreted as rapid uptake of melphalan by the tissue of the perfused extremity.,Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978649/),min,5 to 10,216542,DB00120,L-Phenylalanine
,3978649,half-life,"The terminal portion of the curve with a half-life of approximately 35 to 50 min is interpreted as due predominantly to the hydrolysis of melphalan, with a lesser component of loss due to absorption of melphalan to the filters and tubing of the perfusion apparatus.",Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978649/),min,35 to 50,216543,DB00120,L-Phenylalanine
,30847504,flow rate,"The supernatant (5 µL) was injected onto an Acquity™ BEH C18 LC column (2.1 × 50 mm, 1.7 µm) and eluted with 25 mM NH4AC (pH 4.7)-acetonitrile in a gradient mode at a flow rate of 0.6 mL/min.",Determination of melphalan in human plasma by UPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30847504/),[ml] / [min],0.6,217140,DB00120,L-Phenylalanine
,30847504,retention times,The retention times were typically 2.11 min for melphalan and 2.38 min for the internal standard.,Determination of melphalan in human plasma by UPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30847504/),min,2.11,217141,DB00120,L-Phenylalanine
,30847504,retention times,The retention times were typically 2.11 min for melphalan and 2.38 min for the internal standard.,Determination of melphalan in human plasma by UPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30847504/),min,2.38,217142,DB00120,L-Phenylalanine
,30847504,Total run time,Total run time is 4 min per sample.,Determination of melphalan in human plasma by UPLC-UV method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30847504/),[min] / [sample],4,217143,DB00120,L-Phenylalanine
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],7.9,217944,DB00120,L-Phenylalanine
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],8.4,217945,DB00120,L-Phenylalanine
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],6.5,217946,DB00120,L-Phenylalanine
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],6.9,217947,DB00120,L-Phenylalanine
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],5.8,217948,DB00120,L-Phenylalanine
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],4.1,217949,DB00120,L-Phenylalanine
,15005635,clearance,Median clearance in three carriers of two deficient CYP2D6 alleles was 9.4 L/h.,Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],9.4,217950,DB00120,L-Phenylalanine
,28590055,Tmax,"Tmax of MeSD was observed at 0.25 h, which is beneficial for efficient management of postprandial sugar.",Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28590055/),h,0.25,219661,DB00120,L-Phenylalanine
,19041063,overall response rate (ORR,"Complete responses (CR) were seen in 12 of 48 patients (25%), with an overall response rate (ORR = CR + PR) of 85%.",Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041063/),%,85,221266,DB00120,L-Phenylalanine
,19041063,progression-free survival (PFS),Median progression-free survival (PFS) was 25 months; median overall survival (OS) has not yet been reached.,Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19041063/),month,25,221267,DB00120,L-Phenylalanine
,1490503,bioavailability,Almost equivalent bioavailability (85-90%) of levodopa was demonstrated for the controlled-release formulations relative to that of conventional Madopar capsules.,Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490503/),%,85-90,222528,DB00120,L-Phenylalanine
,3896742,half-life,"Guanadrel has a rapid onset of action and a half-life of about 10 hours, thus dose titration can be achieved more rapidly than with guanethidine, and twice daily administration is appropriate.",Guanadrel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896742/),h,10,223353,DB00120,L-Phenylalanine
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],5,224309,DB00120,L-Phenylalanine
,10829343,minimum detectable concentration,"Using this method, the minimum detectable concentration was estimated to be 5 and 8 ng ml-1 for L-dopa and C-dopa, respectively.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),[ng] / [ml],8,224310,DB00120,L-Phenylalanine
,10829343,Recovery,"Recovery studies ranged from 93.83 to 89.76%, with a relative standard deviation of less than 7%.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),%,93.83 to 89.76,224311,DB00120,L-Phenylalanine
less,10829343,half-lives,"The data also indicated a very low accumulation of both levodopa and carbidopa following repeated administration of the drugs, which was consistent with their relatively short half-lives (less than 2 h).",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,2,224312,DB00120,L-Phenylalanine
,10829343,half-life,"In contrast, the half-life for the metabolite 3-orthomethyl dopa (3-OMD) is in the order of 13 h.",Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829343/),h,13,224313,DB00120,L-Phenylalanine
,2685649,bioavailability,"Results indicate a levodopa bioavailability of 71% for Sinemet CR, in contrast to a bioavailability of 99% for Sinemet for these subjects.",Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,71,225396,DB00120,L-Phenylalanine
,2685649,bioavailability,"Results indicate a levodopa bioavailability of 71% for Sinemet CR, in contrast to a bioavailability of 99% for Sinemet for these subjects.",Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,99,225397,DB00120,L-Phenylalanine
,2685649,bioavailability,The carbidopa bioavailability of Sinemet CR was 58% relative to that of Sinemet.,Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2685649/),%,58,225398,DB00120,L-Phenylalanine
,8295005,accumulation,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),[%id] / [g],0.38,226440,DB00120,L-Phenylalanine
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,2.5,226441,DB00120,L-Phenylalanine
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,7.4,226442,DB00120,L-Phenylalanine
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,1.9,226443,DB00120,L-Phenylalanine
,8295005,tumor-to-nontumor ratios,"After 1 hr, the accumulation of 67Ga[DFO]-octreotide was 0.38 +/- 0.08 %ID/g and the tumor-to-nontumor ratios for blood, muscle, liver and intestine were 2.5, 7.4, 1.9 and 1.6, respectively.",Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),,1.6,226444,DB00120,L-Phenylalanine
,8295005,residence half-life,PET studies with 68Ga[DFO]-octreotide recorded a very rapid accumulation at the tumor and a subsequent residence half-life of about 6 hr.,Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8295005/),h,6,226445,DB00120,L-Phenylalanine
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,17.7,227456,DB00120,L-Phenylalanine
,19804823,absolute bioavailabilities,"The absolute bioavailabilities of oral and nasal preparations containing C-dopa were 17.7 and 45.4%, respectively.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),%,45.4,227457,DB00120,L-Phenylalanine
less,19804823,half-life,"Although the half-life after nasal administration was relatively short (less than 30 min) in both blood and brain regardless of C-dopa addition, the systemic exposure was promising due to rapid absorption.",Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19804823/),min,30,227458,DB00120,L-Phenylalanine
,20231306,peak plasma concentration,These effects were associated with a peak plasma concentration of 20.9 microM and an area under the curve from 0 to 24 h of 136.1 h x microM (36 mg/kg).,"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20231306/),μM,20.9,227585,DB00120,L-Phenylalanine
,20231306,area under the curve from 0 to 24 h,These effects were associated with a peak plasma concentration of 20.9 microM and an area under the curve from 0 to 24 h of 136.1 h x microM (36 mg/kg).,"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20231306/),h·μM,136.1,227586,DB00120,L-Phenylalanine
,12940610,AUC(0-6),"Mean pharmacokinetic parameters (AUC(0-6) 10.45 mg/l/h; t(1/2) 1.89 h, Cl/F 10.19 l/h) were comparable with those reported in healthy subjects.",Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12940610/),[mg] / [h·l],10.45,228071,DB00120,L-Phenylalanine
,12940610,t(1/2),"Mean pharmacokinetic parameters (AUC(0-6) 10.45 mg/l/h; t(1/2) 1.89 h, Cl/F 10.19 l/h) were comparable with those reported in healthy subjects.",Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12940610/),h,1.89,228072,DB00120,L-Phenylalanine
,12940610,Cl/F,"Mean pharmacokinetic parameters (AUC(0-6) 10.45 mg/l/h; t(1/2) 1.89 h, Cl/F 10.19 l/h) were comparable with those reported in healthy subjects.",Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12940610/),[l] / [h],10.19,228073,DB00120,L-Phenylalanine
,26936272,absorption rate constant (KA),"Pharmacokinetic analysis identified a one-compartment model with the following parameter values [bootstrap 95 % CI]: absorption rate constant (KA) 1.86 1/h [1.08-3.25], clearance 36.6 L/h [31.3-42.8], and volume of distribution 42.9 L [34.3-52.3].",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[1] / [h],1.86,228871,DB00120,L-Phenylalanine
,26936272,clearance,"Pharmacokinetic analysis identified a one-compartment model with the following parameter values [bootstrap 95 % CI]: absorption rate constant (KA) 1.86 1/h [1.08-3.25], clearance 36.6 L/h [31.3-42.8], and volume of distribution 42.9 L [34.3-52.3].",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[l] / [h],36.6,228872,DB00120,L-Phenylalanine
,26936272,volume of distribution,"Pharmacokinetic analysis identified a one-compartment model with the following parameter values [bootstrap 95 % CI]: absorption rate constant (KA) 1.86 1/h [1.08-3.25], clearance 36.6 L/h [31.3-42.8], and volume of distribution 42.9 L [34.3-52.3].",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),l,42.9,228873,DB00120,L-Phenylalanine
,26936272,Residual var,Residual variability was 1120 μg/L [886-1290].,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[μg] / [l],1120,228874,DB00120,L-Phenylalanine
,26936272,KE0,UPDRS III and dyskinesia were best described with an effect compartment and similar KE0 values of 1.37 1/h [1.01-1.77].,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[1] / [h],1.37,228875,DB00120,L-Phenylalanine
,26936272,E0,"For UPDRS III, the E0, EC50, Emax, and Hill coefficient were 31.4 [28.4-35.3], 1410 μg/L [1200-1700], 0.72 [0.71-0.75], and 4.26 [3.20-5.58], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,31.4,228876,DB00120,L-Phenylalanine
,26936272,Hill coefficient,"For UPDRS III, the E0, EC50, Emax, and Hill coefficient were 31.4 [28.4-35.3], 1410 μg/L [1200-1700], 0.72 [0.71-0.75], and 4.26 [3.20-5.58], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,4.26,228877,DB00120,L-Phenylalanine
,26936272,EC50,"For dyskinesia, the EC50 and Emax were 6280 μg/L [3420-37,900] and 17.9 [12.3-80.8], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),[μg] / [l],6280,228878,DB00120,L-Phenylalanine
,26936272,Emax,"For dyskinesia, the EC50 and Emax were 6280 μg/L [3420-37,900] and 17.9 [12.3-80.8], respectively.",A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,17.9,228879,DB00120,L-Phenylalanine
,26936272,Residual,Residual variability was 3.15 [2.75-3.53] for UPDRS III and 2.66 [1.94-3.51] for dyskinesia.,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,3.15,228880,DB00120,L-Phenylalanine
,26936272,Residual,Residual variability was 3.15 [2.75-3.53] for UPDRS III and 2.66 [1.94-3.51] for dyskinesia.,A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26936272/),,2.66,228881,DB00120,L-Phenylalanine
,17398055,flow rate,"Separation was developed on a reverse-phase C(18) column (250 mm x 4.6mm i.d., 5 microm particle size), using a mixture of acetonitrile (ACN):10mM phosphate buffer (PBS, pH 3.0) in the ratio of 70:30(%v/v) at a flow rate of 1.0 ml/min with UV detection at 203 nm within 8 min, and quantified based on drug/IS peak area ratios.",Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17398055/),[ml] / [min],1.0,229029,DB00120,L-Phenylalanine
,17398055,limit of detection (LoD),"The limit of detection (LoD) and limit of quantitation (LoQ) were found to be 2.91 and 9.70 ng/ml, respectively.",Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17398055/),[ng] / [ml],2.91,229030,DB00120,L-Phenylalanine
,17398055,limit of quantitation (LoQ),"The limit of detection (LoD) and limit of quantitation (LoQ) were found to be 2.91 and 9.70 ng/ml, respectively.",Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17398055/),[ng] / [ml],9.70,229031,DB00120,L-Phenylalanine
,21789689,total clearance,"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.70,234089,DB00120,L-Phenylalanine
,21789689,total clearance,"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.50,234090,DB00120,L-Phenylalanine
,21789689,Cl(observed),"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.70,234091,DB00120,L-Phenylalanine
,21789689,Cl(observed),"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.50,234092,DB00120,L-Phenylalanine
,21789689,Cl(observed),"Mean simulated total clearance of high- and low-dose etoposide was 0.70 ml/min/kg (Cl(observed): 0.70 ml/min/kg) versus 0.50 ml/min/kg (Cl(observed): 0.60 ml/min/kg), respectively.",Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21789689/),[ml] / [kg·min],0.60,234093,DB00120,L-Phenylalanine
,17765074,flow rate,"The fluorescent derivatives were separated under isocratic conditions on a Hypersil BDS-C8 analytical column (250.0 mm x 2.1 mm i.d., particle size 5 microm) with a mobile phase that consisted of 65% acetonitrile in water and pumped at a flow rate of 0.50 mL min(-1).",Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17765074/),[ml] / [min],0.50,234157,DB00120,L-Phenylalanine
,24525207,tumor-to-,The accumulation of (18)F-FBPA-Fr in brain tumors and the tumor-to-contralateral brain ratio were significantly elevated after intravenous injection of (18)F-FBPA-Fr with BBB-D. (18)F-FBPA-Fr administration after sonication showed that the tumor-to-contralateral brain ratio for the sonicated tumors (3.5) was approximately 1.75-fold higher than that for the control tumors (2.0).,Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24525207/),,3,234744,DB00120,L-Phenylalanine
,2117017,permeability,"The individual permeabilities were determined by linear regression analysis, according to which the average methyl-FDOPA permeability in the blood-brain barrier was twice that of FDOPA, which averaged 0.037 ml g-1 min-1.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),[ml] / [g·min],0.037,235129,DB00120,L-Phenylalanine
,2117017,perme,"The permeability ratio was used to determine the fractional clearance from the brain of FDOPA (and hence of methyl-FDOPA), which averaged 0.081 min-1.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),1/[min],0.081,235130,DB00120,L-Phenylalanine
,2117017,fractional clearance,"The permeability ratio was used to determine the fractional clearance from the brain of FDOPA (and hence of methyl-FDOPA), which averaged 0.081 min-1.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),1/[min],0.081,235131,DB00120,L-Phenylalanine
,2117017,de,"In the striatum, the measured average FDOPA decarboxylation rate constant (kD3) was 0.010 min-1, or no more than 1% of the rate of striatal decarboxylation of DOPA measured in vitro and in vivo.",Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2117017/),1/[min],0.010,235132,DB00120,L-Phenylalanine
,1904753,clearance,"2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[ml] / [kg·min],4.43,235664,DB00120,L-Phenylalanine
,1904753,clearance,"2. Gludopa had a clearance of 4.43 +/- 1.50 ml min-1 kg-1 and 4.92 ml min-1 kg-1 at the higher and lower doses, respectively.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[ml] / [kg·min],4.92,235665,DB00120,L-Phenylalanine
,1904753,half-lives,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),min,29.2,235666,DB00120,L-Phenylalanine
,1904753,half-lives,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),min,32.5,235667,DB00120,L-Phenylalanine
,1904753,volumes of distribution,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),[l] / [kg],0.183,235668,DB00120,L-Phenylalanine
,1904753,volumes of distribution,"Corresponding half-lives were 29.2 +/- 3.7 min and 32.5 +/- 5.6 min, and volumes of distribution were 0.183 +/- 0.052 l kg-1 and 0.235 +/- 0.07/ l kg-1.",Disposition of gamma-glutamyl levodopa (gludopa) after intravenous bolus injection in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1904753/),1/[kg·l],0.235,235669,DB00120,L-Phenylalanine
,7679331,survival,The median survival for patients on this trial was 11.5 months.,Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7679331/),month,11,236189,DB00120,L-Phenylalanine
,14718682,bioavailability,"In switching patients who are receiving levodopa/carbidopa controlled-release (CR), it should be noted that the bioavailability of levodopa from levodopa/carbidopa CR is approximately 70-75% that of levodopa/carbidopa IR products, including Stalevo.",Levodopa/carbidopa/entacapone (Stalevo). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14718682/),%,70-75,236483,DB00120,L-Phenylalanine
,8314919,k0,"Population means for k0 (0.011 +/- 0.002 min-1) and k-1 (0.010 +/- 0.003 min-1) were used to generate ""simulated"" plasma curves.","Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314919/),1/[min],0.011,236798,DB00120,L-Phenylalanine
,8314919,k-1,"Population means for k0 (0.011 +/- 0.002 min-1) and k-1 (0.010 +/- 0.003 min-1) were used to generate ""simulated"" plasma curves.","Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314919/),1/[min],0.010,236799,DB00120,L-Phenylalanine
,14748619,bioavailability,"The pharmacokinetics of nateglinide are characterised by rapid absorption and elimination, with good (73%) bioavailability.","Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748619/),%,73,236941,DB00120,L-Phenylalanine
,11221961,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),μM,9.11,237106,DB00120,L-Phenylalanine
,11221961,area under the plasma concentration time curve (AUC),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),h·μM,145,237107,DB00120,L-Phenylalanine
,11221961,area under the plasma concentration time curve (AUC),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),[l] / [h·m2],8.06,237108,DB00120,L-Phenylalanine
,11221961,apparent clearance (Clapp),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),h·μM,145,237109,DB00120,L-Phenylalanine
,11221961,apparent clearance (Clapp),"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),[l] / [h·m2],8.06,237110,DB00120,L-Phenylalanine
,11221961,t,"The maximal plasma concentration (Cmax), area under the plasma concentration time curve (AUC), apparent clearance (Clapp), duration of plasma concentration above 0.05 microM (t > 0.05 microM) for paclitaxel were (means SD): 9.11 +/- 7.45 microM, 145 +/- 88 microM x h, 8.06 +/- 2.90 l/h per m2 and 82.4 +/- 31.2 h, respectively.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),h,82.4,237111,DB00120,L-Phenylalanine
,11221961,nadir,Median nadir count for platelets was 66 x 10(9)/l (range 13-160 x 10(9)/l).,The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),,66 x 10,237112,DB00120,L-Phenylalanine
>,11221961,t,"Pharmacodynamic analysis showed no correlation between pharmacokinetic parameters (Cmax, AUC, t > 0.05 microM) and time to neutropenic nadir, duration of neutropenia, platelet count nadir and grades of neuropathy or mucositis.",The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221961/),μM,0.05,237113,DB00120,L-Phenylalanine
,16269600,tumor-to-ipsilateral brain ratio,The high boron concentration in brain tumor (76.6 mug/g) and the high tumor-to-ipsilateral brain ratio (6.3) may afford enough radiation doses to destroy the tumor cells while sparing the normal tissues in boron neutron capture therapy.,Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),,6.3,237761,DB00120,L-Phenylalanine
,16269600,k(el),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0206,237762,DB00120,L-Phenylalanine
,16269600,k(12),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0260,237763,DB00120,L-Phenylalanine
,16269600,k(12),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0039,237764,DB00120,L-Phenylalanine
,16269600,k(21),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),1/[min],0.0260,237765,DB00120,L-Phenylalanine
,16269600,V(1),"The pharmacokinetic parameters of k(el), k(12), k(21), and V(1) for intracarotid injection of (18)F-FBPA with BBB-D derived from the open 2-compartment model are 0.0206 +/- 0.0018 min(-1), 0.0260 +/- 0.0016 min(-1), 0.0039 +/- 0.0003 min(-1), and 3.1 +/- 0.1 mL, respectively.",Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269600/),ml,3.1,237766,DB00120,L-Phenylalanine
,9816255,half-life (t1/2),"The median half-life (t1/2), area under the concentration curve, and clearance of MEL were 1.1 h, 5.5 mg h/liter, and 27.5 liter/h, respectively, in patients with a creatinine clearance of <40 ml/min compared to 1.9, 7.9, and 23.6 for the others.",Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816255/),h,1.1,238737,DB00120,L-Phenylalanine
,9816255,area under the concentration curve,"The median half-life (t1/2), area under the concentration curve, and clearance of MEL were 1.1 h, 5.5 mg h/liter, and 27.5 liter/h, respectively, in patients with a creatinine clearance of <40 ml/min compared to 1.9, 7.9, and 23.6 for the others.",Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816255/),[h·mg] / [l],5.5,238738,DB00120,L-Phenylalanine
,9816255,area under the concentration curve,"The median half-life (t1/2), area under the concentration curve, and clearance of MEL were 1.1 h, 5.5 mg h/liter, and 27.5 liter/h, respectively, in patients with a creatinine clearance of <40 ml/min compared to 1.9, 7.9, and 23.6 for the others.",Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816255/),,1.9,238739,DB00120,L-Phenylalanine
,9816255,area under the concentration curve,"The median half-life (t1/2), area under the concentration curve, and clearance of MEL were 1.1 h, 5.5 mg h/liter, and 27.5 liter/h, respectively, in patients with a creatinine clearance of <40 ml/min compared to 1.9, 7.9, and 23.6 for the others.",Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816255/),,7.9,238740,DB00120,L-Phenylalanine
,9816255,clearance,"The median half-life (t1/2), area under the concentration curve, and clearance of MEL were 1.1 h, 5.5 mg h/liter, and 27.5 liter/h, respectively, in patients with a creatinine clearance of <40 ml/min compared to 1.9, 7.9, and 23.6 for the others.",Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816255/),[l] / [h],27.5,238741,DB00120,L-Phenylalanine
,9816255,clearance,"The median half-life (t1/2), area under the concentration curve, and clearance of MEL were 1.1 h, 5.5 mg h/liter, and 27.5 liter/h, respectively, in patients with a creatinine clearance of <40 ml/min compared to 1.9, 7.9, and 23.6 for the others.",Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816255/),,1.9,238742,DB00120,L-Phenylalanine
,9816255,clearance,"The median half-life (t1/2), area under the concentration curve, and clearance of MEL were 1.1 h, 5.5 mg h/liter, and 27.5 liter/h, respectively, in patients with a creatinine clearance of <40 ml/min compared to 1.9, 7.9, and 23.6 for the others.",Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816255/),,7.9,238743,DB00120,L-Phenylalanine
,16139166,AUC,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[min·μg] / [ml],43.4,239238,DB00120,L-Phenylalanine
,16139166,AUC,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[min·μg] / [ml],47.1,239239,DB00120,L-Phenylalanine
,16139166,Cmax,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[μg] / [ml],1.04,239240,DB00120,L-Phenylalanine
,16139166,Cmax,"The extent of levodopa absorbed when administering 100 mg/kg of fiber (AUC=43.4 mug min ml(-1)) is approximately the same as when levodopa is administered alone (AUC=47.1 microg min ml(-1)); however, Cmax is lower (1.04 versus 1.43 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[μg] / [ml],1.43,239241,DB00120,L-Phenylalanine
,16139166,AUC,"Results obtained indicate that fiber at the higher dose increases the extent of levodopa absorbed (AUC=62.2 microg min ml(-1)), being the value of Cmax similar (1.46 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[min·μg] / [ml],62.2,239242,DB00120,L-Phenylalanine
,16139166,Cmax,"Results obtained indicate that fiber at the higher dose increases the extent of levodopa absorbed (AUC=62.2 microg min ml(-1)), being the value of Cmax similar (1.46 microg ml(-1)).",Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),[μg] / [ml],1.46,239243,DB00120,L-Phenylalanine
,16139166,tmax,The value of tmax increases from 10 min when levodopa is administered alone to 20 min when the animals receive fiber.,Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),min,10,239244,DB00120,L-Phenylalanine
,16139166,tmax,The value of tmax increases from 10 min when levodopa is administered alone to 20 min when the animals receive fiber.,Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16139166/),min,20,239245,DB00120,L-Phenylalanine
,24342510,Extraction efficiencies,"Extraction efficiencies for MPA and PPA were approximately 97% and 86%, respectively, and matrix effects were minimal.",Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342510/),%,97,240499,DB00120,L-Phenylalanine
,24342510,Extraction efficiencies,"Extraction efficiencies for MPA and PPA were approximately 97% and 86%, respectively, and matrix effects were minimal.",Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342510/),%,86,240500,DB00120,L-Phenylalanine
,14668056,half-life,"The maximum intracellular melphalan concentration following J1 exposure was reached already after 15 min, thereafter declining with a half-life of approximately 1 h.",Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14668056/),h,1,240627,DB00120,L-Phenylalanine
,26224751,en,"This was attributed to a more rapid release of dietary protein-derived AAs into the circulation, as evidenced by a higher peak plasma l-[1-(13)C]phenylalanine enrichment concentration (2.9 ± 0.2 vs. 2.2 ± 0.2 mole percent excess; P < 0.05).",Jejunal Casein Feeding Is Followed by More Rapid Protein Digestion and Amino Acid Absorption When Compared with Gastric Feeding in Healthy Young Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26224751/),%·mole,2.9,241549,DB00120,L-Phenylalanine
,26224751,en,"This was attributed to a more rapid release of dietary protein-derived AAs into the circulation, as evidenced by a higher peak plasma l-[1-(13)C]phenylalanine enrichment concentration (2.9 ± 0.2 vs. 2.2 ± 0.2 mole percent excess; P < 0.05).",Jejunal Casein Feeding Is Followed by More Rapid Protein Digestion and Amino Acid Absorption When Compared with Gastric Feeding in Healthy Young Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26224751/),%·mole,2.2,241550,DB00120,L-Phenylalanine
,8975846,Maximum tolerated dose,Maximum tolerated dose of melphalan delivered buy means of isolated lung perfusion was 2 mg.,Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8975846/),mg,2,243266,DB00120,L-Phenylalanine
,265185,plasma half-lives,"After a single injection, the average plasma half-lives of phenylalanine ammonia-lyase were 18 to 24 hr in all groups studied.",Clearance of phenylalanine ammonia-lyase from normal and tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/265185/),h,18 to 24,243707,DB00120,L-Phenylalanine
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,82.4,244438,DB00120,L-Phenylalanine
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,66.7,244439,DB00120,L-Phenylalanine
,24363125,absolute bioavailabilities,"The absolute bioavailabilities of nasal preparations with and without Carbopol were 82.4 and 66.7 %, respectively, which were much higher than that of oral delivery (16.2 %).",Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363125/),%,16.2,244440,DB00120,L-Phenylalanine
,1553388,Cmaxs,"Mean PHE Cmaxs ranged from 73.6 to 1,161 nmol/ml in the rat, and from 78.6 to 1,967 nmol/ml in the mouse.",Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553388/),[nM] / [ml],"73.6 to 1,161",245605,DB00120,L-Phenylalanine
,1553388,Cmaxs,"Mean PHE Cmaxs ranged from 73.6 to 1,161 nmol/ml in the rat, and from 78.6 to 1,967 nmol/ml in the mouse.",Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553388/),[nM] / [ml],"78.6 to 1,967",245606,DB00120,L-Phenylalanine
,1553388,Cmaxs,"TYR Cmaxs ranged from 91.6 to 502 nmol/ml and from 89.2 to 792 nmol/ml in the rat and mouse, respectively.",Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553388/),[nM] / [ml],91.6 to 502,245607,DB00120,L-Phenylalanine
,1553388,Cmaxs,"TYR Cmaxs ranged from 91.6 to 502 nmol/ml and from 89.2 to 792 nmol/ml in the rat and mouse, respectively.",Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553388/),[nM] / [ml],89.2 to 792,245608,DB00120,L-Phenylalanine
,1553388,Peak plasma PHE/LNAA ratios,Peak plasma PHE/LNAA ratios ranged from 0.112 to 1.117 in rats and from 0.121 to 1.769 in mice.,Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553388/),,0.112 to 1.117,245609,DB00120,L-Phenylalanine
,1553388,Peak plasma PHE/LNAA ratios,Peak plasma PHE/LNAA ratios ranged from 0.112 to 1.117 in rats and from 0.121 to 1.769 in mice.,Plasma concentrations and pharmacokinetics of phenylalanine in rats and mice administered aspartame. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1553388/),,0.121 to 1.769,245610,DB00120,L-Phenylalanine
,27214664,tmax,Dipraglurant was rapidly absorbed (tmax = 1 hour).,A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214664/),h,1,246701,DB00120,L-Phenylalanine
,27214664,Cmax,The 100-mg dose led to a mean Cmax of 1844 ng/mL on day 28.,A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27214664/),[ng] / [ml],1844,246702,DB00120,L-Phenylalanine
,15752378,clearance (CL),Children who did not have carboplatin (n = 27) had median melphalan clearance (CL) of 15.5 l h(-1) m(-2) (interquartile range: 12.4-19.9 l h(-1) m(-2)) and steady state volume of distribution (Vss) of 14.9 l m(-2) (interquartile range: 12.7-18.3 l m(-2)).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2·h],15.5,247614,DB00120,L-Phenylalanine
,15752378,steady state volume of distribution (Vss),Children who did not have carboplatin (n = 27) had median melphalan clearance (CL) of 15.5 l h(-1) m(-2) (interquartile range: 12.4-19.9 l h(-1) m(-2)) and steady state volume of distribution (Vss) of 14.9 l m(-2) (interquartile range: 12.7-18.3 l m(-2)).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2],14.9,247615,DB00120,L-Phenylalanine
,15752378,CL,Children who had carboplatin (n = 25) had 34% lower median CL (10.2 l h(-1) m(-2)) and 18% lower median Vss (12.2 l m(-2)) (P < 0.001).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2·h],10.2,247616,DB00120,L-Phenylalanine
,15752378,Vss,Children who had carboplatin (n = 25) had 34% lower median CL (10.2 l h(-1) m(-2)) and 18% lower median Vss (12.2 l m(-2)) (P < 0.001).,"Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752378/),[l] / [(m)^2],12.2,247617,DB00120,L-Phenylalanine
,2774511,distribution half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,5,247981,DB00120,L-Phenylalanine
,2774511,elimination half-life,"In 11 of 15 subjects, the disappearance of drug could be described by a two-compartment model, with a distribution half-life of 5 minutes and an elimination half-life of 33 minutes.",Peripheral pharmacokinetics of apomorphine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774511/),min,33,247982,DB00120,L-Phenylalanine
,24909314,flow rate,Chromatographic separation was achieved by a reverse phase C18 column using a mixture of acetonitrile:methanol:10mM phosphate buffer (pH 3.5) in the ratio of 56:14:30 (%v/v) as the mobile phase at a flow rate of 1.0ml/min and quantified based on drug/IS peak area ratios.,Maltodextrin based proniosomes of nateglinide: bioavailability assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24909314/),[ml] / [min],1.0,248656,DB00120,L-Phenylalanine
,2775615,plasma clearance,2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],14.2,249584,DB00120,L-Phenylalanine
,2775615,plasma clearance,2. The plasma clearance of levodopa following intravenous administration of 50 mg was 14.2 +/- 2.8 (s.d.) ml min-1 kg-1 in the elderly compared with 23.4 +/- 4.1 ml min-1 kg-1 in the young (P less than 0.01) which resulted in a 49% greater area under the plasma concentration-time curve (AUC) in the older subjects (P less than 0.01).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],23.4,249585,DB00120,L-Phenylalanine
,2775615,volume of distribution (Vss),The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[l] / [kg],1.01,249586,DB00120,L-Phenylalanine
,2775615,volume of distribution (Vss),The volume of distribution (Vss) was lower in the elderly (1.01 +/- 0.29 l kg-1) than in the young (1.65 +/- 0.39 l kg-1) (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[l] / [kg],1.65,249587,DB00120,L-Phenylalanine
,2775615,AUC,3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ng] / [ml],2512,249588,DB00120,L-Phenylalanine
,2775615,AUC,3. Following oral administration of 250 mg of levodopa the AUC was 2512 +/- 588 ng ml-1h in the elderly compared with 1056 +/- 282 ng ml-1h in the young (P less than 0.002).,The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ng] / [ml],1056,249589,DB00120,L-Phenylalanine
,2775615,bioavailability,"The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),,0.63,249590,DB00120,L-Phenylalanine
,2775615,bioavailability,"The bioavailability of levodopa was significantly greater in the elderly (0.63 +/- 0.12 compared with 0.41 +/- 0.16, P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),,0.41,249591,DB00120,L-Phenylalanine
,2775615,plasma clearance,"4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],5.8,249592,DB00120,L-Phenylalanine
,2775615,plasma clearance,"4. In the presence of carbidopa, the plasma clearance of intravenous levodopa (50 mg) was reduced in both age groups but remained lower in the elderly (5.8 +/- 0.9 ml min-1 kg-1 compared with 9.3 +/- 1.0 ml min-1 kg-1; P less than 0.01).",The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2775615/),[ml] / [kg·min],9.3,249593,DB00120,L-Phenylalanine
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],603.2,249714,DB00120,L-Phenylalanine
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],612.0,249715,DB00120,L-Phenylalanine
,25112783,Cmax,"Levodopa Cmax was very similar in the initial situation (603.2 ng/ml) and after placebo administration (612.0 ng/ml), being slightly lower (547.8 ng/ml) when Plantago ovata husk was given.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[ng] / [ml],547.8,249716,DB00120,L-Phenylalanine
,25112783,AUC,"AUC was very similar in the three groups: initial situation.- 62.87 μg.min/ml, fiber treatment.- 64.47 μg.min/ml and placebo treatment.- 65.10 μg.min/ml.",A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25112783/),[min·μg] / [ml],62.87,249717,DB00120,L-Phenylalanine
,11333844,whole-body clearance (Cl(tot)),"In patients with sepsis, whole-body clearance (Cl(tot)) of total amino acids was 74% higher than in control subjects (x +/- SEM: 13,161 +/- 1659 and 7566 +/- 91 mL/min, respectively; P < 0.01), the Cl(tot) of essential amino acids was 64% higher (P < 0.02), that of nonessential amino acids was 82% higher (P < 0.01), and that of both branched-chain amino acids and glucogenic amino acids was 97% higher (P < 0.001).",Amino acid kinetics in patients with sepsis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11333844/),[ml] / [min],"13,161",250304,DB00120,L-Phenylalanine
,11333844,whole-body clearance (Cl(tot)),"In patients with sepsis, whole-body clearance (Cl(tot)) of total amino acids was 74% higher than in control subjects (x +/- SEM: 13,161 +/- 1659 and 7566 +/- 91 mL/min, respectively; P < 0.01), the Cl(tot) of essential amino acids was 64% higher (P < 0.02), that of nonessential amino acids was 82% higher (P < 0.01), and that of both branched-chain amino acids and glucogenic amino acids was 97% higher (P < 0.001).",Amino acid kinetics in patients with sepsis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11333844/),[ml] / [min],7566,250305,DB00120,L-Phenylalanine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.35,251269,DB00120,L-Phenylalanine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],0.82,251270,DB00120,L-Phenylalanine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],2.14,251271,DB00120,L-Phenylalanine
,11847938,maximum concentration (Cmax),"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),[ng] / [ml],3.27,251272,DB00120,L-Phenylalanine
,11847938,time to Cmax,"The maximum concentration (Cmax) values of brasofensine observed in plasma after oral administration were 0.35, 0.82, 2.14, and 3.27 ng/mL for the 0.5-, 1-, 2-, and 4-mg doses, respectively; these concentrations occurred 4 hours (time to Cmax) after administration in all cases.",Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847938/),h,4,251273,DB00120,L-Phenylalanine
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.39,254017,DB00120,L-Phenylalanine
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.36,254018,DB00120,L-Phenylalanine
,2720699,Half-times,"Half-times for the equilibration between plasma and the effect compartment were 0.39 h for tapping, 0.36 h for walking, and 0.34 h for the global score.",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),h,0.34,254019,DB00120,L-Phenylalanine
,2720699,Emax,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[taps] / [60·s],53.2,254020,DB00120,L-Phenylalanine
,2720699,EC50,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[μg] / [ml],0.58,254021,DB00120,L-Phenylalanine
,2720699,Emax,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),,5.0,254022,DB00120,L-Phenylalanine
,2720699,EC50,"Pharmacodynamic data were fit best with an Emax model with baseline effect for tapping (Emax = 53.2 taps/60 s, EC50 = 0.58 microgram/ml) and global score (Emax set at 5.0 by limits of scale, EC50 = 2.53 micrograms/ml).",Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720699/),[μg] / [ml],2.53,254023,DB00120,L-Phenylalanine
<,12127523,IC(50),Further optimization led to several highly potent compounds (IC(50) <1 nM).,N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12127523/),nM,1,254644,DB00120,L-Phenylalanine
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],2.3,255437,DB00120,L-Phenylalanine
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],1.3,255438,DB00120,L-Phenylalanine
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],1.15,255439,DB00120,L-Phenylalanine
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],0.8,255440,DB00120,L-Phenylalanine
,17393167,AUC,"No difference in AUC values was observed between weight strata (mean +/- SD 1248 +/- 205 micromol.min), whereas a significant difference in Bu clearance was demonstrated.",Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17393167/),min·μM,1248,256642,DB00120,L-Phenylalanine
,17393167,AUC,"At dose 1, 91% of patients achieved the targeted AUC range (900-1500 micromol.min) while no patients were underexposed.",Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17393167/),min·μM,900-1500,256643,DB00120,L-Phenylalanine
,9067961,constant flow rate,The limb was perfused with Krebs Heinseleit buffer at 37 degrees C containing 4.7% bovine serum albumin at a constant flow rate of 4 ml per min for 30-60 min with 100% survival of the animals.,Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9067961/),[ml] / [min],4,257475,DB00120,L-Phenylalanine
<,9067961,Systemic leakage,"Systemic leakage, assessed using [125I]albumin and melphalan and detected by a gamma-counter and HPLC respectively, was < 0.5%.",Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9067961/),%,0.5,257476,DB00120,L-Phenylalanine
,24288267,midazolam concentration,We found a high interindividual variability of serum midazolam concentrations in asphyxiated neonates with therapeutic hypothermia; median midazolam concentration was 369.3 ng/ml (minimum 36.6; maximum 3 218.6 ng/ml).,Disposition of midazolam in asphyxiated neonates receiving therapeutic hypothermia--a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24288267/),[ng] / [ml],369.3,258007,DB00120,L-Phenylalanine
,24288267,clearance,"The population pharmacokinetic model revealed a midazolam clearance of 2.57 ml/kg/min, comparable to midazolam clearances observed in normothermic critically ill neonates.",Disposition of midazolam in asphyxiated neonates receiving therapeutic hypothermia--a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24288267/),[ml] / [kg·min],2.57,258008,DB00120,L-Phenylalanine
,10980240,clearance half-life,Total extracellular [18F] radioactivity in rat striata was observed to rise and peak at 30 min post-injection (p.i.) and declined with clearance half-life of 2 h.,6-fluoroDOPA metabolism in rat striatum: time course of extracellular metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980240/),h,2,258340,DB00120,L-Phenylalanine
,28684379,total area under the curve (AUC),"Bu dosing was adjusted to target a total area under the curve (AUC) of 20,000 μM × min.",Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684379/),min·μM,"20,000",258488,DB00120,L-Phenylalanine
,28684379,total AUC,"PK testing resulted in 86% of patients achieving an estimated total AUC of 20,000 ± 2500 μM × min.",Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684379/),min·μM,"20,000",258489,DB00120,L-Phenylalanine
,28684379,overall response rate (ORR),"The overall response rate (ORR) at day +100 after ASCT was 100% in the evaluable patients, with 11% of patients achieving a complete response.",Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684379/),%,100,258490,DB00120,L-Phenylalanine
,26245808,peak concentrations,"After RYGB, basal plasma leucine concentration did not change, but marked changes were seen postprandially with 1.7-fold increased peak concentrations (before—mean: 217 μmol/L; 95% CI: 191, 243 μmol/L; 3 mo—mean: 377 μmol/L; 95% CI: 252, 502 μmol/L; P = 0.012) and 2-fold increased incremental AUC (before-mean: 4.1 mmol ∙ min/L; 95% CI: 2.7, 5.5 mmol ∙ min/L; 3 mo-mean: 9.5 mmol ∙ min/L; 95% CI: 4.9, 14.2 mmol ∙ min/L; P = 0.032).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),[μM] / [l],217,258711,DB00120,L-Phenylalanine
,26245808,peak concentrations,"After RYGB, basal plasma leucine concentration did not change, but marked changes were seen postprandially with 1.7-fold increased peak concentrations (before—mean: 217 μmol/L; 95% CI: 191, 243 μmol/L; 3 mo—mean: 377 μmol/L; 95% CI: 252, 502 μmol/L; P = 0.012) and 2-fold increased incremental AUC (before-mean: 4.1 mmol ∙ min/L; 95% CI: 2.7, 5.5 mmol ∙ min/L; 3 mo-mean: 9.5 mmol ∙ min/L; 95% CI: 4.9, 14.2 mmol ∙ min/L; P = 0.032).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),[μM] / [l],377,258712,DB00120,L-Phenylalanine
,26245808,AUC,"After RYGB, basal plasma leucine concentration did not change, but marked changes were seen postprandially with 1.7-fold increased peak concentrations (before—mean: 217 μmol/L; 95% CI: 191, 243 μmol/L; 3 mo—mean: 377 μmol/L; 95% CI: 252, 502 μmol/L; P = 0.012) and 2-fold increased incremental AUC (before-mean: 4.1 mmol ∙ min/L; 95% CI: 2.7, 5.5 mmol ∙ min/L; 3 mo-mean: 9.5 mmol ∙ min/L; 95% CI: 4.9, 14.2 mmol ∙ min/L; P = 0.032).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),[mM·min·∙] / [l],4.1,258713,DB00120,L-Phenylalanine
,26245808,AUC,"After RYGB, basal plasma leucine concentration did not change, but marked changes were seen postprandially with 1.7-fold increased peak concentrations (before—mean: 217 μmol/L; 95% CI: 191, 243 μmol/L; 3 mo—mean: 377 μmol/L; 95% CI: 252, 502 μmol/L; P = 0.012) and 2-fold increased incremental AUC (before-mean: 4.1 mmol ∙ min/L; 95% CI: 2.7, 5.5 mmol ∙ min/L; 3 mo-mean: 9.5 mmol ∙ min/L; 95% CI: 4.9, 14.2 mmol ∙ min/L; P = 0.032).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),[mM·min·∙] / [l],9.5,258714,DB00120,L-Phenylalanine
,26245808,peak rate,"These concentration differences were mainly caused by changes in leucine appearance rate from orally ingested caseinate: peak rate increased nearly 3-fold [before—mean: 0.5 μmol/(kg fat-free mass ∙ min); 95% CI: 0.4, 0.5 μmol/(kg fat-free mass ∙ min); 3 mo—mean 1.4 μmol/(kg fat-free mass ∙ min); 95% CI: 0.8, 1.9 μmol/(kg fat-free mass ∙ min); P = 0.002], and time to peak was much shorter (before—mean: 173 min; 95% CI: 137, 209 min; 3 mo—mean: 65 min; 95% CI: 46, 84 min; P < 0.001).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),[μM] / [kg],0.5,258715,DB00120,L-Phenylalanine
,26245808,peak rate,"These concentration differences were mainly caused by changes in leucine appearance rate from orally ingested caseinate: peak rate increased nearly 3-fold [before—mean: 0.5 μmol/(kg fat-free mass ∙ min); 95% CI: 0.4, 0.5 μmol/(kg fat-free mass ∙ min); 3 mo—mean 1.4 μmol/(kg fat-free mass ∙ min); 95% CI: 0.8, 1.9 μmol/(kg fat-free mass ∙ min); P = 0.002], and time to peak was much shorter (before—mean: 173 min; 95% CI: 137, 209 min; 3 mo—mean: 65 min; 95% CI: 46, 84 min; P < 0.001).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),[μM] / [kg],1.4,258716,DB00120,L-Phenylalanine
,26245808,time to peak,"These concentration differences were mainly caused by changes in leucine appearance rate from orally ingested caseinate: peak rate increased nearly 3-fold [before—mean: 0.5 μmol/(kg fat-free mass ∙ min); 95% CI: 0.4, 0.5 μmol/(kg fat-free mass ∙ min); 3 mo—mean 1.4 μmol/(kg fat-free mass ∙ min); 95% CI: 0.8, 1.9 μmol/(kg fat-free mass ∙ min); P = 0.002], and time to peak was much shorter (before—mean: 173 min; 95% CI: 137, 209 min; 3 mo—mean: 65 min; 95% CI: 46, 84 min; P < 0.001).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),min,173,258717,DB00120,L-Phenylalanine
,26245808,time to peak,"These concentration differences were mainly caused by changes in leucine appearance rate from orally ingested caseinate: peak rate increased nearly 3-fold [before—mean: 0.5 μmol/(kg fat-free mass ∙ min); 95% CI: 0.4, 0.5 μmol/(kg fat-free mass ∙ min); 3 mo—mean 1.4 μmol/(kg fat-free mass ∙ min); 95% CI: 0.8, 1.9 μmol/(kg fat-free mass ∙ min); P = 0.002], and time to peak was much shorter (before—mean: 173 min; 95% CI: 137, 209 min; 3 mo—mean: 65 min; 95% CI: 46, 84 min; P < 0.001).",Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26245808/),min,65,258718,DB00120,L-Phenylalanine
less,8270977,half-life (t1/2),"The pattern of GCS inhibition mirrored the plasma BSO concentrations with peak values (level 6, 4 to 8 mmol/L L,R+L,S BSO) observed at the end of the infusion with a rapid decrease in plasma concentrations with an estimated half-life (t1/2) of less than 2 hours.",Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8270977/),h,2,258888,DB00120,L-Phenylalanine
,29339228,plasmatic half-life (t1/2,"In particular, its short plasmatic half-life (t1/2 ~ 1 h) is related to its low bound fraction to whole plasmatic proteins and in particular to human serum albumin (HSA).",Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29339228/),h,1,259351,DB00120,L-Phenylalanine
,29339228,t1/2,"Prodrugs 4-6 were found to be relatively stable at pH 7.4 (t1/2 between 4.1 and 57.8 h), while also demonstrated adequate stabilities in human plasma at 37 °C (t1/2 between 1.0 and 2.1 h).",Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29339228/),h,4.1 and 57.8,259352,DB00120,L-Phenylalanine
,29339228,t1/2,"Prodrugs 4-6 were found to be relatively stable at pH 7.4 (t1/2 between 4.1 and 57.8 h), while also demonstrated adequate stabilities in human plasma at 37 °C (t1/2 between 1.0 and 2.1 h).",Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29339228/),h,1.0 and 2.1,259353,DB00120,L-Phenylalanine
,2011051,absolute nasal bioavailability,The absolute nasal bioavailability was calculated to be 96.3% when 5 mg/kg dose was given to fasted rats.,Systemic absorption of L- and D-phenylalanine across the rat nasal mucosa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2011051/),%,96.3,259504,DB00120,L-Phenylalanine
,2011051,absolute bioavailability,The absolute bioavailability declined to 66.8% when 12.5 mg/kg of L-Phe was given intranasally while the time to reach peak concentration remained at 45 min.,Systemic absorption of L- and D-phenylalanine across the rat nasal mucosa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2011051/),%,66.8,259505,DB00120,L-Phenylalanine
,2011051,time to reach peak concentration,The absolute bioavailability declined to 66.8% when 12.5 mg/kg of L-Phe was given intranasally while the time to reach peak concentration remained at 45 min.,Systemic absorption of L- and D-phenylalanine across the rat nasal mucosa. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2011051/),min,45,259506,DB00120,L-Phenylalanine
,2011051,peak time,"On the other hand, when 5 mg/kg of D-Phe was given intranasally, slow and incomplete absorption was observed resulting in a peak time of 60 min and an absolute bioavailability of only 35.2%, suggesting specificity of the carrier for natural L-amino acids.",Systemic absorption of L- and D-phenylalanine across the rat nasal mucosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2011051/),min,60,259507,DB00120,L-Phenylalanine
,2011051,absolute bioavailability,"On the other hand, when 5 mg/kg of D-Phe was given intranasally, slow and incomplete absorption was observed resulting in a peak time of 60 min and an absolute bioavailability of only 35.2%, suggesting specificity of the carrier for natural L-amino acids.",Systemic absorption of L- and D-phenylalanine across the rat nasal mucosa. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2011051/),%,35.2,259508,DB00120,L-Phenylalanine
>,30820862,tumor-to-normal tissue ratio,"In some clinical trials, a tumor-to-normal tissue ratio of 18F-FBPA > 2.5 was an inclusion criterion for BNCT.",4-Borono-2-18F-fluoro-L-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30820862/),,2.5,260912,DB00120,L-Phenylalanine
,1637666,ratio of AUCa/AUCs,"The pharmacokinetic advantages of ILP can be quantified by the ratio of AUCa/AUCs, median value 37.8 (2.1-131).",The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1637666/),,37.8,261113,DB00120,L-Phenylalanine
,21125810,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of alpha-methyldopa was 270.3-1864.9 ng/ml for the test and 224.5-1585.6 ng/ml for the reference formulation.,Single dose bioequivalence study of alpha-methyldopa tablet formulations using a modified HPLC method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21125810/),[ng] / [ml],270.3-1864.9,262986,DB00120,L-Phenylalanine
,21125810,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of alpha-methyldopa was 270.3-1864.9 ng/ml for the test and 224.5-1585.6 ng/ml for the reference formulation.,Single dose bioequivalence study of alpha-methyldopa tablet formulations using a modified HPLC method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21125810/),[ng] / [ml],224.5-1585.6,262987,DB00120,L-Phenylalanine
,21125810,AUC0-infinity,"The mean AUC0-infinity of alpha-methyldopa was 2002.1-10614.8 and 2076.8- 9056.3 ng x h/ml for the test and reference formulation, respectively.",Single dose bioequivalence study of alpha-methyldopa tablet formulations using a modified HPLC method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21125810/),[h·ng] / [ml],2002.1-10614.8,262988,DB00120,L-Phenylalanine
,21125810,AUC0-infinity,"The mean AUC0-infinity of alpha-methyldopa was 2002.1-10614.8 and 2076.8- 9056.3 ng x h/ml for the test and reference formulation, respectively.",Single dose bioequivalence study of alpha-methyldopa tablet formulations using a modified HPLC method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21125810/),[h·ng] / [ml],2076.8- 9056.3,262989,DB00120,L-Phenylalanine
,18197560,apparent plasma clearance (CL),"During initial screening, 1 exhibited an apparent plasma clearance (CL) of 227 ml min(-1) kg(-1) in Sprague-Dawley rats following an intravenous bolus dose formulated in an aqueous solution containing 40% polyethylene glycol.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),[ml] / [kg·min],227,263246,DB00120,L-Phenylalanine
,18197560,apparent plasma CL,"However, the apparent plasma CL was reduced to 97 ml in(-1) kg(-1) when a 2-min time point was added to sample collections, and further decreased to 48 ml min(-1) kg(-1) after the dose was formulated in rat plasma.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),[ml] / [in·kg],97,263247,DB00120,L-Phenylalanine
,18197560,apparent plasma CL,"However, the apparent plasma CL was reduced to 97 ml in(-1) kg(-1) when a 2-min time point was added to sample collections, and further decreased to 48 ml min(-1) kg(-1) after the dose was formulated in rat plasma.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),[ml] / [kg·min],48,263248,DB00120,L-Phenylalanine
>,18197560,hepatic extraction,"The lung extraction of 1 in rats was negligible whereas the hepatic extraction was > or =90%, based on comparison of area under the curve (AUC) values derived from intra-artery, intravenous, and portal vein administration.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),%,90,263249,DB00120,L-Phenylalanine
,25125340,areas under the concentration-time curves (AUC),The areas under the concentration-time curves (AUC) of oxaliplatin at the maximal tolerated dose (MTD) of 100 mg oxaliplatin ranged from 11.9 mg/L h to 16.5 mg/L h.,Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25125340/),[mg] / [h·l],11.9,263629,DB00120,L-Phenylalanine
,25125340,areas under the concentration-time curves (AUC),The areas under the concentration-time curves (AUC) of oxaliplatin at the maximal tolerated dose (MTD) of 100 mg oxaliplatin ranged from 11.9 mg/L h to 16.5 mg/L h.,Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25125340/),[mg] / [h·l],16.5,263630,DB00120,L-Phenylalanine
,7575677,apparent rate constant,"In arterial plasma, FDOPA was O-methylated with an apparent rate constant (0.031 min-1) 3-fold that of [3H]DOPA in the same rats.","Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575677/),1/[min],0.031,263766,DB00120,L-Phenylalanine
,7575677,rate constant,The O-methylated metabolite of FDOPA (OMe-FDOPA) was eliminated from plasma at a rate constant (0.018 min-1) 3-fold that of OMe-[3H]DOPA.,"Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575677/),1/[min],0.018,263767,DB00120,L-Phenylalanine
,7575677,blood-brain clearance,The mean unidirectional blood-brain clearance of FDOPA (4.5 mL.hg-1.min-1) in six brain regions was 60% higher than that of [3H]DOPA.,"Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575677/),[ml] / [hg·min],4.5,263768,DB00120,L-Phenylalanine
,8943896,steady-state volume of distribution,"Pharmacokinetic parameters (mean values of steady-state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half-life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports.",A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943896/),[l] / [m2],14.6,264846,DB00120,L-Phenylalanine
,8943896,total body clearance,"Pharmacokinetic parameters (mean values of steady-state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half-life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports.",A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943896/),[ml] / [m2·min],313,264847,DB00120,L-Phenylalanine
,8943896,elimination half-life,"Pharmacokinetic parameters (mean values of steady-state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half-life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports.",A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943896/),min,46,264848,DB00120,L-Phenylalanine
,8943896,response rate,"In multiple myeloma the response rate was 89% in heavily pretreated patients, suggesting that HDM 220 could be considered earlier in the course of the disease as an alternative consolidation therapy.",A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943896/),%,89,264849,DB00120,L-Phenylalanine
,29267138,Cmax,"Cmax was highest in ocular anterior segment tissues: 5,190-14,200 ng/g [conjunctiva (palpebral/bulbar), cornea, anterior sclera].",Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29267138/),[ng] / [g],"5,190-14,200",264956,DB00120,L-Phenylalanine
<,29267138,Cmax,Plasma concentrations were low (Cmax <18 ng/mL).,Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29267138/),[ng] / [ml],18,264957,DB00120,L-Phenylalanine
,29267138,Tissue/plasma tmax,Tissue/plasma tmax was ∼0.25-1 h.,Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29267138/),h,∼0.25-1,264958,DB00120,L-Phenylalanine
,12860494,half-life,"Mean nateglinide half-life was similar for all 5 treatments (range, 81.3-94.6 minutes).",The effect of nateglinide taken with food on gastric emptying rates in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860494/),min,81.3-94.6,266093,DB00120,L-Phenylalanine
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,29,266411,DB00120,L-Phenylalanine
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,45,266412,DB00120,L-Phenylalanine
,18303486,ON time,"After the levodopa test doses, ON time significantly increased 29 minutes with 75 mg nebicapone, 45 minutes with 150 mg nebicapone, and 16 minutes with 200 mg entacapone.","Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303486/),min,16,266413,DB00120,L-Phenylalanine
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],3620,266437,DB00120,L-Phenylalanine
,8112370,area under the plasma concentration curve (AUC),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],52,266438,DB00120,L-Phenylalanine
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,1.5,266439,DB00120,L-Phenylalanine
,8112370,elimination half-life (t1/2el),"Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h.ng.ml-1 and prolonged its elimination half-life (t1/2el) from 1.5 h to 2.0 h.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h,2.0,266440,DB00120,L-Phenylalanine
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,122,266441,DB00120,L-Phenylalanine
,8112370,AUC,"The mean AUC of 3,4-dihydroxyphenylacetic acid (DOPAC), the monoamine oxidase-dependent metabolite of levodopa, was significantly increased from 122 to 343 h.micrograms.","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),h·μg,343,266442,DB00120,L-Phenylalanine
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],455,266443,DB00120,L-Phenylalanine
,8112370,AUC,"A small decrease in the AUC of homovanillic acid (HVA), the COMT dependent metabolite of levodopa, was observed (from 455 to 303 h.ng.ml-1).","Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112370/),[h·ng] / [ml],303,266444,DB00120,L-Phenylalanine
,2653660,maximum tolerated doses,"The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively.","High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2653660/),,5,267119,DB00120,L-Phenylalanine
,7641197,maximum tolerated dose,Toxicity studies in nontumor-bearing athymic rats yielded a maximum tolerated dose of 0.8 mg for i.a. administered melphalan.,Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641197/),mg,0.8,268384,DB00120,L-Phenylalanine
,7641197,apparent mean blood-to-tissue transport [K],"This dosage was superior in spite of different xenograft permeabilities (apparent mean blood-to-tissue transport [K] values for alpha-aminoisobutyric acid, 5.8 for D-54 MG and 1.3 for D-456 MG).",Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641197/),,5.8,268385,DB00120,L-Phenylalanine
,7641197,apparent mean blood-to-tissue transport [K],"This dosage was superior in spite of different xenograft permeabilities (apparent mean blood-to-tissue transport [K] values for alpha-aminoisobutyric acid, 5.8 for D-54 MG and 1.3 for D-456 MG).",Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641197/),,1.3,268386,DB00120,L-Phenylalanine
,1516606,time to 90% emptying,The time to 90% emptying on the gamma scan was increased significantly from 40 min to 65 min in the presence of levodopa.,The influence of levodopa on gastric emptying in healthy elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516606/),min,40,269805,DB00120,L-Phenylalanine
,1516606,time to 90% emptying,The time to 90% emptying on the gamma scan was increased significantly from 40 min to 65 min in the presence of levodopa.,The influence of levodopa on gastric emptying in healthy elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516606/),min,65,269806,DB00120,L-Phenylalanine
,3841366,Total systemic clearance,"Total systemic clearance, defined as the sum of elimination by all routes from the general circulation of the administered dose, and corrected for enterohepatic recirculation, averaged (+/- SD) 99.4 +/- 24.6 ml/min in the dog.",The pharmacokinetics of alpha-methyldopa in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841366/),[ml] / [min],99.4,270720,DB00120,L-Phenylalanine
,3841366,apparent terminal half-life,An extended average apparent terminal half-life of 6.0 +/- 5.2 hr was exhibited after oral administration compared to an average half-life of 3.1 +/- 1.8 hr following intraarterial administration.,The pharmacokinetics of alpha-methyldopa in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841366/),h,6.0,270721,DB00120,L-Phenylalanine
,3841366,half-life,An extended average apparent terminal half-life of 6.0 +/- 5.2 hr was exhibited after oral administration compared to an average half-life of 3.1 +/- 1.8 hr following intraarterial administration.,The pharmacokinetics of alpha-methyldopa in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841366/),h,3.1,270722,DB00120,L-Phenylalanine
,27163503,Maximum,Maximum S-COMT inhibition (Emax ) ranged from 67.8% (25 mg OPC) to 100% (100 mg OPC).,"Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163503/),%,67.8,270904,DB00120,L-Phenylalanine
,27163503,Maximum,Maximum S-COMT inhibition (Emax ) ranged from 67.8% (25 mg OPC) to 100% (100 mg OPC).,"Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163503/),%,100,270905,DB00120,L-Phenylalanine
,21175446,C(max),There were no differences observed for C(max) at the end of melphalan infusion (placebo 3431 ± 608 ng ml⁻¹ vs. aprepitant 3269 ± 660 ng ml⁻¹).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),ml⁻¹·ng,3431,271890,DB00120,L-Phenylalanine
,21175446,C(max),There were no differences observed for C(max) at the end of melphalan infusion (placebo 3431 ± 608 ng ml⁻¹ vs. aprepitant 3269 ± 660 ng ml⁻¹).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),ml⁻¹·ng,3269,271891,DB00120,L-Phenylalanine
,21175446,Total clearance,Total clearance of melphalan was 304 ± 58 ml min⁻¹ m⁻² (placebo) which was not influenced by aprepitant (288 ± 78 ml min⁻¹ m⁻²).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),min⁻¹·ml·m⁻²,304,271892,DB00120,L-Phenylalanine
,21175446,Total clearance,Total clearance of melphalan was 304 ± 58 ml min⁻¹ m⁻² (placebo) which was not influenced by aprepitant (288 ± 78 ml min⁻¹ m⁻²).,The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21175446/),min⁻¹·ml·m⁻²,288,271893,DB00120,L-Phenylalanine
<,33823167,area under the curve (AUC),Busulfan doses were adjusted to achieve to an average daily area under the curve (AUC) <5500 µM × minute.,Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33823167/),min·μM,5500,272393,DB00120,L-Phenylalanine
,33823167,AUC,"The median busulfan AUC was 4558 µM × min (range, 3462 to 5189 µM × minute) for patients with SOS and 3512 µM × min (2360 to 5455 µM × minute) (P = .0142).",Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33823167/),min·μM,4558,272394,DB00120,L-Phenylalanine
,33823167,AUC,"The median busulfan AUC was 4558 µM × min (range, 3462 to 5189 µM × minute) for patients with SOS and 3512 µM × min (2360 to 5455 µM × minute) (P = .0142).",Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33823167/),min·μM,3512,272395,DB00120,L-Phenylalanine
,25316499,IC50,"In vitro, AFQ056/mavoglurant had an IC50 of 30 nM in a functional assay with human mGluR5 and was selective over the other mGluR subtypes, iGluRs and a panel of 238 CNS relevant receptors, transporter or enzymes.","AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316499/),nM,30,273800,DB00120,L-Phenylalanine
,29368001,maximum concentration (Cmax),"For treated eyes, maximum concentration (Cmax) in the retina was 4.95 μM and area under the curve (AUC0→∞) was 5.26 μM·h.","Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368001/),μM,4.95,273977,DB00120,L-Phenylalanine
,29368001,area under the curve (AUC0→∞),"For treated eyes, maximum concentration (Cmax) in the retina was 4.95 μM and area under the curve (AUC0→∞) was 5.26 μM·h.","Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368001/),h·μM,5.26,273978,DB00120,L-Phenylalanine
,29368001,Cmax,Treated eye vitreous Cmax was 2.24 μM and AUC0→∞ was 4.19 μM·h.,"Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368001/),μM,2.24,273979,DB00120,L-Phenylalanine
,29368001,AUC0→∞,Treated eye vitreous Cmax was 2.24 μM and AUC0→∞ was 4.19 μM·h.,"Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368001/),h·μM,4.19,273980,DB00120,L-Phenylalanine
,29368001,Cmax,Peripheral blood Cmax was 1.04 μM and AUC0→∞ was 2.07 μM·h.,"Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368001/),μM,1.04,273981,DB00120,L-Phenylalanine
,29368001,AUC0→∞,Peripheral blood Cmax was 1.04 μM and AUC0→∞ was 2.07 μM·h.,"Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29368001/),h·μM,2.07,273982,DB00120,L-Phenylalanine
